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Canine myxomatous mitral valve disease (MMVD) is the most common cardiac 
disease in dogs affecting all breeds, and it shares many similarities with the 
equivalent human disease. From the only transcriptomic report for canine MMVD 
published in 2006, serotonin signalling was identified as a contributing factor and has 
been widely studied since. Two transcriptomic profiling studies in human MMVD 
have also identified oxidative stress response and bone morphogenic protein 
signalling contributing to disease pathology. All studies at the transcriptional level 
have identified a variety of biological functions in MMVD suggesting dynamic 
extracellular matrix (ECM) remodelling processes are on-going. Moreover, cellular 
changes found in MMVD are somewhat reminiscent of the events seen in early heart 
valve, suggesting possible re-activation of signalling pathways of which those 
driving development and endothelial-to-mesenchymal transition (EndoMT) are 
particularly interesting. EndoMT, in which endothelial cells change their identity to 
mesenchymal phenotype and migrate into the cardiac jelly underneath the 
endothelium, is a crucial mechanism in valvulogenesis. Whether or not gene 
regulation of EndoMT and valve development also plays a role in MMVD is 
unknown. 
In this study, the MMVD cellular changes in the Cavalier King Charles Spaniel 
(CKCS), a breed with the highest prevalence, earliest onset, and rapid progression of 
the disease, was investigated. Secondly, transcriptional profiling was conducted 
using the latest canine microarray chips, a single affected breed (CKCSs), stringent 
sample quality control and statistical thresholds, with quantitative polymerase chain 
reaction (Q-PCR) for data validation. After transcriptional mapping, multi-platform 
in silico analysis was conducted to identify relationship between differentially 
expressed genes and their relevant biological functions. Next, a comparison study 
using immunohistochemistry was performed on different severities of myxomatous 
valves to localize the proteins of interest. Finally, to model the transcriptional factors 
and their downstream targets, mitral valve endothelial cell (MVEC) clones were 




Cellular changes of MMVD between CKCS and non-CKCS populations showed no 
difference in their distribution, number and phenotypic markers. Global genomic 
expression analysis identified similar (inflammation, up-regulation of serotonin 
receptor and bone morphogenic protein) and novel biological functions (epithelial-to-
mesenchymal transition) compared to the previous study in 2006. Key transcriptional 
factors and genes associated with EndoMT including SNAI1, TAGLN, ACTA2, 
ACTG2, HAS2, and CTNNB1 were found up-regulated, and NID1, LAMA2, CDH5 
were down-regulated in the MMVD group. In myxomatous mitral valves, increased 
expression of HAS2 in myofibroblasts, SNAI1 expression in endothelial cells, and 
co-expression of CDH5 and α-smooth muscle actin (α-SMA) also suggested the 
presence of EndoMT compared to normal valves. Nevertheless, there is also 
evidence of EndoMT in normal valves (α-SMA positive endothelial cells) which 
might suggest contribution to life-long valve re-modelling. In addition, there was a 
decreased expression of microRNAs associated with modulation of extracellular 
matrix transcripts, including miR-23, miR-29, and miR-218, indicating epigenetic 
regulation in MMVD. 
Based on the cellular changes, MMVD in CKCS appears to be representative of 
MMVD in all breeds and the early-onset of MMVD in that breed does not lead to 
different end-stage pathology. Novel biological functions such as EndoMT, were 
identified by transcriptional profiling, and by using powerful bioinformatic tools 
providing insight into understanding gene regulation in MMVD. Furthermore, a 
relationship between developmental biology processes and MMVD pathogenesis was 
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1 Chapter 1 Introduction 
From genesis to degeneration, the mitral valve is constantly in an active remodelling 
state, which is in response to uninterrupted and dynamic cues from both the internal 
and external environment such as normal aging, turbulent flow secondary to chamber 
geometry, and assaults from pathogens. The morphogenesis of valves is under 
sophisticated orchestration of cellular events including activation, migration, 
differentiation, and extracellular matrix deposition and organization. Mechanisms 
governing valve formation and extracellular matrix turnover also play important 
roles in myxomatous mitral valve degeneration. A well-described mechanism in 
valve development is endothelial-to-mesenchymal transition (EndoMT), in which 
endothelial cells switch their phenotype from endothelial to mesenchymal, and 
contribute to the formation of endocardial cushion and valves. 1,2 In a mouse model, 
EndoMT has also been shown to give rise to 25% of the fibroblasts in myocardial 
fibrosis, and this finding supports the idea that developmental pathways govern not 
only valvulogenesis, but could contribute to valve degeneration. 3 However, whether 
EndoMT is also involved or not in myxomatous degeneration is unknown. Therefore, 
a thorough understanding of heart morphogenesis is important in understanding 
disease pathogenesis and developing a hypothesis and inference on the role of valve 
developmental biology in disease. 
1.1 Myxomatous Mitral Valve Disease 
1.1.1 Historical Overview 
Myxomatous mitral valve disease (MMVD) is the most common heart disease in 
dogs, and it has been known for more than a century. The earliest record of canine 
mitral valve disease can be traced back to 1817, when Delabere Blain identified an 
unusual thrill on the chest of a sick dog. 4 In humans, although the syndrome of a 
systolic murmur, now known as Barlow’s disease, was first described in 1887 by 
Cuffer and Barbillon, it was not until the 1960s that these findings were recognized 
to be due to mitral valve prolapse. 5 Mitral valve prolapse due to mucoid 
degeneration in humans described by Read in 1965, shared similar pathology with 




gross pathology grading system of canine MMVD was firstly introduced by 
Whitney. 6 The most common terminology used for the laminated mitral valve 
structure: atrialis, spongiosa, fibrosa, and ventricularis (not often used in mitral valve 
histopathology), was devised by Gross and Kugel. Pathological changes of MMVD 
have also been reported in an experimental heart failure canine model with ascites by 
Jarcho at Johns Hopkins Hospital. 7 In recent years, comparison between human and 
canine MMVD has suggested the potential role of dogs as a naturally occurring 
mitral valve degeneration model. 7 
1.1.2 Prevalence 
MMVD accounts for ~75% of the cardiac disease in dogs, and the incidence 
increases with age in all canine breeds 8–11. In general, geriatric animals and small 
breeds have the highest incidence of MMVD. Predisposed breeds include CKCS, 
Miniature Poodle, Miniature Schnauzer, Cocker Spaniel, Fox Terrier, Dachshund, 
Yorkshire Terrier, Chihuahua, Beagle, and Boston terrier, with highest frequencies in 
chondrodystrophoid breeds. 12 Although small breeds are most commonly affected, 
large breeds with dilated cardiomyopathy have been reported to be affected as well. 
13,14 In one study, the incidence of clinical signs with MMVD was found to be 
positively associated with age, and more than one third of dogs were showing signs 
of congestive heart failure. Postmortem examination shows that nearly 93% of dogs 
aged between 9 and 12 years old are affected, and no dogs that are over 12 years old 
are free from MMVD (Table 1-1). 6 However, dogs that are younger than 5 years old 
are less likely to be affected by MMVD, with the exception of the cavalier King 
Charles spaniel (CKCS), which is reported to have 10% affected in dogs less than 1 
year old, and particularly high prevalence and severe early onset characteristics. 15 
The interesting and unusual CKCS-specific characteristics of MMVD  have resulted 










Post-mortem                
(Whitney Grade I - IV) 
5-8 Years Old 10% n/a 
9-12 Years Old 25% 93% 
> 12 Years Old 35% 100% 
 
1.1.3 Cavalier King Charles Spaniel 
In the 16th century, several types of Spaniel were popular among the European 
aristocracy. However, it was under the Stuarts that the name of King Charles 
Spaniels was given to one breed of spaniel. It is said that King Charles II was seldom 
seen without a few spaniels at his heels (Figure 1-1). 16 The long nosed style of 
spaniel went out of popularity during the reign of King William III, and the Pug (a 
popular breed in the Netherlands) became popular in England as well. It is suspected 
that at this time cross-breeding may have occurred with pugs, or other flat nosed 
breeds, as the King Charles Spaniels took on some Pug-like characteristics (Figure 
1-2). 16,17 It was not until a prize was set up by an American Spaniel lover in order to 
restore the original features of the King Charles Spaniel, and later the founding of the 
club (Cavalier King Charles Spaniel Club) in 1928, that the modern CKCS came into 
shape and received popularity with the public. 16 
In World War II, there was a drastic setback to the breed, with the most of the 
breeding facilities lost or destroyed. For example, in the Ttiweh Cavalier Kennel, 
CKCS numbers dropped from 60 to only 3 during the 1940s. Following the war, only 
six dogs would be used from which all CKCSs are descended. This narrow founder 
base with subsequent in-breeding inevitably passed heritable defects throughout the 






Figure 1-1 A Young King Charles II with his beloved Kings Charles Spaniels. Anthony van 
Dyck (1599–1641), Royal Collection. 
 
Figure 1-2 Modern Cavalier King Charles Spaniel with a flat nose characteristics 
The main breed-related health issues with CKCSs are myxomatous mitral valve 
disease, syringomyelia, and cataracts and multi-focal retinal dysplasia, and chronic 
fibrosing pancreatitis; disorders which suggest complex global connective 
collagenous disorders. More recently, two research groups in Scotland and Denmark 
have conducted genome-wide analysis of single nucleotide polymorphism (SNP) 




aimed to identify the genotype in early onset MMVD phenotype. French et al did not 
identify a single gene defect, whereas Madsen et al identified two loci suspected of 
contributing to early development of MMVD. 18,19 These findings also suggested the 
development of MMVD is governed by polygenic mode of inheritance rather than a 
single gene mutation, and this could partly explain why CKCS breeding schemes 
have failed to eliminate MMVD in the CKCS population. 20 The conflicting result 
between the two studies might also be due to the heterogeneous phenotypes of 
MMVD, or the early-advanced progression form of MMVD might be under control 
by multiple genes in response to epigenetic factors unique to the CKCS. Other 
abnormalities associated with CKCSs such as platelet dysfunction, 
macrothrombocytopenia, hypomagnesemia, natriuretic peptides, and serum serotonin 
level have been identified (Table 1-2). 21–29 With respect to MMVD the elevated  
serotonin levels is of greatest interest, due to its involvement in carcinoid syndrome 
valvulopathy in humans.  
Table 1-2 CKCS specific research in recent years 
 
Serotonin, 5-hydroxytryptamine (5-HT), is a neurotransmitter, and has been found to 
be linked to heart valve disease. In carcinoid tumors (serotonin producing tumors 
such as chromaffin cell adenocarcinoma) and experimentally-induced animal models, 
serotonin has been demonstrated to be linked to valvulopathy which shares some 
similarities with MMVD. 30 The other important finding is that serotonin related 
drugs such as the anorexogen fenfluramine (Fen, 5-HT receptor agonist and 5-HT-
releasing activity) and phentermine (Phen, monoamine oxidase inhibitor) are 
reported to induce pathology of valves which resembles that seen with carcinoid 
syndrome. 31–33 Since platelets are the main storage of serotonin in the circulating 
Hypomagnesemia Platelet Function Natriuretic peptide Serotonin 
Pedersen, 1998 25 Olsen, 2001 22 
Pedersen, 2002 29 
Tarnow, 2003 21 
Cowan, 2004 23 
Davis, 2008 24 
Tarnow, 2009 26 
 
Arndt, 2009 27 




system and platelet abnormalities affect CKCS, one popular hypothesis is that the 
serotonin-TGF-β (transforming growth factor β) signalling pathway activates mitral 
valve interstitial cell activation and remodelling. Alternatively the 5-HT effect might 
be due to local production and have no platelet component (paracrine effect). Studies 
have shown that mitral valve interstitial cells undergo activation and phenotypic 
alteration in response to serotonin TGF-β signalling. The activated valve interstitial 
cells (VICs) show increased secretion of MMPs (matrix metalloproteinases) and 
ECM (extracellular matrix) deposition, which lead to mitral valve remodelling. 30,34–
38  
1.1.4 Mitral Valve Complex 
The normal mitral valve complex consists of six basic elements: 1) the posterior left 
atrial wall, 2) mitral valve annulus, 3) mitral valve leaflets, 4) chordae tendineae, 5) 
left ventricular papillary muscles and 6) associated left ventricular wall. (Figure 1-3) 
The synergistic interplay of each element determines the competence and integrity of 
the mitral valve during the cardiac cycle. Intact and correct orientation of chordae 
tendineae and papillary muscles with the valve leaflets and restraint of the annulus 
determines the tensile and compressive pressure loads created by ventricular and 
atrial systole. 39–41 
 
Figure 1-3 Mitral valve complex, canine. 
1 posterior left atrial wall, 2 MV annulus, 3 MV anterior leaflet, 3’MV posterior 





The mitral valve 
The mitral valve is composed of anterior (septal) and posterior (parietal, mural) 
leaflets, separated by commissures. Leaflets are defined as the structures with 
attached chordae tendineae anchored at the papillary muscles, and both leaflets are 
semicircular in shape. At the edges of leaflets, there is a rough zone where the 
leaflets come in contact during systole and chordae tendineae attach to. Normal 
appearance of mitral valves is thin and translucent without nodules and thickening at 
the tip of leaflets. The anterior mitral valve leaflet is larger and longer than the 
posterior leaflet. 7,12 
Heart Skeleton and Fibrous Annulus 
The two leaflets are hinged at the supportive fibrous tissue in between the left atrium 
and left ventricle. Annulus fibrosus is a structure of elastin, dense collagen fibers, 
and scant cartilage, with various thicknesses in different anatomic locations, and is 
also referred to as the skeleton of the heart. 12,42 The functions of this fibrous skeleton 
include internal reinforcement of the myocardium, valve anchorage, restriction of 
valvular orifices, insertion of atrial and ventricular myocyte bundles, and insulation 
of electrical impulses between atria and ventricles. 42 The fibrous base lying around 
the caudal margin of aortic root is where the anterior leaflet is flanked by two main 
fibro-collagenous trigones (Figure 1-4). The fibrous extension of anterior mitral 
valve leaflet also forms part of the left ventricular outflow tract, and is joined by the 
continuity of the dorsal aspect of the non-coronary aortic valve cusps at the aortic 
root. This extensive fibrous continuity attached to both mitral and aortic valves has 
been described as the aortic mitral curtain (Figure 1-4). 12,43,44 The posterior mitral 
valve leaflet attaches to the endocardium at the left atrioventricular junction, and the 
posterior annulus is formed by merging of the left ventricular outflow tract and left 
ventricular posterior wall. In chronic volume overloading, annulus dilation further 





Figure 1-4 Fibro-collagenous trigones and aortic mitral curtain 
LVOT: left ventricular outflow tract, T: fibro-collagenous trigone, Av: aortic valve, 
P: papillary muscle 
 
The Chordae Tendineae and Papillary Muscles 
The subvalvular apparatus helps to restrict mitral valve motion during systole and 
diastole. Both mitral valve leaflets are joined to two major papillary muscles 
(anterior and posterior) in the left ventricle through first- and second-order chordae, 
with occasional direct attachment to the ventricular wall by chordae tendineae. 
Coordination of these structures not only maintains adequate closure and left 
ventricle performance, but also prevents mitral regurgitation or mitral valve prolapse. 














Arise from papillary muscle 
Insertion on the free edges 
Originate from common or 
bifurcating chordae 
Stiffer with higher stress,  
Prevent valve prolapse 
Second-order 
Arise from papillary muscle 
Larger than first-order chordae 
Insertion on the ventricular 
surface 
Originate from common or 
bifurcating chordae 
Thicker, more elastic, less stress 
Tendon-like structure between 
annulus and myocardium 
Maintain geometry and systolic 
function 
Third-order 
(less common in dogs) 
Arise from septal wall 




In general, papillary muscles are less likely to have geometrical and morphological 
variation. The anterior papillary muscle derives from the mid-area of the anterior left 
ventricular wall, whereas the posterior papillary muscle originates from the apical 
area of the posterior wall. Both the origins of papillary muscles are close to the 
sinuosal interventricular groove. During isovolumetric relaxation in the left ventricle, 
shortening of the papillary muscles assists mitral valve opening, while elongation of 
papillary muscles allows mitral valve closure during late diastole. 47 
 
1.1.5 Gross Morphology and Histopathology of the Mitral Valve 
 Normal Mitral Valve 
The mitral valve leaflets are laminated and heterogeneous structures, and the distinct 
3- (or 4) layered characteristics of mitral valve leaflets are most prominently seen at 
the mid-zone. From atrial to ventricular side, they are atrialis, spongiosa, fibrosa and 
ventricularis (the adopting of ventricularis as a 4th mitral valve layer is not yet 
universal). The atrialis consists of a thin layer of endothelial cells with underlying 
loose collagen fibres and interstitial cells. At the proximal zone (closer to the 
annulus), adipocytes are usually present in the spongiosa. The fibrosa contains layers 




ventricularis is used to describe the elastin-rich layer on the ventricular side of the 
aortic valve, but not found in mitral valve. So the use of the  term “ventricularis” in 
mitral valve only implies a thin layer of endothelium without supportive collagen 
fibres and smooth muscle cell. The lining of endothelial cells on the ventricularis 
also extends to the surface of the chordae tendineae. The compositions of the 
different layers are summarized in Table 1-4. 6,12,42,48,49. The spongiosa is a layer rich 
in glycosaminoglycans (GAGs), proteoglycans, supportive collagen fibres, elastic 
fibres, interstitial cells and rarely smooth muscle cells. 
 
Table 1-4 Normal mitral valve composition and cell types with  
Layer Cell types Composition 
Atrialis (A) 
Endothelial cells, smooth 
muscle cells, interstitial cells 
Basement membrane: laminin, 
fibronectin, collagen I, III, IV, 
VI, and heparan sulphate, 
hyaluronan, elastin 
Spongiosa (S) Interstitial cells, adipocytes 





Fibrosa (F) Interstitial cells 
Predominant collagen I, III, VI, 
and elastin 
Ventricularis Endothelial cells 
Small quantity of collagen I, III, 
and elastin 
Chordae Tendineae 
Endothelial cells, interstitial 
cells, nerve cells 
Loose meshed collagen 
Dense wavy collagen bundle 
Elastic fibers 
 
Representative image of a normal canine mitral valve  
 
Gross Mitral Valve Pathology in MMVD 
The normal thin, translucent appearance of mitral valves is lost in the early stages of 
MMVD, where opaqueness and thickening of the valve edge are most prominent. 
With disease progression, thickened nodules coalesce and form a larger affected area, 




portion is remarkably thickened and protrudes into the left atrium causing mitral 
valve prolapse. In 1967, Whitney introduced a simple classification method 
(Whitney Grade I-IV) grading gross myxomatous lesions based on nodulariy, 
thickening, and deformity (Figure 1-5). 6,7 However, it is important to note that due 
to the pathologic heterogeneity of myxomatous degeneration, different grades can be 
often seen on the same affected leaflet. It is the extent of coverage of the valve edge 
by lesions that tends to give the most accurate grading. Illustrative examples are 
shown in Figure 1-6, Figure 1-7, and Figure 1-8. 
 
Grade Description 
Normal Thin, translucent leaflet without chordae tendineae thickening 
Grade I A few small nodules at valve edge. Proximal leaflet area with opacity. 
Grade II Larger nodules, with coalescing. Diffuse area with Opacity. 
Grade III Larger nodules. Coalesced plaque-like deformity. Chordae tendineae 
thickened and elongated. Mitral competence affected. 
Grade IV Generalized distortion and ballooning of the cusps. Chordae tendineae 
thickened, elongated, and sometimes ruptured. Mitral competence 
affected. 






Figure 1-6 Normal mitral valve. Canine. 
 
Figure 1-7 MMVD Grade I. Canine. 
 





Histopathologic findings vary with the severity of myxomatous degeneration and 
location of the lesions, and the most prominent pathological changes are expansion 
of the spongiosa layer and destruction of the fibrosa layer. In the spongiosa, 
thickening of the layer with increased deposition of glycosaminoglycans, 
proteoglycans and oedematous ground substance are the main findings, while the 
normal alignment of dense collagen bundles in the fibrosa layer is disrupted and 
attenuated. Generally speaking, the distinct laminated structures are gradually lost 
with myxomatous progression. Aupperle and colleagues have reported a three tiered 
grading system based on the microscopic analysis and immunohistopathology, and 
this grading system is summarized in Table 1-5. 50 
Table 1-5 Immunohistopathology grading system by Aupperle. 50 
Grade Histopathologic findings 
Mild 
Hyperplastic endothelium, activated interstitial cell, proliferation of fibroelastic 
tissue, production of laminin and collagen VI at the atrialis 
Disruption of basement membrane components: collagen IV, laminin 
Mild deposition of proteoglycans at the fibrosa 
Loss of dense collagen I and III structure, replaced by loose fibrils at the atrialis 
and spongiosa 
Moderate 
Remarkable increased glycosaminoglycan and proteoglycan deposition in the 
distal end of the valve 
Mild disarray of collagen bundles at the fibrosa 
Intact valve structure in the proximal half of the valve 
Severe 
Large quantity of glycosaminoglycan and proteoglycan deposition and complete 
destruction of the fibrosa layer in the distal end of the valve 
 
Cellular and Morphological Changes  
Changes in the extracellular matrix components and phenotypes of valve resident 
cells in myxomatous lesions are well described in this disease. In the myxomatous 
nodular lesions, there is a general reduction in connective tissue density and re-
distribution of interstitial cells. 6,12,51,52 In the myxomatous nodules, relatively 




peripheral regions, they are surrounded by large spindle-shaped interstitial cells, 
which are responsible for collagen I, IV, fibronectin, and basement membrane 
component production. 53 Interestingly, ectopic deposition of basement membrane 
components such as laminin, elastin, and collagen IV implies the reorganization of 
the valve structure. Since valve interstitial cells and endothelial cells both contribute 
to the synthesis of the basement membrane, and endothelial cells show ability to 
regulate interstitial cell phenotypes under shear stress, it is important to understand 
the endothelial-interstitial-extracellular matrix interaction. 54,55 
The majority of the valve interstitial cells in normal mitral valves are vimentin+ and 
α-SMA- (alpha smooth muscle actin), and phenotypic alteration from a quiescent 
phenotype α-SMA- to and an activated α-SMA+ myofibroblast phenotype is 
prominent in MMVD. 56 These activated valve interstitial cells present a smooth-
muscle-cell-like or myofibroblastic phenotype, and are positively associated with 
disease severity. 48,52,56 It has also been suggested that increased expression of the 
contractile proteins α-SMA and SMemb (embryonic smooth muscle myosin) in valve 
interstitial cells may be in response to gradual loss of integrity, competence, and 
increased mechanical stress in the mitral valve, in order to counteract the increased 
tensile strength. 57,58 Moreover, these activated interstitial cells also demonstrate 
higher extracellular matrix synthetic activity in vivo and in vitro compared to normal. 
In human myxomatous mitral valves, there is an increased expression of catabolic 
enzymes (MMPs, cathepsin K) which is thought to be responsible for valve 
remodelling. 56,58 Members of the TGF-β superfamily, which includes the bone 
morphogenic proteins (BMPs), have been shown to trigger valve interstitial cell 
differentiation and activation. 59–64 Autocrine serotonin-TGF-β signalling has also 
been demonstrated in myxomatous mitral valves. 36,65 The expression of SMemb by 
VICs is more closely correlated to MMPs expression than α-SMA expression. 38 
Mechanical factors have also been shown to modulate phenotype differentiation, 
extracellular matrix synthesis, and catabolic enzyme production. 38 All these findings 
suggest that valve interstitial cells are likely to be constantly undergoing  phenotypic 





The valve endothelium is a single-cell-layer structure lying on both sides of the valve 
surface. 49 VECs are similar to those endothelial cells elsewhere in the circulation 
from a structural and functional perspective, in that endothelial cells maintain vessel 
and valve integrity by interacting with the underlying tissues and smooth muscle 
cells. 66 However, studies have identified the heterogeneity of endothelial cells across 
the different circulatory sites. 66 Surface morphology changes due to endothelial 
damage in myxomatous mitral valve have been identified by electron microscopy, 
and the surface morphology change is presented by patchy endothelial denudation 
with exposure of subendothelial basement membrane, while adjacent intact 
endothelium shows cell pleomorphism. 49,67 This endothelial damage might be 
secondary to altered mitral valve motion and turbulent flow with increased 
mechanical force during valve closure. 68 Also, endothelial cells generate endothelin, 
nitric oxide and other potent vessel tone regulators. Damaged endothelial cells will 
impair the endothelial synthesis of these mediators and affected their interaction with 
sub-endothelial tissues and interstitial cell functions. Butcher et al have demonstrated 
how endothelial cells regulate interstitial cell morphology and phenotype. 55 In a 
canine study increased endothelin receptor density at the tip of myxomatous valves 
has been identified. 69 Interestingly in valve development, foetal valve endothelial 
cells show higher expression of catabolic enzymes (MMPs), mesenchymal markers 
(α-SMA, SMemb), and cell adhesion molecules such as intercellular adhesion 
molecules (ICAM-1, CD54) and vascular cell adhesion molecule 1 (VCAM-1, 
CD106) compared to adult valve endothelial cells, features that are in-part also 
apparent in MMVD.70 The role of developmental pathways in embryogenesis of the 
heart valves and in adult valves is discussed later. 
1.1.6 Aetiology 
The cause of myxomatous mitral valve disease is unknown. In small breed dogs, 
myxomatous valve disease is thought to be inherited. In the Cavalier King Charles 
spaniel, studies have suggested a polygenic threshold trait, and parental heart 
condition (onset of murmur and murmur intensity) is an important determinant of the 




Similar pathology of the mitral valve is also noticed in human mitral valve prolapse 
patients with congenital abnormalities, such as Marfan syndrome. 11,72 In fact, 
chondrodystrophoid breeds such as Dachshunds, have already been shown to be 
prone to have connective tissue associated disorders like tracheobronchomalacia 
(trachea collapse), intervertebral disc disease (IVDD), cranial cruciate ligament 
rupture. 7,9–12,15,73 These observations suggest a global collagenous abnormality might 
be present. The histologic lesions seen in the valves of human patients with 
connective tissue abnormalities suggest that a similar pathogenesis might be the 
cause of MMVD in dogs, but such comparisons need to be treated with caution as 
there are differences between the two species. For example, tissue overlays are a 
common pathological feature of human MMVD but are not present in dogs. 74 
Barlow’s Disease and fibroelastic deficiency are the two types of degeneration 
leading to mitral valve prolapse in human. The manifestation of both diseases 
includes thickening of the leaflet due to deposition of myxomatous material, but 
there are differences in aetiology. In fibroelastic deficient mitral valves, myxomatous 
degeneration is secondary to insufficient production of collagen and elastin which 
leads to mitral valve prolapse. It is usually associated with aging, and the 
myxomatous lesions are localized at the prolapsed segments. In Barlow’s Disease, 
the aetiology is also unknown. The generalized myxoid infiltration and disruption of 
the normal mitral valve three layer structures are similar to pathologic findings in 
canine MMVD. 5 In canine MMVD, the pathology shows a more homogeneous 
pathology without calcific and fibrotic lesions compared to Barlow’s Disease and 
fibroelastic deficiency (Table 1-6). Overall, because of the prevalence of MMVD and 
the asymptomatic presentation of early myxomatous degeneration, it is challenging 
for both humans and dogs to be able to differentiate age-related myxomatous 







Table 1-6 Classification and comparison of degenerative mitral valve disease in human and 
dogs. Modified from 5. 
 Barlow’s Disease Fibroelastic Deficiency Canine MMVD 





Age Young (<60 years old) Older (>60 years old)  Older (> 5years old) 
Long history of 
murmur 
Yes, usually present No 
Present and gradual 
progress 





Thin leaflets, prolapse of 
single segment, ruptured 
chord(s) 





or rupture of chordae  
Calcification, fibrosis or 








Rupture and elongation 
of chordae tendineae. 




Myxomatous lesions affect the coaptation of the leaflets, leading to mitral valve 
incompetence and regurgitation. A fraction of stroke volume from the left ventricle 
then is ejected into the left atrium through the regurgitant orifice, and this will raise 
the left atrial pressure which results in left atrial dilatation. Since the left ventricular 
filling in diastole is from the left atrium, the additional regurgitant volume with the 
normal blood return from the lung will impose volume load on the left ventricle and 
the left atrium. Increased end-diastolic pressures and volume lead to eccentric 
hypertrophy of the left ventricle. The increased filling pressure will also reflect 
backwardly to the pulmonary vein pressure, and results in pulmonary oedema in 
decompensated heart. In dogs with mitral regurgitation, neuroendocrine (renin-
angiotensin-aldosterone system, RAAS) activation and other compensatory 
mechanisms (eg. Frank-Starling’s Law) allow the heart to cope with the mitral 
regurgitation and the disease can remain clinically silent for years until the disease is 
advanced. 7-10 In severe mitral regurgitation, patient starts showing signs of 




this is due to progressive maladaptation of neuroendocrine response and loss of 
myocardium contractility. 9–11 
1.1.8 Clinical Presentation 
In most mildly affected dogs, MMVD itself does not cause clinical signs, and it 
could be an incidental finding in a patient presented for annual health check or for 
other non-cardiac disease. When clinical signs emerge in patients with MMVD, 
coughing is one of the signs that may be observed by owners. Dry cough could be 
due to bronchial compression by enlarged left atrium due to volume overload. 
Productive and moist cough due to pulmonary edema (left side congestive heart 
failure) may be accompanied by other signs including exercise intolerance and 
tachypnea. 9–11 Syncope is occasionally reported by owners in MMVD dogs. 
Syncopal episodes could be the result of insufficient cerebral perfusion owing to 
impaired cardiac function, where the cardiac output does not increase adequately in 
order to meet the physiological demands like exercise. Another pathophysiology of 
syncope could be due to arrhythmia secondary to chamber enlargement. 11 
During auscultation, a systolic murmur with maximal point of intensity over the left 
cardiac apex can be heard in MMVD dogs. Crackles may also be auscultated in dogs 
with pulmonary edema due to congestive heart failure.10 
1.1.9 Diagnosis 
The diagnosis of mitral regurgitation due to MMVD can be based on signalment, 
history, physical examination, and thoracic radiographs. Echocardiography is the 
most useful diagnostic tool for MMVD. Measurement of enlarged chamber and 
quantification of mitral regurgitant jet can be obtained from echocardiography. 11 
1.1.10 Treatment 
Medical management of congestive heart failure secondary to MMVD is case-
dependent. In brief, the four most common drugs used in veterinary cardiology to 
treat congestive heart failure are angiotensin converting enzyme inhibitor (ACEi), 
loop diuretic (furosemide), aldosterone antagonist (spironolactone), and inodilator 
(pimobendan). The actions of these drugs and indications for use are summarized in 





Table 1-7 Common drugs used in veterinary medicine to treat congestive heart failure 
Drug Trade Name  Action Indication 




Inhibits sodium and potassium 






Potassium sparing diuretic 
Volume overload 
Mild effect of diuretics 
Pimobendan 
Phosphodiesterase II inhibitor and 
calcium sensitizer which shows both 





Mitral valve repair is the optimal and curative way to treat myxomatous mitral valve 
disease in humans. With the assistance of the robotic technology and interventional 
radiology techniques, specialized cardio-surgeons can achieve mitral valve repair 
with minimal invasiveness. 75 In veterinary medicine, surgical interventions have 
been attempted but with a low success rate and questionable clinical improvement in 
dogs affected by MMVD. 76 Nevertheless, Uechi has recently reported the highest 
success rate in mitral valve repair on 48 dogs with significant resolved clinical sign, 
longer life expectancy, and reverse cardiac remodelling. 77 However, due to the 
predisposed breeds (small size), cost-benefit (cardiopulmonary by-pass, life-
expectancy), animal welfare (invasive surgery), and post-operative management 
(systemic thromboembolism, dysfunction of prosthetic valves and chordae), mitral 
valve repair procedures remain controversial in veterinary medicine and are unlikely 
to become widespread. More innovative approaches are required to develop novel 
treatments for both humans and dogs, and these are likely to be based around 
understanding of the molecular events that occur on diseased valves and the 





1.2 Heart Valve Development  
1.2.1 Overview 
Formation of the Heart Tube 
At the early three- to four-somite stage, the heart arises in the mesoderm from the 
paired endocardial tubes (consisting of endocardium only). Later they are enclosed 
by thickened splanchnic mesoderm (epimyocardium). Epimyocardium then 
differentiates into epicardium and myocardium. These paired endocardial tubes 
migrate centrally and fuse to form a single straight cardiac tube (Figure 1-9). 9 
  
Figure 1-9 Endocardial tube formation. Modified From78. 
Convolution of the Heart Tube 
The straight cardiac tube contains ventral aortae (cranial) and omphalomesenteric 
veins (caudal), which firmly anchor within the pericardial sac. Therefore, elongation 
is only possible by folding and bending the cardiac tube into an S-shaped loop. 
During the looping of the heart, primary subdivisions of the heart are gradually 





Figure 1-10 Looping of the heart. Modified from 79. 
Formation Primitive 4-Chambered Heart  
After the stage of cardiac looping, a series of septations occur in order to divide the 
left and right sides of the chambers. The primitive atrium joins with the primitive 
ventricle through a common atrioventricular canal. During heart septation, the cranial 
and caudal atrioventricular (AV) endocardial cushions grow towards each other and 
fuse, dividing the primitive common atrioventricular canal into left and right 
atrioventricular canals. In ventricular septation, tissue grows from trabeculation 
processes at the heart apex towards the atrioventricular canal to form the primary 
inter-ventricular foramen, which is later closed by fusion with the atrioventricular 
endocardial cushion growth. In the atrium, extension of the septum primum from 
atrial wall towards AV canal forms the ostium primum. This opening is closed when 
the septum primum fuses with the endocardial cushion. At the same time perforations 
from the superior portion of the septum coalesce to form the ostium secundum. 
Another septum originates from atrial wall, descends down the right side of the 
septum primum and joins the AV cushion. On the septum secundum the fossa ovalis 
is a persistent opening and is normally covered by the septum primum. Defects in 





Figure 1-11 Development of the AV valve and septation of the heart. Modified from 9 
1.2.2 Valve Morphogenesis 
The AV and semilunar (SL) valve have the same developmental mechanisms 
occurring at the endocardial cushions. The only difference is the anatomical location. 
The sites of the valve morphogenesis are the main sites of EndoMT. Under the effect 
of factors such as TGF-β and BMP secreted by the adjacent myocardial cells, 
endocardial endothelial cells undergo phenotypic transition by losing endothelial 
phenotype markers such as platelet endothelial cell adhesion molecule (PECAM-1, 
CD31), and vascular endothelial cadherin (VE-cadherin, CD144, CDH5) and 
acquiring a mesenchymal α-SMA positive phenotype. The migratory ability is also 
obtained by losing cell-cell contact and secreting MMPs which degrade the 
endocardial basal lamina (collagen IV) allowing invasion. At the endocardial 
cushion, EndoMT contributes to the mesenchymal cells by the migration of the 
transformed endothelial cells into the underlying hyaluronan- and chondroitin 
sulfates-rich cardiac jelly. 80–84 Under continual effects of growth factors such as 




secreted from the endocardium and the myocardium, these cells contribute to the 
early expansion and elongation of the primitive valves by ECM deposition and cell 
proliferation. Finally, atrioventricular valve maturation is achieved by delamination 
from the muscular walls (Figure 1-12), whereas in semilunar valves, there are 
excavations of cushions from the aortic and pulmonary sides inward. 83,85 
 
Figure 1-12 Morphogenesis of atrioventricular valve. Modified from 83. 
Although septation of the heart occurs early in embryogenesis, atrioventricular 
valves development is observed in the first trimester in mammals. At the 
atrioventricular canal, fusion of the ventral and dorsal atrioventricular endocardial 
cushion with the atrial and ventricular septa gives rise to the mitral and tricuspid 
valves. 9 For the semilunar valves, protrusion of three endocardial cushions at the 
aortic and pulmonary lumen forms the aortic valves and pulmonic valves. 
1.2.3 Endothelial Mesenchymal Transition 
During valvulogenesis, the term “endothelial mesenchymal transition” describes the 
process where the endocardial endothelial cells at the valve–developing region 




the cardiac jelly, a hyaluronan-rich space underlying the valvulogenic endocardial 
cushion. The initiation of EndoMT is closely regulated by several growth factor-
mediated signalling pathways including vascular endothelial growth factor (VEGF), 
TGF-β, BMP and NOTCH. 83 
VEGF. Vascular endothelial cell growth factor regulates endothelial cell 
proliferation during valve development, and is expressed by endocardium and 
myocardium near the valve forming region. Though VEGF has been shown to have 
some EndoMT antagonist activity, basal level of VEGF expression is indispensable 
for endocardial cushion formation, possibly due to the maintenance of endocardial 
integrity and endothelial cell population during EndoMT. 80,83,86 
Wnt/β-catenin. Wnt/β-catenin signalling is expressed locally at the valve forming 
region, and is important in patterning of the heart-forming field. In addition, β-
catenin acts as a link between actin and VE-cadherin that constructs the adherens 
junction, which mediates cell-cell adhesion and cell polarity in endothelial cells. In 
animal models, inhibition of Wnt signalling results in no EndoMT, whereas 
overexpression leads to excessive endocardial cushion formation. Wnt/β-catenin 
signalling also triggers expression of EndoMT associated genes during the phenotype 
transition. 86 
NOTCH. NOTCH is a cell fate determining factor expressed in embryonic and adult 
tissues alike. Expression of NOTCH at the valve forming region induces EndoMT. 
The mechanism is by selective induction of the TGF-β signalling pathway, and Snail 
is the downstream transcription factor which represses expression of endothelial 
markers (VE-Cadherin, PECAM1), but increases mesenchymal markers (α-SMA, 
fibronectin). Therefore, NOTCH transforms the regional endocardium into active and 
unstable mesenchyme. 83,85,87 Finally, functional studies on animal models show that 
disruption of NOTCH results in no EndoMT, and constitutive activation of NOTCH 
leads to hypercellular valves. 83 
TGF-β. Transforming growth factors and BMPs are part of the TGF-β superfamily. 
TGF-β ligands play an important role mediating cell differentiation in physiological 
and pathological states in multiple tissues. 83 In atrioventricular valve formation, 




suggested that endocardial expression of TGF-β2 is essential for endothelial cell 
separation and hypertrophy, and expression of TGF-β3 is important for mesenchymal 
transformation and migration. 88 Degradation of basal lamina component collagen IV 
by MMPs is also triggered by TGF-β3. 89 Simultaneously with the acquired 
mesenchymal phenotype of the endocardium, this permits the migration of the 
transformed endothelial cells. In animal models, blocking of the TGF-β receptors 
results in complete inhibition of EndoMT, and in a mouse model TGF-β2 has been 
showed to activate mesenchymal transformation through activation of Snail/Slug. 
87,90,91 .  
BMP. BMPs, as the name suggested, are osteogenic cytokines, but also crucial for 
cellular differentiation in early valvulogenesis with BMP2 and BMP4 expression 
particularly noticed in the valve forming region. 82,83,86 In general, BMPs are 
expressed in the myocardium earlier than the onset of EndoMT, and BMP signalling 
also triggers multiple pathways including TGF-β, HAS2 (hyaluronic acid synthase 2)   
and NOTCH, as well as the transcription factors Snail and Twist. 92–94 Because of the 
pre-EndoMT expression of BMPs, the action of BMPs could be divided into two 
phases. Initially, before the onset of EndoMT, BMP stimulates HAS2 expression and 
creates an hyaluronan-rich environment which permits the activation and migration 
of endocardium by other growth factors. Later, synergistic signalling with TGF-β 
and NOTCH drive the EndoMT and allow invasion of cells into the cardiac jelly. 59 
Experimentally, inhibition of BMP signalling results in complete silencing of 
EndoMT in atrioventricular cushion explants. 95 
Extracellular Matrix. Underlying the valve forming endocardial cushion, cardiac 
jelly is mainly composed of hyaluronan (HA), initially produced from adjacent 
myocardium through HAS2 and UDP-glucose dehydrogenase (UGDH). 96 The 
accumulation of hyaluronan causes expansion of the extracellular space by binding to 
salt and water. The hyaluronan-rich environment also favors migration of 
transformed endothelial cells, and induces PI3K and ErbB2/3 signalling and valve 
mesenchyme formation. 97 In cultured embryos, disruption of hyaluronan synthesis 
leads to no endocardial cushion formation, and a similar result is found in HAS2-null 




Another important proteoglycan found in cardiac jelly is versican, which links 
protein between hyaluronan and collagen, and versican-null mice do not form 
endocardial cushions at the valvulogenic region. 99 
 
1.2.4 Extracellular Matrix (ECM) Maturation and Organization 
The dynamic environment during valve development contains numerous molecules, 
which play crucial roles in the regulation of cellular events. The main components 
found in valve formation include hyaluronan, fibronectin, fibrillin, proteoglycans and 
collagens. 100 The mesenchymal cells regulate valve elongation, expansion, fusion, 
stratification and maturation by ECM remodelling during valve formation. This 
process involves a tight balance between degradation and deposition of extracellular 
matrix. Detailed information of ECM genes associated with development and disease 




Table 1-8 Animal models of extracellular matrix genes associated with cardiovascular 
development. All studies performed on mouse except aggrecan (chicken). Modified from 100 
Extracellular Matrix 
Expression during Heart 
Formation 
Cardiovascular Phenotype 
in animal models 
Hyaluronan, Proteoglycans and Link Proteins 
Aggrecan Epicardium, mesenchyme of the 
OFT and AVC 
None reported 
Cartilage link protein 
(CRLT1) 
Endocardium, mesenchyme of the 
OFT AVC 
ASD, VSD, AVSD 
Hyaluronic acid 
synthase 2 (HAS2) 
Myocardium, endocardium of 
heart tube, OFT cushions, AV 
valves 
Fail to form AVC 
Perlecan Basement membrane, OFT, SMCs 
of Ao and pulmonary artery 
Defects in OFT rotation 
Versican AV and OFT cushions, 
mesenchyme of the PAS 
Fail to form RV, OFT, AVC 
Collagens   
Collagen I AV valves, vasculature Vascular defects, aortic dissection 
Collagen II AV valves Cartilage and bone disease 
Collagen III AV valves, vasculature Vessel rupture 
Collagen IV AV valves Vascular defect 
Collagen V Ao, annulus fibrosus, MV mural 
leaflet 
Decreased Ao stiffness 
Collagen VI AV valves, myocardium, 
epicardium, Ao, and pulmonary 
artery 
None reported 
Collagen XI Not reported Thickened heart valves 
Collagen XV BM, myocardial capillaries Vascular defects, cardiomyopathy 
Collagen XVIII BM, endocardium, semilunar 
valves 
Broadened AV valves 
Proteases   
ADAMTS1 Endocardium, myocardium, AV 
cushion 
Hypertrabeculation 
ADAMTS5 Endocardium, myocardium, 
pericardium, Ao, aortic valves 
Normal 
ADAMTS9 Myocardium, right-sided OFT 
cushion, SLV, Ao, MV 
Myxomatous mitral valve 
Others   
Periostin Endothelium, cushion of OFT and 
AVC, AV valves 
Leaflet abnormalities and valve 
disease 
Fibronectin Embryonic mesoderm, AVC, 
endocardium 
Vascular defect, failure of heart 
tube formation 
Fibrillin 1 Endocardium, AVC and cushion 
of OFT, AV valves 
Fail to form EC, mitral valve 
prolapse, aortic aneurism  
Laminins Basement membrane Compromised cardiovascular 
function 
Tensacin AV valves Mitral valve prolapse 
Elastin AV valves Malformation of aortic valve 
SMC, smooth muscle cell; OFT, Outflow tract; AVC, atrioventricular cushion; AV, atrioventricular; 
ASD, atrial septal defect; VSD, ventricular septal defect; AVSD, atrioventricular septal defect; CT, 




The mechanisms controlling post-EndoMT valve remodelling are understudied and 
poorly understood. Before EndoMT, the endocardial cushion is rich in hyaluronan 
and versican. After the endocardial cushion is cellularized through EndoMT, 
migrated mesenchymal cells start to synthesize network collagens (mainly fibrillar 
collagen I, III, V), and proteases as well as cartilage- and tendon- related ECM 
proteins such as aggrecan and tenascin, during valve maturation. 80,86 Over time, 
increased cellularity and collagen deposition directly contribute to rigidity and 
elongation of the valves. The mechanisms contributing to patterning and 
stratification of each specialized layer in valves remain unknown. Based on 
transcriptional patterns, a regulatory model controlling atrioventricular valve 
stratification was proposed by Combs. 81 In the atrialis, NOTCH expression is 
localized to the flow side. In the spongiosa, Sox-9 up-regulation is mediated by 
BMP2 signalling, and this triggers cartilage-related ECM (aggrecan) deposition. In 
the fibrosa layer, fibroblast and preosteoblast associated ECM proteins (such as 
periostin) are positively controlled by Wnt expression and signalling. Finally, 
chordae tendineae and other subvalvular apparatus development is initiated by FGF4 
signalling. FGF4 signalling increases expression of the tendon-related transcriptional 
factor SCX (scleraxis) and other ECM components (tenascin) alike. 82 
In the matured and laminated valves, structurally distinct layers have unique 
biomechanical properties. Elastin fiber is abundant in the atrialis, and it gives valve 
elasticity responding to the blood flow. The spongiosa layer is rich in chondroitin 
sulfate proteoglycans that provide valve compressibility which is biomechanically 
similar to cartilage. The collagen-rich fibrosa layer provides stiffness and strength of 
the leaflets against tension and flexure. 80 Mutations in ECM genes associated with 
valve abnormalities have been reported in human literature and give a clear insight 








Table 1-9 Gene mutations associated with valve abnormalities in human. Modified from 80. 
Gene Valve phenotype 
Fibrillin-1, FBN1 Aortic root dilation, BAV, MVP 
Elastin, ELN SVAS, BAV, MVP 
TGF-β Receptor, TGFBR1 Aortic aneurism, MVP 
Collagen I, COL1A1 Aortic valve prolapse, MVP 
Collagen III, COL3A1 Aortic root dilation, BAV, MVP 
NOTCH1 BAV, CAVD, CVM 
α-smooth muscle actin, ACTA2 Aortic aneurism, BAV 
Myosin heavy chain 11, MYH11 Aortic aneurism, BAV 
Filamin A, FLNA BAV, MVP 
BAV, bicuspid aortic valve; MVP, mitral valve prolapse. SVAS, supravalvular aortic stenosis. 
CAVD, calcific aortic valve disease. CVM, cardiovascular malformation. 
 
1.2.5 Biomechanics 
Both atrioventricular and semilunar valves maintain the unidirectional flow of blood 
in the heart. The normal average human heart rate is 60 beats per minute, and 
accounts for more than 100,000 beats per day and approximately 3 billion beats 
throughout a 70 year lifespan. In dogs, depending on breed size, the average heart 
rate varies from 70-100, and also contributes to approximately half a billion beats in 
a 10 -15 years of life expectancy. 101  
The movement of valves (opening and closing) is primarily passively controlled by 
the pressure differences in the heart chambers, with a contribution from the papillary 
muscles, valve associated myocardium and valve annulus, and the left side of the 
heart maintains higher pressures than the right side in the normal heart. 101 The three 
main mechanic forces affecting heart valves are flexure, shear and tension. Flexure 
occurs during valve opening and closing. Shear stress is created when blood flow 
passes through the opening valve surface. Tension occurs when the valve is stretched 
by the annulus and sub-valvular apparatus at coaptation. 85 Hence, the cellular and 
matrix composition are crucial for considering valve dynamics and loading force 
endurance. 
Using α-SMA and heat shock protein 47 (HSP47) to quantify cellular stiffness and 




interstitial cells to have higher quantities of both α-SMA and HSP47, and this finding 
implies that valve interstitial cells are exposed to higher forces. In response to the 
greater forces created by left side of the heart, the valve interstitial cells increase 
collagen and cellular (cytoskeletal) stiffness in order to maintain homeostasis. 101 
Another study by Aikawa also demonstrated similar cellular events; during the 
postnatal valve development, interstitial cells gradually become quiescent in 
accordance with the collagen maturation and biomechanical adaptation. 70 By 
manipulating the papillary muscle tethering and mitral valve geometry in a sheep 
model, localized thickening (collagen deposition) and EndoMT (migration and 
increased α-SMA expression) of the mitral valve in adaptation to increased 
mechanical force was identified to be associated with reactivation of developmental 
pathways. 102 These studies all point out the unique plasticity of mitral valves and 
their adaptive potential to haemodynamics. 
 
Study Aims and Hypothesis 
The aim of this study was to evaluate changes in the mitral valves of cavalier King 
Charles spaniels, with particular reference to cell and gene profiles.  
The first aim was to characterise the cellular changes in CKCS with the hypothesis 
that there are no differences between CKCS and other equally affected dogs and that 
the valve pathology is the same irrespective of breed. With that in mind the CKCS 
could be used examined as a model of MMVD in the dog. 
The second aim was to evaluate expression of developmental genes in CKCS valves 







2 Chapter 2 Cellular changes in Myxomatous Mitral Valve 
Disease in Cavalier King Charles Spaniel 
2.1 Introduction 
The CKCS breed is recognised to be particularly pre-disposed to the development of 
MMVD in terms of age of onset, progression and severity. 15,20,29,71 MMVD is highly 
heritable in the CKCS breed and it is reasonable to suppose heritability also has a 
role in disease appearance and progression. 18–20 Additionally, there are CKCS-
specific traits that might be implicated in the development of MMVD, such as 
differences in platelet numbers and platelet aggregation tendency and higher serum 
magnesium and 5-HT levels compared to other dogs. 21,23,24,26,27,29,103 CKCS are also 
more predisposed to chronic fibrosing pancreatitis, multi-focal retinal dysplasia, 
syringomyelia, which with MMVD might reflect a breed-specific global connective 
tissue abnormality. 20,67 
Cellular changes that occur with MMVD are well described in canine and human 
MMVD. In general, there is an increase in α-SMA positive VICs (activated 
myofibroblasts) which locate mainly towards the valve free-edge (valve tip) in a 
linear cluster pattern and beneath endothelium. 51,56,104 In normal valve stroma the 
majority of cells are quiescent vimentin-positive VICs (qVIC), with a few desmin-
positive cells. 52,104 In overtly myxomatous areas of affected valves some cells also 
appear to be activated myofibroblasts based on their expression of myosin SMemb, 
and SMemb positive cells are shown to be more associated with catabolic serotonin 
synthesis. 36,38,51 A small increase in mast cell numbers is also noted, but there is no 
increase in macrophage numbers and no inflammatory cell infiltration is evident. 
51,104 Changes in endothelial cell morphology, coupled with endothelial cell 
denudation are also reported. 49,57,104 
Of the histopathology studies to date, all have presented data from a mix of pedigree 
and cross-bred dogs. Considering the susceptibility of the CKCS to MMVD, the aim 
of this study was to determine if there are differences in valve cellular changes in the 




2.2 Material and Methods 
2.2.1 Tissue samples 
Mitral valve leaflets were obtained from six elderly CKCS (12-14 years) and six 
elderly mixed breed dogs (8-12 years) with MMVD. Control samples were obtained 
from four young adult mixed breed dogs (1-2 years) with no evidence of disease. 
Briefly, after removal of the heart the mitral valve leaflets were exposed by opening 
from left atrium and ventricle through the lateral wall between the two papillary 
muscles. The mitral valve leaflets were examined for MMVD lesions and 
photographed. The whole mitral valve leaflets were then surgically dissected from 
the attachments of annulus and pupillary muscles, and immediately immersed in 4% 
paraformaldehyde and fixed at 4oC for 36 hours. Samples were then rinsed in PBS 
and stored in 70% ethanol at 4oC until required. All samples were collected with full 
owner consent and the study conformed to national (UK) and institutional ethical 
guidelines for the use of animals in research.  
Affected valves were pathologically graded Whitney Grade 3 or 4 by at least two 
observers. 6 Representative samples of similar gross pathological appearance 
(nodular and thickening at valve tip) were cut from each valve, paraffin-embedded 
and 4 consecutive 5µm sections were collected onto slides. 
2.2.2 Hematoxylin & Eosin (H&E) 
Sections were de-waxed in xylene for 5 minutes and rehydrated through 100% 
ethanol, 95% ethanol, 90% ethanol, 70% ethanol, and distilled water for 2 minutes 
each. Standard H&E staining was performed using a programmed autostainer 
(Autostainer XL Leica ST5010). Briefly, slides were immersed in hematoxylin 
reagent for 4 minutes before rinsing in running tap water for 30 seconds. Sections 
then were rinsed with acid alcohol for 2 seconds and rinsed with running tap water 
for 30 seconds. Sections were then counterstained in eosin for 2 minutes. Before 
mounting with mounting medium (DePex; Gurr-BDH Chemicals Ltd), sections were 






Sections were de-waxed firstly in xylene for 10 minutes. The slides were then 
rehydrated through graded ethanol: 100% ethanol, 95% ethanol, 90% ethanol, 70% 
ethanol, and distilled water for 5 minutes each. All slide rehydration was done in a 
programmed autostainer (Autostainer XL Leica ST5010). For antigen retrieval, 
sections were heated in citrate buffer (0.01M, pH 6.0) or Tris-EDTA (10mM Tris 
base, 1mM EDTA solution, pH 8.0) for 5 minutes at 120˚C by HISTO5 Rapid 
Microwave Histoprocessor (Milestone). After antigen retrieval, slides were rinsed 2 
times for 5 minutes in distilled water. At this stage slides were ready to be mounted 
using sequenza cassettes (Thermo Scientific, Shandon Sequenza Immunostaining 
Cassettes) with 200 µm of 0.5% PBS-Tween20 with the following steps. 
Peroxidase Method: For the peroxidase technique, sections were incubated with 1% 
hydrogen peroxide (H2O2 in phosphate-buffered saline (PBS pH 7.4) for 10 minutes 
to block the endogenous peroxidase. Next, permeabilization and non-specific-block 
of antigens were performed with 10% goat serum (diluted in 0.5% Tween 20) 
(Vector Laboratories Inc.) for 30 minutes at room temperature. Sections were then 
incubated for 60 minutes at room temperature with the primary antibodies. Slides 
were washed with 0.5% PBS-Tween20 5 times for 5 minutes and incubated for 30 
minutes at room temperature with biotinylated secondary antibodies (goat anti-mouse 
or anti-rabbit IgG; Vector Laboratories Inc.). After another 5-times-5-minute washes, 
slides were incubated with avidin-biotin complex (VECTASTAIN ABC system, 
Vector Labs Inc.) for 30 minutes. After ABC reagent complex conjugation, slides 
were developed with NovaRED (NovaRED peroxidase substrate kit, Vector Labs 
Inc.) as a chromagen. Mayer’s Haematoxylin solution (Sigma-Aldrich) was used for 
counterstaining for 90 seconds followed by 10 seconds in Scott’s tap water. Finally, 
slides were manually dehydrated in a glass slide stainer through distilled water, 70% 
ethanol, 90% ethanol, 95% ethanol, fresh 100% ethanol for 5 minutes each and fresh 
xylene for 10 minutes. After dehydration, slides were mounted in a xylene-based 
medium (DePex; Gurr-BDH Chemicals Ltd). 
Indirect fluorescence: For immunofluorescence, the basic protocol was the same for 




conjugated antibody (AlexaFluor488 and 568, Invitrogen) was applied for 60 
minutes at room temperature in a dark humid chamber. Slides were washed in 0.5% 
PBS-Tween20 (5x 5min) between primary antibody probing, secondary antibody 
probing, and mounting. Mounting medium with nuclear counterstain DAPI was used 
to mount slides (ProLong Gold Antifade Reagent, Invitrogen). Briefly, Prolong Gold 
was brought to room temperature 10 minutes before use. After the slides were 
mounted and sealed with nail polish, they were left in a tin-foil wrapped paper box at 
room temperature to cure overnight. The next morning, sealed slides were ready to 
be viewed or stored at -20 ˚C. 
Double indirect fluorescence: For double-labelling methods, two primary 
antibodies targeting two antigens were selected (from different species, mouse and 
rabbit), and were mixed up in one buffer for the primary antibody incubation. The 
secondary antibodies were also mixed up in one buffer for incubation, and species 
specific secondary antibodies were designed to bind the designated primary 
antibodies. In addition, the fluorescent tags on secondary antibodies were different in 
excitation range for antigen differentiation (AlexaFluor488, 568). The incubation 
time for primary and secondary antibodies, washing, and mounting in double 
labelling method were the same as indirect single fluorescent labelling method. 
Sections were examined for the presence of the universal mesenchymal cell marker 
vimentin, the inflammatory cell markers CD11c and CD45, the VEC markers Von 
Willebrand factor (vWF) and CD31, the activated myofibroblasts (aVIC) markers α-
SMA, SMemb and the cell proliferation marker Ki-67. The details for each antibody 
are shown in Table 2-1. Double staining was carried out for α-SMA and SMemb 








Table 2-1 Details of each antibody used in this study 
Name Clonality IHC Supplier Cat. No. 
Primary Antibody     
α-SMA Ms monoclonal 1:400 Sigma A2547 
SMemb Rb polyclonal 1:1000 Abcam Ab24761 
Vimentin Ms monoclonal 1:1600 Sigma V6389 
vWF Rb polyclonal 1:1000 Abcam Ab6994 
CD31 Rb polyclonal 1:100 Abcam Ab28364 
Ki-67 Rb polyclonal 1:200 Abcam Ab15580 
CD-11c Ms monoclonal 1:100 Abcam Ab76911 
CD-45 Ms monoclonal 1:100 AbD Serotec MCA2035S 
Secondary Antibody     
Alexafluor 488 Goat anti-Ms IgG (H+L) 1:100 Invitrogen A10667 
Alexafluor 568 Goat anti-Rb IgG (H+L) 1:100 Invitrogen A11011 
Biotinylated Antibody Goat anti-Ms IgG (H+L) 1:1000 Vector BA-9200 
Biotinylated Antibody Goat anti-Rb IgG (H+L) 1:1000 Vector BA-1000 
*Abbreviation: H+L, heavy and light chain. Ms, mouse. Rb, rabbit.  
 
For each dog a minimum of four sections were examined for each antibody. Positive 
controls included canine spleen, lymph node and duodenum, and for negative 
controls the primary antibody was omitted. Images were taken using a light 
microscope with fluorescent capability (Leica-DMRB, Leica Microsystems, Leitz).  
2.2.4 Image capture and Statistical analysis 
For quantitative assessment (ImageJ cell counter plug-in; National Institutes of 
Health) nine selected (x400 magnification) images, from the same region of interest 
for each valve, were digitally captured from close to the valve edge (tip of leaflet) to 
the valve base (zone adjacent to the annulus). Qualitative assessment only was 
carried out on the NovaRed stained sections (longitudinal and horizontal), and 
quantitative assessment on the fluorescent labelled sections (longitudinal only).  
The positive cell counts for α-SMA, SMemb, and vimentin for all groups of mitral 
valves were analysed using GraphPad Prism® . Data were expressed as mean ± 
standard deviation of the mean. Inferential statistical analysis involved one-way 
analysis of variance testing with a p-value of <0.05. Where ANOVA detected 
significant difference, inter-group differences were compared using the post-hoc 
Tukey Simultaneous test. Due to small sample size (n= 4 to 6) in this study, 
normality testing was not performed and non-parametric testing was not considered 





2.3.1 Gross histology 
Gross and histological changes in myxomatous mitral valves from CKCS and non-
CKCS were not appreciably different, and not dissimilar to previous reports (Figure 
2-1). In general, there was marked thickening at the valve tip in both CKCSs and 
non-CKCSs. In the myxomatous nodular lesion sites, there was higher cellularity at 
the periphery than in the centre. Intact fibrosa layer with dense collagen bundle was 
seen in the mid portion in both MVs (Figure 2-1). Chordae tendineae attachments 





Figure 2-1 H&E staining of myxomatous mitral valve from (A) a CKCS (B) a non-CKCS dog, 
and (C) a normal mitral valve from a Beagle. Note at the valve tip (black arrow), loss of distinct 
laminated structures was found on both myxomatous mitral valves, and it is featured by 
thickening and nodular changes at the valve edge. Hollow arrow indicates chordae tendineae. A, 





2.3.2 Cellular changes in myxomatous mitral valve disease 
Similar changes in the distribution of immunoreactive cells were noted for 
longitudinal and horizontal sections.  
 
Figure 2-2 Photomicrograph immunostaining for (A)(B)α-SMA, (C)(D) SMemb, and (E)(F) 
vimentin of myxomatous mitral valve tip from  (A)(C)(E) CKCS and (B)(D)(F) non-CKCS. Tip 
of the leaflet. Scale bar = 50µm. 
In the normal mitral valves, most cells were vimentin positive and evenly distributed, 




were also evenly distributed but the highest density was adjacent to the endothelial 
layer (Figure 2-2). In the diseased and normal mitral valves, the endothelial cells at 
atrialis and ventricularis sides of the leaflet were both vimentin positive. 
No cell staining was observed in any valve for the inflammatory cell markers CD11c 





Figure 2-3 Positive staining control for (A) CD45 and (B) CD11c. Canine cortex of pre-scapular 
lymph node. Scale bar = 25µm.  
In normal mitral valves, very few α-SMA or SMemb positive cells were seen and 
these were typically located adjacent to the endothelium in the mid zone. In diseased 




clustering mostly at the free edge with a few cells present in the valve stroma. 
SMemb positive cells were also found clustering around the myxomatous areas and 
close to the free edge, but there was positive staining throughout the leaflet depth. 
There were no clear differences comparing CKCS and the non-CKCS (Figure 2-4). 
In addition, both SMemb positive cells and α-SMA positive cells were observed in 
the spongiosa in the diseased mitral valves, and a spindle-shaped, elongated cell 





Figure 2-4 Immunostaining for (A) α-SMA and (B) SMemb. Mid-portion of canine myxomatous 










Figure 2-5 Photomicrograph for (A) continual and (B) interrupted expression of vWF staining. 
Canine myxomatous mitral valves. Scale bar = 50µm. Arrows show mild staining of interstitial 
cells in myxomatous region (A) and spongiosa (B).  
vWF positive endothelial cells were found along the whole leaflet length, but with 
areas of discontinuity in the diseased dogs (Figure 2-5). A consistent finding in both 
diseased groups (5/6 CKCS; 6/6 non-CKCS) was clusters of vWF-positive cells in 
the myxomatous sites away from the valve edge (Figure 2-6). In addition, mild vWF 
positive staining was also present in the interstitial cells in the spongiosa layer. 
Polymorphism and denudation of the endothelium was also noted in the diseased 








Figure 2-6 Photomicrography of vWF immunostaining. (A) Clusters of spindle-shaped 
interstitial cells were positive for vWF. Scale bar = 50µm. (B) Polymorphism of endothelial cells 
with evidence of endothelial denudation. Canine myxomatous mitral valve (CKCS). Scale bar = 
25µm. 
No CD31 positive cells were seen in any sample examined. (Note: identifying CD31 
positive cells in any canine paraformaldehyde fixed tissues has not been possible, but 











Figure 2-7 Photomicrograph of Ki-67 immunostaining. Canine (CKCS) myxomatous mitral 
valves. Scale bar = 50µm (A)(B), and 25 µm (C). (A) Hyperplastic endothelium at the valve tip 
showed Ki-67 reactivity, and this pattern is similar to staining pattern of α-SMA and SMemb. 
(B) Clusters of Ki-67 positive interstitial cells in the overtly myxomatous lesion site. (C) 






In normal mitral valve, Ki-67 staining was mild and negligible (non-specific 
staining). Ki-67 positive cells formed linear clusters typically at the leaflet tip, but 
also were distributed sparsely throughout the myxomatous valves of both groups 
(Figure 2-7). This patchy distribution was similar to that seen for α-SMA and 
SMemb positive cells (linear clusters under endothelium). Ki-67 positive staining 
was also found occasionally in small clusters in the overtly myxomatous region. In 
affected valves, flattened elongated cells at the valve surface (presumed to be VECs) 
also showed positive staining for Ki-67 (Figure 2-7).  
2.3.3 Immunofluorescence; Qualitative and Quantitative Analysis  
In myxomatous mitral valves from both CKCS and non-CKCS, linear clusters of α-
SMA positive cells were discovered at the myxomatous valve tip under endothelium, 
and the majority of these cells were elongated, spindle-shaped (Figure 2-8A). 
Similarly, SMemb positive cells appeared to be clustered linearly at the myxomatous 
valve tip, and the morphology was spindle-shaped. However, round-shaped SMemb 
positive cells were occasionally seen under the endothelium (Figure 2-8B). The 
staining of vimentin was generalized and vimentin was expressed by almost all cells 
in the mitral valve. In myxomatous mitral valve, higher cellularity with 
polymorphism was noted at the endothelium, whereas in the stroma most valve cells 
were elongated and spindle-shaped (Figure 2-8C). Co-expression of  SMemb and α-













Figure 2-8 Photomicrograph for (A) α-SMA in green, (B) SMemb in red, and (C) vimentin in 
green immunostaining. Canine (CKCS) myxomatous mitral valve (tip). In B, the white arrow 













Figure 2-9 Photomicrograph for double immunofluorescence staining of α-SMA and SMemb. 







While the pattern of staining for α-SMA and SMemb at the valve edge was similar in 
both affected groups, only a few of those cells co-expressed both antigens (Figure 
2-9). In overtly myxomatous areas, the overall pattern of cellular staining (indirect 
immunofluorescence) for α-SMA and SMemb was similar in the CKCS and non-
CKCS, and was in agreement with staining pattern using the peroxidase method. 
The total cell counts for α-SMA, SMemb, and vimentin of CKCS, non-CKCS, and 
normal control (section 2.2.4) are summarized in Table 2-2. The total number of cells 
positive for α-SMA was significantly increased in the CKCS group and non-CKCS 
group compared to normal (CKCS vs control, p=0.0052; non-CKCS vs control, 
p=0.0005), and there was no difference between CKCS and non-CKCS (p=0.5376). 
SMemb positive cells were significantly increased in the two diseased groups 
compared to normal (CKCS vs control, p=0.0126; non-CKCS vs control, p=0.0012), 
and there was no difference between CKCS and non-CKCS. Vimentin positive cells 
made up the largest number in all groups of valves, and cell numbers in both 
diseased valves approached twice that seen in normal valves (Figure 2-10). However, 
statistically there was no difference between any of the groups sampled (CKCS vs 
control, p=0.4669; non-CKCS vs control, p=0.2265; CKCS vs non-CKCS, 
p=0.7612).  
Table 2-2 Quantification of positive staining cells for α-SMA, SMemb, and vimentin in the 
diseased mitral valves from CKCS, Non-CKCS, and the normal mitral valves. 
 α-SMA SMemb Vimentin 
CKCS (n=6) 33.95 ± 12.13 23.13 ± 5.72 40.52 ± 18.41 
Non-CKCS (n=6) 25.70 ± 2.67 29.55 ± 3.06 46.95 ± 17.65 
Control (n=4) 10.75 ± 2.95 14.53 ± 3.96 26.75 ± 7.24 





Figure 2-10 Total positive cell counts for α-SMA, SMemb, and vimentin. The data is presented 





The CKCS breed predisposition to MMVD is well recognised and heritability has a 
role in disease appearance and progression. 18,20 Certain CKCS-specific traits are 
associated with MMVD, and it is not known if this may result in a disease phenotype 
and pathology different to that seen in other dogs. 21,23–25,27 By assessing for a range 
of markers for inflammation, proliferation and mesenchymal cell phenotypic 
differentiation no evidence was found that cell changes in the CKCS valve are 
fundamentally different to that seen in other dogs.  
There was no evidence of inflammatory cells in any of the samples examined and 
this is in agreement with the only other report. 104 Small numbers of macrophages 
and mast cells have been previously found in MMVD valves and there was an 




106, but there still is no clear evidence that inflammation has an important role in the 
aetio-pathogenesis of this disease. 52,106 
Aggregation of activated α-SMA positive valve interstitial cells in canine MMVD is 
well recognised, particularly in the distal portion of the valve and close to the valve 
edge, and this was again noted in the present study in all affected dogs. 52,104 
Increased α-SMA positive cells numbers were seen in the two affected groups. In 
MMVD, the increased expression of α-SMA by valve interstitial cells may be a 
compensation to maintain mitral valve stiffness secondary to mitral valve 
incompetence. 101,107 SMemb is expressed in synthetic phenotypes of mesenchymal 
cells, or myofibroblasts, and myofibroblasts play multiple physiological roles in 
heart development and tissue repair (myocardial infarction). 80,108,109 Increased 
SMemb positive cell numbers have also been previously reported and were found 
again to be increased in this study. 104 An association between SMemb positive 
interstitial cells, tryptophan hydroxylase 1 (TPH1) expression and serotonin 
synthesis has also been reported in MMVD 38 Pleomorphism of myofibroblasts 
positive for SMemb was noted in the current study and this might imply 
heterogeneity of the myofibroblast population. Using vimentin as a general 
mesenchymal cell marker, total cell numbers in the two affected groups were similar. 
However, it should be noted the normal valves were not age-matched and increased 
cell numbers associated with aging cannot be discounted. The lack of age-matched 
normal controls is a study limitation, but finding normal mitral valves in aged dogs is 
not readily achievable. 
While vimentin expression is widespread in many cell types, interstitial cells 
expressing vimentin are generally considered to be a quiescent phenotype form of 
VIC in the normal mitral valve. 52,104 In the diseased valve cells retaining vimentin 
expression and/or not expressing the two activation markers (α-SMA and SMemb) 
may represent an expanded population available for phenotypic alteration in response 
to appropriate triggers, such as TGF-β and serotonin. There was localized expression 
of the cell proliferation marker Ki-67 in the MMVD valves and this was most 
noticeable where there was the largest number of α-SMA positive cells close to the 




minimal expression in diseased valves. 104 This contradictory finding may reflect the 
heterogeneous pathology of MMVD or could be a temporal effect. For example, in a 
valve injury model myofibroblast proliferation peaked at the 4th day post injury. 
110,111  
The co-expression of α-SMA and SMemb in a small number of cells close to the 
valve edge identifies a population that has greater differentiation potential than those 
expressing α-SMA or SMemb alone, and such cells are believed to have greater 
phenotypic differentiation capability in response to injury. 108 In the case of MMVD, 
a similar capacity for phenotypic versatility might exist where endothelial damage 
has occurred. 
Von Willebrand factor expression demonstrated the presence of the endothelium in 
all valves and the loss of endothelial cells along some sections of affected valve 
edges. Endothelial damage and denuding is now recognised to be a cardinal feature 
of MMVD, and might be a major triggering event driving the phenotypic changes 
seen with VICs and proliferation of aVICs close to the valve edge. 21,49,57 Recently, 
one study found that the secretion of haemostatic proteins such as vWF, tissue 
plasminogen activator (tPA), and tissue factor pathway inhibitor by aortic valve 
endothelial cells is age-dependent. 112 The localised expression of vWF in cells 
within the stroma of the diseased valves was an unexpected finding. Possible  
explanations might be migration of endothelial cells or the presence of  
mesenchymal-endothelial transition (MEndoT) of stromal VICs. This finding needs 
to be investigated further as it might also due to extravasation. Successful staining 
for CD31 would have been helpful in clarifying the cell identity as endothelial. 
In conclusion, this study confirms that there is no evidence for inflammatory cell 
involvement in canine MMVD, that the cell changes are not different for CKCS 
compared with other dogs and that the changes in cell numbers in MMVD are due to 
cell proliferation. This study further suggests MMVD is not a heterogeneous disease 
(detailed assessment of pathology and ECM changes is still required) and the CKCS 
form of the disease differs only in its time of onset and speed of progression. It is this 
temporal presentation that is likely to be the inherited feature of MMVD in the 




Table 2-3 Summary of IHC findings 
Markers 
Myxomatous Mitral Valves Normal Mitral 
Valves CKCS Non-CKCS 
CD11c No staining No staining No staining 


















Small numbers of 
positive cells found at 
atrialis and spongiosa 
in middle portion 
SMemb* 








Similar to α-SMA and 
no change (vs MMVD) 
Vimentin* 
Diffuse but no 
change (vs normal) 
Diffuse but no 
change (vs normal) 




at myxomatous area 
and in EC 
Spindle-shaped cells 
at myxomatous area 
and in EC 
Negligible 





3 Chapter 3 Transcriptional Profile of Canine Myxomatous 
Mitral Valves 
3.1 Introduction 
Transcriptomics is the study of overall ribonucleic acid (RNA) such as messenger 
RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) transcribed from the 
genome in a single cell or from a heterogeneous population of cells in a certain organ 
or tissue at a specific time point. By studying the transcriptome, it not only helps us 
to understand the relationship between gene activities within the functional cells, but 
also provides insight into the transcriptional regulation of diseases. Proteomics is the 
quantitative study of the set of proteins and their diversity. However, proteins are 
technically challenging to characterise because, for example, they have post-
translational modifications and may interact with other molecules. 113 Measuring the 
intermediate step between genes and proteins, that is the expression of transcripts of 
mRNA, helps connecting the gap between genome and functional molecules.  
Microarrays have been reliably utilized for many kinds of studies due to the their 
cost-effectiveness and the ability to screen and compare more than 20,000 transcripts 
at once. The only genomic study of canine MMVD to date used the Affymetrix 
Canine Gene 1.0 array covering approximately 23,000 gene transcripts, but did not 
include transcripts for microRNAs (miRNAs). 106 This study only compared mixed 
breed dogs. Since that study there have been significant advances in the quality of 
canine gene microarrays (Affymetrix Canine Gene 1.0 ST Array based on Genome 
database CanFam2.0) with much improved transcript annotation (27,681 genes), 
transcript sensitivity (590,097 probes, 24 probes/gene) and bioinformatics. The study 
by Oyama et al in 2006 106 identified only 229 probe sets that were differentially 
expressed in MMVD compared to normal valves (at least 2-fold change; 70% up-
regulated and 30% down-regulated) of which 166 could be assigned to recognised 
genes. The main functional classes attributed to the affected genes, in descending 
order, included cell signalling, metabolism extracellular matrix, inflammation, cell 
defence, immunity, cell transport and cell structure. 106 Of particular note was the ~4-




which fits in with the serotonin hypothesis of MMVD pathogenesis. 34,106 Limited 
numbers of studies of gene expression have also been undertaken in human MMVD 
with the number of differentially expressed genes reported varying between 400 and 
2000 114,115. One study demonstrated changes in metallothioneins and ADAMTS (a 
disintegrin and metalloproteinase with thrombospondin motifs) genes, processes that 
are implicated in extracellular matrix remodelling. 115 The other study found higher 
expression for bone morphogenic protein 4 (BMP-4, TGF-β superfamily), 
proteoglycans (bigylcan, decorin, lumican, and versican), collagens (collagen I, and 
collagen III), and chondrogenic associated transcripts such as Sox-9, CRTAC1 
(cartilage acidic protein). 114 However, the number of reported differentially 
expressed genes in any transcriptomic study is markedly affected by the corrected 
Benjamini-Hochberg false discovery rates (FDR) 116,117, fold change thresholds 
(correction for signal intensity) and batch effects. Although a single snap-shot of the 
genomic expression will not reflect the whole dynamic remodelling process and 
cellular events during the myxomatous degeneration, transcriptomic profiling 
remains a useful tool to identify key genes regulating MMVD pathogenesis.  
The aim of this study, therefore, was to use more stringent threshold criteria and 
quality control, than used in previous studies, in line with current recommended 
protocols and with the affected group all from the same breed (cavalier King Charles 
spaniel) to identify gene regulation in canine MMVD. While this study would give 
information on changes in the entire transcriptome, a particular aim was to 
investigate the possible changes in expression of genes typically associated with 
developmental pathways, valvulogenesis and endothelial-to-mesenchymal transition. 
3.2 Material and Methods 
3.2.1 Tissue Sample 
Myxomatous mitral valve anterior leaflets (n=10, Whitney grade ≥ 3) from CKCS 
were either collected by the author from CKCS presenting to the Hospital for Small 
Animals, Royal (Dick) School of Veterinary Study, the University of Edinburgh, or 
received from pathology units from the Queen’s Veterinary Hospital, Cambridge 
Veterinary School, University of Cambridge, and The Veterinary Teaching Hospital, 




tissue collection scheme. All dogs previously had been clinically confirmed to have 
MMVD and were on a range of treatments for congestive heart failure. Control 
normal anterior mitral valve leaflets (n=6) were collected from young adult dogs 
(beagles) euthanized for reasons other than cardiac disease. Based on the same 
protocol, all samples were collected within 10 minutes of death and classified by two 
investigators according to Whitney’s MMVD grading system. 6 After removal of the 
heart and flushing with cold PBS (phosphate-buffered saline), the mitral valve 
leaflets were exposed by opening from the left atrium and ventricle through the 
lateral wall between the two papillary muscles. The mitral valve leaflets were 
examined for MMVD lesions and photographed. The whole mitral valve leaflets then 
were surgically dissected from the annulus and papillary muscles, and immediately 
immersed in RNAlater (Invitrogen). After overnight incubation at 4 ˚C, samples were 
transferred to -20˚C freezer for long-term storage. All tissue samples were collected 
with full owner consent and the study conformed to national (UK) and institutional 
ethical guidelines for the use of animals in research. 
3.2.2 RNA Extraction 
Mitral valve leaflets in RNAlater tubes were taken from -20˚C freezer and thawed on 
ice. The dis-membranator equipment (ball, lid, and flask) was submerged in liquid 
nitrogen for a few minutes. Mitral valve anterior leaflets were weighed and minced 
with a sterile scaple blade. A hundred mg of tissue was then gathered in an eppendorf 
tube and snap-frozen in liquid nitrogen. Shortly after removing the dis-membranator 
from  liquid nitrogen, snap-frozen tissues and 500 µl of phenol/guanidine HCl 
reagents (TriReagent, Sigma) and the ball were transferred to the flask, the lid closed 
and tightly screwed into the dis-membranator. (Braun Mikro Dis-membranator 
Vessel, Braun Biotech International, Melsungen, Germany). Next, speed of the 
machine was set at 30 m/s, and the duration of vibration was 90 seconds. After 
pulverising, tissue-TriReagent powdered samples were scraped into an Eppendorf 
tube containing 0.5 ml of TriReagent (1ml/100mg tissue weight) and mixed 
thoroughly, left to stand for 45 minute at room temperature and spun  at 12,000 rpm 
(in a microfuge) for 10 minutes at 4˚C. The supernatant was carefully transferred into 
another clean tube. and the cell and matrix debris were discarded. 200 µl of 




was left at room temperature for 10 minutes then spun at 12,000 rpm at 4˚C for 15 
minutes. The supernatant was again transferred to another clean tube and 400µl of 
70% ethanol was added in with gentle pipetting to mix with the RNA sample. RNA 
extraction, purification and DNA digestions were carried out using commercially 
available kits (RNeasy Mini Kit & RNase-Free DNase Set Qiagen). Detailed 
protocols for the column-based RNA extraction and DNA digestion can be found in 
the manufacturer manual. Final elution was completed by adding 30µl of RNase-free 
water. The RNA samples were stored at -80°C prior to reverse transcription. 
3.2.3 RNA Quality Assessment 
The RNA sample purity and quantity was analysed by spectrophotometery (Thermo 
Scientific NanoDrop™ 1000). 1µl of each sample was pipetted onto the pedestal and 
the ratio of absorbance at 260 nm and 280 nm (260/280, pure RNA = 2.0) was used 
to assessed the purity of RNA. The ratio of 260 nm and 230 nm (260/230, normal 
range 2.0-2.2) was used for secondary assessment of RNA purity. 118 
For final standardization of RNA quality, the sample RNA quantity and integrity 
were further characterized by using Agilent 2100 Bio-analyser and RNA 6000 
LabChip. Degradation of total RNA, mRNA and ribosomal RNA contamination 
could be identified by electropherogram, electrophoretic trace of the RNA sample, 
and the given RNA integrity number (RIN). RIN ≥ 7 was considered acceptable for 
further analysis. 119 
3.2.4 Microarray Analysis 
The two cycle RNA-cDNA amplification, hybridization, and chip scanning were 
undertaken by ARK-Genomics (Roslin Institute, UK). Affymetrix Gene Chip WT 
Terminal Labelling Kit, combined with Ambion WT Expression Kit, was used to 
generate amplified and biotinylated sense-strand DNA targets for the Affymetrix 
Canine Gene 1.0 ST Array.  
Differential gene expression analysis and signal intensity profile for each array were 
also performed by ARK-Genomics (Roslin Institute, UK). First, all the raw 
Affymetrix CEL files representing each array were imported into Partek Genomic 
Suite 6.6 (PGS). In the PGS post-hybridization quality control was conducted by 




were produced for general array expression patterns. The volcano plot and the heat 
map were also generated by PGS. Robust Multi-array Average (RMA) was used for 
data normalization and final summarization. 120 The ANOVA was used to identify 
differentially expressed genes between the two groups. To determine the 
differentially expressed genes, p < 0.05 with Benjamini-Hochberg false-discovery 
correction and at least a 1.5 fold change in expression were used. 117 Normalized 
signal intensity data for whole probe sets and attributed transcripts were produced by 
Affymetrix Expression Console. Seasonal annotation-updates for canine transcripts 
were released from Affymetrix, and were also applied to the data set to synchronize 
with the latest online database.  
The initial differentially expressed gene list produced by ARK-Genomics was further 
filtered by an signal intensity stringency filter as following: 
1. Signal Intensity ≥ 1000, fold change ≥ 1.5 or ≤ -1.5 
2. Signal intensity between 1000 and 500, fold change ≥ 2.5 or ≤ -2.5 
3. Signal intensity ≤ 500, fold change ≥ 3.5 or ≤ -3.5 
4. Remove transcripts without annotation, non-protein coding RNA 
 
3.2.5 Multi-platform Data Mining 
ToppFun. ToppFun is web-based gene list enrichment tool for transcriptome, 
ontology, phenotype, proteome using ToppGene Suite. The IDs of differentially 
expressed genes without fold-change values were uploaded to the platform followed 
by manually modifying the unmatched gene ID The statistical correction used the 
Bonferroni method with the cutoff set to be p = 0.05. The submitted gene lists were 
analysed and the associated results assigned to different categories: GO (gene 
ontology): molecular function, GO: biological process, GO: cellular component, 
human phenotype, mouse phenotype, pathway, microRNA, drug, and disease. 121 
DAVID. The database for annotation, visualization and integrated discovery 
(DAVID 6.7) was another gene network analysis tool used to identify gene 
connections. Finalized gene lists were submitted to the DAVID web-based 
bioinformatics resources for function annotation analysis. Candidate genes were 




database. Functional annotation clustering analysis was conducted at “high” 
classification stringency with cutoff set for enrichment score (no less than 1.5) and p-
value (p > 0.05). 122 
IPA. Pathway analysis was undertaken using the Ingenuity Pathways Analysis (IPA, 
Qiagen) database by uploading the differentially expressed gene list (finalized gene 
list including transcript ID, fold-change, and p-value) to the online server. Core 
analysis was performed at the default settings, and this included canonical pathways, 
disease and biological functions, gene networking, up-stream analysis and toxicity. 
Functional analysis of a network identified the biological functions that were most 
attributable to the genes in the network. 
BioLayout Express3D. Network analysis and visualization was conducted using 
BioLayout Express3D version 3.3. Briefly, signal intensity value (≥ 100) for all 
probes for all samples were formatted in an excel file following the software manual 
instructions. 123 The network graph was then illustrated using a correlation threshold 
of r ≥ 0.94. Markov clustering algorithm (MCL) analysis was conducted at an 
inflation value 1.6 (controlling granularity of clustering) according to 
recommendations. 123 Clustered genes were analysed using the ToppFun as described 
previously. 
3.3 Results 
3.3.1 RNA Quality Assessment 
Using the standardized RNA extraction technique and the final elution volume (30 
µl), the yield of RNA from mitral valve leaflets was variable (303.23 ± 127.21 ng/ 
µl). The highest RNA concentration was 541.6 ng/µl and the lowest was 78.5 ng/µl. 
The values for absorbance of 260/280 were between 1.99 and 2.10 (2.046 ± 0.031, 
pure RNA ≈ 2). Another indicator for RNA purity was 260/230 absorbance, and the 
values were generally consistent and acceptable except 5 samples, 811M_003, 
811m_006, 811M_010, 811M_011, and 811M_012 that were far below the reference 





Table 3-1 Summary of RNA assessment for 10 diseased (CKCS) and 6 control mitral valves. 




260/280 260/230 RIN 
811M_001 Cam CKCS 325 28 2.04 2.15 5.00 
811M_002 Han CKCS 461.5 28 2.01 2.01 5.50 
811M_003 Dublin CKCS 78.5 28 1.99 1.56 6.30 
811M_004 Dublin R CKCS 407.6 28 2.00 1.98 6.00 
811M_005 Shay 
(MMVD005) 
CKCS 349 28 2.05 2.01 7.30 
811M_006 Cam R CKCS 122.8 28 2.03 1.76 4.10 
811M_007 Dublin R CKCS 541.6 28 2.10 1.99 6.60 
811M_008 Han R CKCS 431.1 28 2.01 1.98 6.20 
811M_010 Control05 Beagle 275.5 28 2.04 1.42 7.20 
811M_011 Control02 Beagle 338.8 28 2.05 1.68 8.50 
811M_012 Control06 Beagle 112.7 28 2.08 1.00 7.00 
811M_013 Control03 Beagle 304.1 28 2.05 2.11 6.70 
811M_014 Control04 Beagle 449.4 28 2.02 2.07 7.80 
811M_015 Control01 Beagle 420.3 28 2.02 2.09 7.60 
811M_016 Bonnie 
(MMVD016) 
CKCS 265.7 28 2.07 2.18 7.60 
811M_017 Cinders CKCS 192.3 28 2.06 2.13 6.90 
811M_018 Emily CKCS 129.5 28 2.08 2.15 6.40 
811M_019 Joe 
(MMVD019) 
CKCS 465.7 28 2.01 2.19 8.10 
811M_020 Cinders R CKCS 247.1 28 2.08 2.21 6.40 
811M_021 Emily R CKCS 140.5 28 2.10 2.12 5.70 
811M_022 Eric CKCS 260.5 28 2.08 2.16 7.10 
811M_023 Eric R CKCS 351.6 28 2.06 2.04 6.80 
811M_024 Tom 
(MMVD024) 
CKCS 303.5 28 2.05 2.16 7.80 










From the electrophoresis studies of RNA samples, 18S and 28S ribosomal RNA 
could be identified as the thickest bands at 2000 and 4000 nucleotides (nt) 
respectively, and there were variable degrees of mRNA degradation in 6 of 23 
samples (smearing below 2000 nt), and poor integrity in 7 of 23 samples (multiple 
bands) (Figure 3-1).  
 
 
Figure 3-1 Electrophoresis of RNA samples. C (control) and D (diseased) RNA samples were 
selected for the microarray hybridization and labelling. F (failed RIN test) were excluded, and 
blanks were borderline. 
Electrophoresis and associated fluorescence signals were captured and transformed 
into electropherogram. Based on the electropherogram the RIN (RNA integrity 
index) was determined by the Bioanalyser (Figure 3-1). Only 10 samples passed the 
RIN cutoff (RIN ≥ 7) and one sample was borderline (RIN = 6.9). The remaining 5 
valve samples failed to pass the pre-hybridization quality control (Figure 3-2), after 









811M_001, RIN = 5.00 
 
811M_002, RIN = 5.50 
 
811M_003, RIN = 6.30 
 
811M_004, RIN = 6.00 
 
811M_005, RIN = 7.30 
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811M_024, RIN = 7.80 
 
 
Figure 3-2 RNA integrity numbers (RIN) for pre-hybridization quality assessment. 
By evaluating the spectrophotometer measurements (260/280), RNA electrophoresis 
(visual representation), and electropherogram (RIN), a final four samples for each 




811M_010, 811M_011, 811M_014, 811M_015) were selected for transcriptomic 
analysis. The details of the 8 samples can be found in Table 3-2. 
 
Table 3-2 Details of final RNA samples for the diseased and the control group. 









MMVD        
811M_005 Shay 11Y4M 4/6 Male 3/4 7.3 2.05 
811M_016 Bonnie 12Y 4/6 Female 4/4 7.6 2.07 
811M_019 Joe 11Y 6/6 Male 3/4 8.1 2.01 
811M_024 Tom 12Y 3/6 Male 3/4 7.8 2.05 
Control       
811M_010 Control05 1Y 0/6 Female 0/4 7.2 2.04 
811M_011 Control02 1Y 0/6 Female 0/4 8.5 2.05 
811M_014 Control04 1Y 0/6 Male 0/4 7.8 2.02 
811M_015 Control01 1Y 0/6 Male 0/4 7.6 2.05 
Y, year; M, month. 
3.3.2 Overview of Microarray Data 
Post-hybridization Quality Control 
A PCA plot was produced for general array expression pattern and quality control 
(QC). Two major clusters representing diseased and control groups were identified, 
and one outlier within each group (811M_005 and 811M_011) was also noted 
(Figure 3-3A). The histogram plots of arrays showed the signal intensity distribution 
of each sample and  the same samples in each group were again found to have a 
different distribution pattern and were confirmed as outliers (Figure 3-3B). The rest 
of the lines followed the same pattern indicating that there is no distributional 
difference in probe signal intensity. There was another signal intensity plot for 
Affymetrix internal control probe-sets. This graph gave quality control information 
from control and experimental probes on the Affymetrix chips. One sample showed 
abnormally signal intensity (Figure 3-3C). Together with all the evidence, post-
hybridization QC provided confidence in the quality of the microarray data and 





A  B  
C  
Figure 3-3 Post-hybridization QC (A) PCA plot, (B) Signal intensity plot for internal control. X-
axis = intensity of the probes, Y-axis = frequency of the probe intensity (C) Histogram plot with 
summarized intensity value of Affymetrix control probe-sets. Arrows in each figure indicate the 
outliers. 
Differentially Expressed Gene List 
With inclusion of the two outliers, differential expression analysis was examined 
using One-way ANOVA comparing the 4 diseased CKCS and 4 control samples. 
This only identified 18 differentially expressed genes (p-value p < 0.05, FDR <0.05, 
and fold change ≥ 1.5 or ≤ -1.5). Excluding the two outliers, 5397 transcripts were 
identified to be differentially expressed passing the following cut-off: fold-change 
(>1.5 or <-1.5), false discovery rate (FDR, <0.05), and p-value (<0.05). A volcano 




vertical (fold-change value at 1.5 and -1.5) and one horizontal (p-value = 0.05) cut-
off lines were also applied to the plot. In general, the plot was equally distributed, but 
the significantly down-regulated genes in zone 3 were more diffusely distributed 
compared with the significantly up-regulated genes in zone 4. In zone 1 and 2, the 
majority of the genes were unchanged. A heat map of the differentially expressed 
genes (excluding outliers) was also generated, and there were two clusters of up- 
(red) and down-regulated (blue) genes in each group (Figure 3-4). 
 
Figure 3-4 Volcano plot (section 3.2.4). Every dot represents one gene. The X-axis is the fold-






Figure 3-5 Heat map (section 3.2.4) of the microarray excluding two outlier samples from 
MMVD and control groups. The vertical axis represent 6 different samples (green, CKCS; 
orange, controls). The bar in red represents up- (red) and down-regulation (blue) in fold-
change. 
In 5397 differentially expressed transcripts, 4002 were annotated, whereas 1395 
probes were not assigned to a specific transcript in the Affymetrix canine database . 
For these unknown transcripts sequences were downloaded in a batch from the 
Affymetrix website and matched with the public genomic information by NCBI 
nucleotide BLAST and miRBase BLAST. 124 Sequences were considered matched 
with the transcript only if the E-score was ≤ 1x10-20. 106 After pairing, only 139 
additional probes were successfully identified as transcript homologs to other 
species, canine microRNAs or a duplicate or triplicate of already annotated 
transcripts (Table 3-3). Within 139 manually annotated transcripts, 59 were matched 
with Canis familiaris microRNA family (cfa-miRNA) (see Chapter 6). 
The gene list (including manually annotated genes) was further narrowed down to 




value and exclusion of microRNAs (described in 3.2.4). Within the finalized gene 
list, 322 genes were up-regulated and 269 genes were down-regulated in the diseased 
group compared with the normal control group. The complete list of differentially 
expressed genes can be found in the appendix 9.1 and 9.2.  
 
Table 3-3 Summary of identified differentially expressed transcripts 
Differential expressed Genes 5,397 
     Annotated transcripts 4,002 
     Uncharacterized, or non-coding 1,395 
Manual pairing 139 
     Transcripts in other species 80 
     miRNAs 59 
Finalized by signal intensity cutoff 591 
     Up-regulated 322 






The list of 591 genes was uploaded to the ToppFun in ToppGene Suite, and 571 of 
591 genes were identified with the HGNC symbol and synonyms. After gene list 
enrichment, 28 significant terms for gene ontology (GO) biological process (BP) 
were derived. The top ten most significant GO: BP terms were inflammatory 
response, response to wounding, biological adhesion, cell adhesion, positive 
regulation of cellular component movement, positive regulation of cell migration, 
positive regulation of cell motility, positive regulation of immune system process, 
blood vessel morphogenesis, and positive regulation of locomotion (Figure 3-6). 
“Positive regulation” in GO terms means the overall biological function is likely to 
be active compared to the control group. 
The GO terms were further categorized into six functional sub-groups: inflammation 
and immune response, cellular adhesion and movement, cardiovascular development, 
extracellular matrix, osteogenesis, and epithelial cell proliferation (Table 3-4) based 
on the biological functions of each gene ontology terms. In addition, there were three 
major clusters of GO: BP terms according to the p-value classification (p < 0.005, 
0.005 < p < 0.03, and 0.03 < p < 0.05) (Table 3-5). The most significant GO: BP 
terms in the first group (p < 0.005) were associated with injury (inflammatory 
response, response to wounding), cell movement, and vasculature development. 
 





Table 3-4 Gene ontology terms for biological process 
Name Term p-value Count in term 
Inflammation and immune response   
GO:0006954 Inflammatory response 3.17E-05 45 566 
GO:0009611 Response to wounding 4.04E-05 74 1202 
GO:0002684 Positive regulation of immune system process 2.31E-03 47 699 
GO:0001775 Cell activation 1.41E-02 52 861 
GO:0006955 Immune response 1.75E-02 72 1353 
GO:0050867 Positive regulation of cell activation 3.89E-02 23 264 
GO:0002687 Positive regulation of leukocyte migration 4.24E-02 12 83 
GO:0045321 Leukocyte activation 4.47E-02 41 642 
Cellular adhesion and movement    
GO:0022610 Biological adhesion 5.73E-05 66 1028 
GO:0007155 Cell adhesion 1.11E-04 65 1023 
GO:0051272 Positive regulation of cellular component 
movement 
1.01E-03 28 300 
GO:0030335 Positive regulation of cell migration 1.42E-03 27 287 
GO:2000147 Positive regulation of cell motility 2.00E-03 27 292 
GO:0051270 Regulation of cellular component movement 5.10E-03 41 588 
GO:0030334 Regulation of cell migration 2.15E-02 35 493 
GO:2000145 Regulation of cell motility 2.88E-02 36 521 
Cardiovascular development    
GO:0048514 Blood vessel morphogenesis 2.90E-03 37 492 
GO:0040017 Positive regulation of locomotion 3.88E-03 27 302 
GO:0001944 Vasculature development 4.48E-03 41 585 
GO:0072358 Cardiovascular system development 1.96E-02 52 871 
GO:0072359 Circulatory system development 1.96E-02 52 871 
GO:0001568 Blood vessel development 2.32E-02 38 559 
GO:0003013 Circulatory system process 3.68E-02 31 421 
GO:0001525 Angiogenesis 4.37E-02 30 404 
Extracellular matrix    
GO:0030198 Extracellular matrix organization 2.11E-02 27 330 
GO:0043062 Extracellular structure organization 2.23E-02 27 331 
Osteogenesis    
GO:0001503 Ossification 3.59E-02 26 320 
Epithelial proliferation    







Table 3-5 Three major clusters of GO: terms identified based on p-value 
GO: BP Terms p-value 
p < 0.005   
GO:0006954 Inflammatory response 3.17E-05 
GO:0009611 Response to wounding 4.04E-05 
GO:0022610 Biological adhesion 5.73E-05 
GO:0007155 Cell adhesion 1.11E-04 
GO:0051272 Positive regulation of cellular component movement 1.01E-03 
GO:0030335 Positive regulation of cell migration 1.42E-03 
GO:2000147 Positive regulation of cell motility 2.00E-03 
GO:0002684 Positive regulation of immune system process 2.31E-03 
GO:0048514 Blood vessel morphogenesis 2.90E-03 
GO:0040017 Positive regulation of locomotion 3.88E-03 
GO:0001944 Vasculature development 4.48E-03 
0.005 < p < 0.03   
GO:0051270 Regulation of cellular component movement 5.10E-03 
GO:0001775 Cell activation 1.41E-02 
GO:0006955 Immune response 1.75E-02 
GO:0072358 Cardiovascular system development 1.96E-02 
GO:0072359 Circulatory system development 1.96E-02 
GO:0030198 Extracellular matrix organization 2.11E-02 
GO:0030334 Regulation of cell migration 2.15E-02 
GO:0043062 Extracellular structure organization 2.23E-02 
GO:0001568 Blood vessel development 2.32E-02 
GO:2000145 Regulation of cell motility 2.88E-02 
0.03 < p < 0.05   
GO:0001503 Ossification 3.59E-02 
GO:0003013 Circulatory system process 3.68E-02 
GO:0050678 Regulation of epithelial cell proliferation 3.78E-02 
GO:0050867 Positive regulation of cell activation 3.89E-02 
GO:0002687 Positive regulation of leukocyte migration 4.24E-02 
GO:0001525 Angiogenesis 4.37E-02 





GO:BP terms relating to endothelial function, developmental pathways and basic 
mitral valve biology included response to wounding, biological adhesion, positive 
regulation of cell migration, cardiovascular system development, extracellular matrix 
organisation, ossification, and regulation of epithelial cell proliferation. Genes 
associated with these terms are listed in the following tables. In each sub-group, GO: 
BP terms selected were response to wounding, biological adhesion, positive 
regulation of cell migration, cardiovascular system development, extracellular matrix 
organization, ossification, and regulation of epithelial cell proliferation. Genes 
involved in these terms are listed in the following tables. (Table 3-6 to Table 3-12) 







14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14409533 6.93 IL18 Interleukin 18 (interferon-gamma-inducing factor) 
14429457 6.74 C4BPA Complement component 4 binding protein, alpha 
14452716 6.40 CCL13 Chemokine (C-C motif) ligand 13 
14387651 5.40 CXCL10 Chemokine (C-X-C motif) ligand 10 
14324893 5.39 CD180 CD180 molecule 
14276379 4.76 IRGM Immunity-related GTPase family, M 
14364302 4.64 OLR1 Oxidized low density lipoprotein (lectin-like) 
receptor 1 
14433991 3.98 PTGS2 Prostaglandin-endoperoxide synthase 2  
14306037 3.87 FCGR1A Fc fragment of IgG, high affinity Ia, receptor 
14409809 3.82 MMP12 Matrix metallopeptidase 12 
14265296 3.67 MIA Melanoma inhibitory activity family 
14298963 3.66 FGG Fibrinogen gamma chain 
14287764 3.65 ANGPT1 Angiopoietin 1 
14457347 3.56 TLR8 Toll-like receptor 8 
14430646 3.02 SELE Selectin E 
14366798 2.95 C3AR1 Complement component 3a receptor 1 
14375983 2.92 TLR1 Toll-like receptor 1 
14316910 2.90 SLC7A11 Solute carrier family 7 (anionic amino acid 
transporter light chain, xc- system), member 11 
14305354 2.81 TACR1 Tachykinin receptor 1 
14401130 2.79 CD48 CD48 molecule 
14330808 2.71 ACP5 Acid phosphatase 5, tartrate resistant 
14430287 2.67 PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
14388619 2.67 CFI Complement factor I 
14455870 2.60 MUSTN1 Musculoskeletal, embryonic nuclear protein 1 
14394611 2.58 F13A1 Coagulation factor XIII, A1 polypeptide 
14355262 2.58 ALOX5AP Arachidonate 5-lipoxygenase-activating protein 




channel, subfamily M, beta member 1 
14262002 2.44 SOD2 Superoxide dismutase 2, mitochondrial 
14457934 2.44 CYBB Cytochrome b-245, beta polypeptide 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 
7 
14279411 2.39 AIF1 Allograft inflammatory factor 1 
14393925 2.38 BMP6 Bone morphogenetic protein 6 
14276284 2.35 TLR4 Toll-like receptor 4 
14370194 2.29 BLNK B-cell linker 
14309451 2.27 CTSS Cathepsin S 
14257638 2.21 JAK2 Janus kinase 2 
14269753 2.20 PLEK Pleckstrin 
14387085 2.20 BMPR1B Bone morphogenetic protein receptor, type IB 
14387277 2.18 AIMP1 Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
14296247 2.17 GUCY1B3 Guanylate cyclase 1, soluble, beta 3 
14329619 2.14 CCR1 Chemokine (C-C motif) receptor 1 
14279522 2.14 CFB Complement factor B 
14370250 2.13 PIK3AP1 Phosphoinositide-3-kinase adaptor protein 1 
14447044 2.12 CCL5 Chemokine (C-C motif) ligand 5 
14341803 2.11 LCP1 Lymphocyte cytosolic protein 1 (L-plastin) 
14347364 2.09 P2RY12 Purinergic receptor P2Y, G-protein coupled, 12 
14326966 2.09 PDPN Podoplanin 
14434527 2.01 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
14265178 1.90 RPS19 Ribosomal protein S19 
14400410 1.75 SERPINE2 Serpin peptidase inhibitor, clade E, member 2 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14343958 1.66 GAS6 Growth arrest-specific 6 
14379164 1.60 RBPJ Recombination signal binding protein for 
immunoglobulin kappa J region 
14319137 1.52 ITGB1 Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
14427965 1.51 GNAI3 Guanine nucleotide binding protein, alpha 
inhibiting activity polypeptide 3 
14262925 1.50 ANXA1 Annexin A1 
14449024 -1.52 ENG Endoglin 
14295467 -1.64 ELK3 ELK3, ETS-domain protein  
14446155 -1.66 NFE2L1 Nuclear factor, erythroid 2-like 1 
14306172 -1.70 ECM1 Extracellular matrix protein 1 
14429473 -1.98 CD55 CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
14305965 -2.01 BCL9 B-cell CLL/lymphoma 9 
14357744 -2.10 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
14281639 -2.12 NT5E 5'-nucleotidase, ecto (CD73) 
14449897 -2.23 ITGB4 Integrin, beta 4 
14448168 -2.33 NOTCH1 NOTCH 1 




14266793 -3.10 KIF5A Kinesin family member 5A 
14347367 -4.43 IGSF10 Immunoglobulin superfamily, member 10 
 




Gene Symbol Gene Name 
14356140 16.43 ADAMDEC1 ADAM-like, decysin 1 
14298902 7.11 SFRP2 Secreted frizzled-related protein 2 
14409533 6.93 IL18 Interleukin 18 (interferon-gamma-inducing 
factor) 
14389567 4.66 CSTA Cystatin A (stefin A) 
14364302 
4.64 
OLR1 Oxidized low density lipoprotein (lectin-like) 
receptor 1 
14265296 3.67 MIA Melanoma inhibitory activity family, member  
14287764 3.65 ANGPT1 Angiopoietin 1 
14388813 3.34 EPHA3 EPH receptor A3 
14408542 3.16 CDH6 Cadherin 6, type 2, K-cadherin (foetal kidney) 
14392321 3.07 CLDN1 Claudin 1 
14430646 3.02 SELE Selectin E 
14316910 2.90 SLC7A11 Solute carrier family 7, member 11 
14266174 2.83 SCN1B Sodium channel, voltage-gated, type I, beta 
subunit 
14336520 2.83 EMR1 Egf-like module containing, mucin-like, hormone 
receptor-like 1, macrophage marker F480 
14295395 2.64 PLXNC1 Plexin C1 
14307331 2.58 CGREF1 Cell growth regulator with EF-hand domain 1 
14311075 2.47 LPXN Leupaxin 
14423570 2.39 GBP7 Guanylate binding protein 7 
14425484 2.29 ITGAD Integrin, alpha D 
14257638 2.21 JAK2 Janus kinase 2 
14304046 2.20 EMILIN1 Elastin microfibril interfacer 1 
14269753 2.20 PLEK Pleckstrin 
14387085 2.20 BMPR1B Bone morphogenetic protein receptor, type IB 
14387277 2.18 AIMP1 Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
14288059 2.18 HAS2 Hyaluronan synthase 2 
14329619 2.14 CCR1 Chemokine (C-C motif) receptor 1 
14447044 2.12 CCL5 Chemokine (C-C motif) ligand 5 
14290397 2.09 ADAM22 ADAM metallopeptidase domain 22 
14347364 2.09 P2RY12 Purinergic receptor P2Y, G-protein coupled, 12 
14326966 2.09 PDPN Podoplanin 
14342436 
2.06 
ITGBL1 Integrin, beta-like 1 (with EGF-like repeat 
domains) 
14303184 2.02 CDKN2A Cyclin-dependent kinase inhibitor 2A 
14434527 2.01 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
14400410 1.75 SERPINE2 Serpin peptidase inhibitor, clade E (member 2 
14343958 1.66 GAS6 Growth arrest-specific 6 




immunoglobulin kappa J region 
14344504 1.60 RPSA Ribosomal protein SA 
14398657 1.55 ARPC2 Actin related protein 2/3 complex, subunit 2 
14319137 1.52 ITGB1 Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
14387670 1.52 SCARB2 Scavenger receptor class B, member 2 
14449024 -1.52 ENG Endoglin 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14402043 -1.54 DDR2 Discoidin domain receptor tyrosine kinase 2 
14318073 -1.56 FAT4 FAT atypical cadherin 4 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14310205 -1.80 LAMB1 Laminin, beta 1 
14453163 -2.04 FLOT2 Flotillin 2 
14357744 -2.10 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
14449897 -2.23 ITGB4 Integrin, beta 4 
14320231 -2.27 PCDHB6 Protocadherin beta 6 
14363340 -2.28 NELL2 NEL-like 2 (chicken) 
14448168 -2.33 NOTCH1 NOTCH 1 
14282609 -2.38 TNXB Tenascin XB 
14263835 -2.44 TTYH1 Tweety family member 1 
14356848 -2.47 COL6A3 Collagen, type VI, alpha 3 
14277414 -2.69 FREM1 FRAS1 related extracellular matrix 1 
14392321 -2.87 CLDN11 Claudin 11 
14409246 -2.88 MPZL2 Myelin protein zero-like 2 
14311489 -3.00 MYBPC3 Myosin binding protein C, cardiac 
14402587 -3.09 NID1 Nidogen 1 
14452015 -3.15 CHAD Chondroadherin 
14408526 -3.22 PDZD2 PDZ domain containing 2 
14256801 -5.16 LAMA2 Laminin, alpha 2 
14432404 -5.18 DSC2 Desmocollin 2 
 




Gene Symbol Gene Name 
14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14452716 6.40 CCL13 Chemokine (C-C motif) ligand 13 
14387651 5.40 CXCL10 Chemokine (C-X-C motif) ligand 10 
14433991 3.98 PTGS2 Prostaglandin-endoperoxide synthase 2  
14265296 3.67 MIA Melanoma inhibitory activity family 
14287764 3.65 ANGPT1 Angiopoietin 1 
14430646 3.02 SELE Selectin E 
14366798 2.95 C3AR1 Complement component 3a receptor 1 
14305354 2.81 TACR1 Tachykinin receptor 1 
14279411 2.39 AIF1 Allograft inflammatory factor 1 
14281184 2.36 PTP4A1 Protein tyrosine phosphatase type 4A, member 1 




14288059 2.18 HAS2 Hyaluronan synthase 2 
14329619 2.14 CCR1 Chemokine (C-C motif) receptor 1 
14447044 2.12 CCL5 Chemokine (C-C motif) ligand 5 
14326966 2.09 PDPN Podoplanin 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit ( 
14343958 1.66 GAS6 Growth arrest-specific 6 
14445842 1.65 MIEN1 Migration and invasion enhancer 1 
14319137 1.52 ITGB1 Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
14278691 -1.51 LPAR1 Lysophosphatidic acid receptor 1 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14402043 -1.54 DDR2 Discoidin domain receptor tyrosine kinase 2 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14310205 -1.80 LAMB1 Laminin, beta 1 
14448168 -2.33 NOTCH1 NOTCH 1 
 
 




Gene Symbol Gene Name 
14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14298902 7.11 SFRP2 Secreted frizzled-related protein 2 
14409533 6.93 IL18 Interleukin 18  
14452716 6.40 CCL13 Chemokine (C-C motif) ligand 13 
14356695 5.78 HTR2B 5-hydroxytryptamine receptor 2B 
14387651 5.40 CXCL10 Chemokine (C-X-C motif) ligand 10 
14421671 4.94 MYH11 Myosin, heavy chain 11, smooth muscle 
14433991 3.98 PTGS2 Prostaglandin-endoperoxide synthase 2 
14287764 3.65 ANGPT1 Angiopoietin 1 
14397988 3.51 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
14388813 3.34 EPHA3 EPH receptor A3 
14366798 2.95 C3AR1 Complement component 3a receptor 1 
14393476 2.45 PDCD10 Programmed cell death 10 
14262002 2.44 SOD2 Superoxide dismutase 2, mitochondrial 
14452113 2.26 TMEM100 Transmembrane protein 100 
14387277 2.18 AIMP1 Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
14288059 2.18 HAS2 Hyaluronan synthase 2 
14447044 2.12 CCL5 Chemokine (C-C motif) ligand 5 
14326966 2.09 PDPN Podoplanin 
14311483 2.08 SPI1 Spleen focus forming virus (SFFV) proviral 
integration oncogene 
14432910 1.73 PLXDC1 Plexin domain containing 1 
14397472 1.72 FRZB Frizzled-related protein 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit  




Immunoglobulin kappa J region 
14360089 1.52 TMED2 Transmembrane emp24 domain trafficking 
protein 2 
14319137 1.52 ITGB1 Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
14449024 -1.52 ENG Endoglin 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14318073 -1.56 FAT4 FAT atypical cadherin 4 
14322498 -1.60 ECE1 Endothelin converting enzyme 1 
14295467 -1.63 ELK3 ELK3, ETS-domain protein (SRF accessory 
protein 2) 
14306172 -1.70 ECM1 Extracellular matrix protein 1 
14383275 -1.70 MYO1E Myosin IE 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14390820 -1.74 HEG1 Heart development protein with EGF-like 
domains 1 
14269237 -1.78 EPAS1 Endothelial PAS domain protein 1 
14433723 -1.86 PTPN14 Protein tyrosine phosphatase, non-receptor type 
14 
14260690 -1.87 NFATC1 Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 
14426693 -1.94 MKL2 MKL/myocardin-like 2 
14269730 -2.06 MEIS1 Meis homeobox 1 
14319305 -2.06 NEBL Nebulette 
14322014 -2.08 WASF2 WAS protein family, member 2 
14259044 -2.19 RASIP1 Ras interacting protein 1 
14451257 -2.27 RAMP2 Receptor (G protein-coupled) activity modifying 
protein 2 
14368859 -2.28 TCF7L2 Transcription factor 7-like 2 (T-cell specific, 
HMG-box) 
14299531 -2.32 HIPK2 Homeodomain interacting protein kinase 2 
14448168 -2.33 NOTCH1 NOTCH 1 
14441890 -2.84 ZFP36L1 ZFP36 ring finger protein-like 1 
14403626 -2.84 ZMIZ1 Zinc finger, MIZ-type containing 1 
14311489 -3.00 MYBPC3 Myosin binding protein C, cardiac 
14459309 -5.48 TNMD Tenomodulin 
 
 




Gene Symbol Gene Name 
14298902 7.11 SFRP2 Secreted frizzled-related protein 2 
14421671 4.94 MYH11 Myosin, heavy chain 11, smooth muscle 
14296316 4.24 RXFP1 Relaxin/insulin-like family peptide receptor 1 
14409809 3.82 MMP12 Matrix metallopeptidase 12(macrophage elastase) 




14304046 2.20 EMILIN1 Elastin microfibril interfacer 1 
14288059 2.18 HAS2 Hyaluronan synthase 2 
14343958 1.66 GAS6 Growth arrest-specific 6 
14319137 1.52 ITGB1 Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
14449024 -1.52 ENG Endoglin 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14402043 -1.54 DDR2 Discoidin domain receptor tyrosine kinase 2 
14383275 -1.70 MYO1E Myosin IE 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14310205 -1.80 LAMB1 Laminin, beta 1 
14418313 -2.04 CRISPLD2 Cysteine-rich secretory protein LCCL domain 
containing 2 
14455291 -2.15 OLFML2A Olfactomedin-like 2A 
14449897 -2.23 ITGB4 Integrin, beta 4 
14451257 -2.27 RAMP2 Receptor (G protein-coupled) activity modifying 
protein 2 
14448168 -2.33 NOTCH1 NOTCH 1 
14282609 -2.38 TNXB Tenascin XB 
14356848 -2.47 COL6A3 Collagen, type VI, alpha 3 
14373535 -2.58 MMP16 Matrix metallopeptidase 16 (membrane-inserted) 
14402587 -3.09 NID1 Nidogen 1 
14274287 -4.52 ADAMTSL4 ADAMTS-like 4 
14256801 -5.16 LAMA2 Laminin, alpha 2 
 




Gene Symbol Gene Name 
14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14298902 7.11 SFRP2 Secreted frizzled-related protein 2 
14409533 6.93 IL18 Interleukin 18  
14433991 3.98 PTGS2 Prostaglandin-endoperoxide synthase 2  
14265296 3.67 MIA Melanoma inhibitory activity family 
14305354 2.81 TACR1 Tachykinin receptor 1 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion 
channel, 7 
14393925 2.38 BMP6 Bone morphogenetic protein 6 
14387085 2.20 BMPR1B Bone morphogenetic protein receptor, type IB 
14329619 2.14 CCR1 Chemokine (C-C motif) receptor 1 
14374668 2.04 CHSY1 Chondroitin sulfate synthase 1 
14437994 1.67 
HIF1A 
Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14379164 1.60 
RBPJ 
Recombination signal binding protein for 
immunoglobulin kappa J region 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14402043 -1.54 DDR2 Discoidin domain receptor tyrosine kinase 2 




14299705 -1.56 PTN Pleiotrophin 
14306172 -1.70 ECM1 Extracellular matrix protein 1 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14403912 -2.12 PDLIM7 PDZ and LIM domain 7 (enigma) 
14368859 -2.28 TCF7L2 Transcription factor 7-like 2 
14448168 -2.33 NOTCH1 NOTCH 1 
14409363 -2.42 SIK3 SIK family kinase 3 
14400025 -2.65 IGFBP5 Insulin-like growth factor binding protein 5 
14347367 -4.43 IGSF10 Immunoglobulin superfamily, member 10 
 




Gene Symbol Gene Name 
14430334 7.93 ANGPT1 Angiopoietin 1 
14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14298902 7.11 SFRP2 Secreted frizzled-related protein 2 
14452716 6.40 CCL13 Chemokine (C-C motif) ligand 13 
14356695 5.78 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B, G 
protein-coupled 
14409809 3.82 MMP12 Matrix metallopeptidase 12(macrophage elastase) 
14305354 2.81 TACR1 Tachykinin receptor 1 
14393925 2.38 BMP6 Bone morphogenetic protein 6 
14387277 2.18 AIMP1 Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
14447044 2.12 CCL5 Chemokine (C-C motif) ligand 5 
14303184 2.02 CDKN2A Cyclin-dependent kinase inhibitor 2A 
14373072 2.02 CYP7B1 Cytochrome P450, family 7, subfamily B, 
polypeptide 1 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit 
14449024 -1.52 ENG Endoglin 
14349213 -1.59 SRSF6 Serine/arginine-rich splicing factor 6 
14306172 -1.70 ECM1 Extracellular matrix protein 1 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14310205 -1.80 LAMB1 Laminin, beta 1 
14307431 -2.08 IFT172 Intraflagellar transport 172 homolog 
14368859 -2.28 TCF7L2 Transcription factor 7-like 2 
14448168 -2.33 NOTCH1 NOTCH 1 








3.3.4 DAVID 6.7 
The same list of 591 genes was submitted to the DAVID web-based bioinformatics 
resources for functional annotation and classification analysis. A total 504 of 591 
genes were firstly matched and identified according to official gene symbol for 
human. In the general gene ontology, 16 biological categories were classified based 
on the gene functions (Table 3-13).  
Table 3-13 Gene Ontology Chart for differentially expressed genes 
Gene Ontology Term 
Gene 
Counts 
Gene % p-value 
Response to wounding 43 8.5 2.10E-08 
Inflammatory response 31 6.2 9.50E-08 
Immune response 42 8.3 4.70E-05 
Cell adhesion 41 8.1 1.40E-04 
Biological adhesion 41 8.1 1.40E-04 
Defence response 37 7.3 1.80E-04 
Vasculature development 20 4 3.10E-04 
Positive regulation of cytoskeleton organization 8 1.6 4.30E-04 
Blood vessel development 19 3.8 6.30E-04 
Regulation of cell proliferation 42 8.3 7.50E-04 
Blood vessel morphogenesis 17 3.4 8.90E-04 
Regulation of cytoskeleton organization 13 2.6 1.10E-03 
Innate immune response 13 2.6 1.20E-03 
Response to oxygen levels 13 2.6 1.40E-03 
Collagen metabolic process 6 1.2 1.50E-03 






Functional annotation clustering analysis was conducted for the final 504 genes. In 
general, 35 clusters were initially classified by similar biological gene function (p < 
0.05). After applying the cutoff (enrichment score with high stringency setting), 10 
clusters remained on the list (Table 3-14). 







Vasculature development 3.25 20 3.10E-04 
Collagen metabolic process 2.57 6 1.50E-03 
Protein processing 2.41 11 2.50E-03 
Vacuole 2.36 18 2.20E-03 
Positive regulation of cytoskeleton organization 2.24 10 4.30E-04 
Regulation of cell motion 1.91 14 7.10E-03 
Regulation of bone mineralization 1.71 5 1.30E-02 
Positive regulation of cell motion 1.71 9 1.10E-02 
Cysteine-type endopeptidase activity 1.61 9 5.40E-03 






Differentially expressed genes related to these biological terms are listed in Table 
3-15 to Table 3-24.  







14409533 6.93 IL18 Interleukin 18 (interferon-gamma-inducing factor) 
14287764 3.65 ANGPT1 Angiopoietin 1 
14397988 3.51 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
14310860 2.28 LMO2 LIM domain only 2 (rhombotin-like 1) 
14387277 2.18 AIMP1 Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
14326996 2.09 PDPN Podoplanin 
14432910 1.73 PLXDC1 Plexin domain containing 1 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14379164 1.60 RBPJ Recombination signal binding protein for 
immunoglobulin kappa J region 
14449024 -1.52 ENG Endoglin 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14295467 -1.63 ELK3 ETS-domain protein (SRF accessory protein 2) 
14383275 -1.70 MYO1E Myosin IE 
14269237 -1.78 EPAS1 Endothelial PAS domain protein 1 
14426693 -1.94 MKL2 Myocardin-like 2 
14322014 -2.08 WASF2 WAS protein family, member 2 
14368859 -2.28 TCF7L2 Transcription factor 7-like 2 (T-cell specific, HMG-
box) 
14448168 -2.33 NOTCH1 NOTCH homolog 1, translocation-associated 
(Drosophila) 
14441890 -2.84 ZFP36L1 Zinc finger protein 36, C3H type-like 1 
14403626 -2.84 ZMIZ1 Zinc finger, MIZ-type containing 1 
 







14260509 2.44 PEPD Peptidase D 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14283991 -2.14 TRAM2 Translocation associated membrane protein 2 
14282609 -2.38 TNXB Tenascin XB; tenascin XA pseudogene 













14429457 6.74 C4BPA Complement component 4 binding protein, alpha 
14388619 2.67 CFI Complement factor I 
14326462 2.45 C1QC Complement component 1, q subcomponent, C chain 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 
14261042 2.23 SEC11C SEC11 homolog C (S. cerevisiae) 
14279522 2.14 CFB Complement factor B 
14436816 -1.53 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
14333938 -1.56 SPCS1 Signal peptidase complex subunit 1 homolog (S. 
cerevisiae) 
14322498 -1.60 ECE1 Endothelin converting enzyme 1 
14429473 -1.98 CD55 CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
14307431 -2.08 IFT172 
Intraflagellar transport 172 homolog 
(Chlamydomonas) 
 




Gene symbol Gene identity 
14276379 4.76 IRGM Immunity-related GTPase family, M 
14337646 3.69 CTSC Cathepsin C 
14330808 2.71 ACP5 Acid phosphatase 5, tartrate resistant 
14282827 2.42 HLA-DMB Major histocompatibility complex, class II, DM 
beta 
14309451 2.27 CTSS Cathepsin S 
14384036 2.27 HEXA Hexosaminidase A (alpha polypeptide) 
14330676 2.22 DNASE2 Deoxyribonuclease II, lysosomal 
14366663 2.20 GABARAPL1 GABA(A) receptors associated protein like 3  
14457364 2.03 RAB9A RAB9A, member RAS oncogene family 
1444139 1.83 NPC2 Niemann-Pick disease, type C2 
14342161 1.66 CLN5 Ceroid-lipofuscinosis, neuronal 5 
14461000 1.65 VAMP7 Vesicle-associated membrane protein 7 
14292191 1.61 ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 
subunit F 
14440227 1.55 LGMN Legumain 
14387670 1.52 SCARB2 Scavenger receptor class B, member 2 
14370464 -1.67 GOT1 Glutamic-oxaloacetic transaminase 1, soluble 
(aspartate aminotransferase 1) 
14451257 -2.27 RAMP2 Receptor (G protein-coupled) activity modifying 
protein 2 













14430646 3.02 SELE Selectin E 
14305354 2.81 TACR1 Tachykinin receptor 1 
14430287 2.67 PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 
14350497 1.82 DSTN Destrin (actin depolymerizing factor) 
14398657 1.55 ARPC2 Actin related protein 2/3 complex, subunit 2, 34kDa 
14438313 -2.37 PLEK Pleckstrin 
14293539 -2.52 CTTNBP2 Cortactin binding protein 2 
14450321 -2.81 MAPT Microtubule-associated protein tau 
14316083 -3.35 CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 
 







14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14387651 5.40 CXCL10 Chemokine (C-X-C motif) ligand 10 
14305354 2.81 TACR1 Tachykinin receptor 1 
14281184 2.36 PTP4A1 Protein tyrosine phosphatase type IVA, member 1 
14257638 2.21 JAK2 Janus kinase 2 
14326996 2.09 PDPN Podoplanin 
14265178 1.90 RPS19 Ribosomal protein S19 pseudogene 3; ribosomal 
protein S19 
14400410 1.75 SERPINE2 Serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 2 
14437994 1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14287965 -1.64 ENPP2 Ectonucleotide phosphodiesterase 2 
14310205 -1.80 LAMB1 Laminin, beta 1 
14315712 -2.01 BBS1 Bardet-Biedl syndrome 1 
14400025 -2.65 IGFBP5 Insulin-like growth factor binding protein 5 














14430287 2.67 PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
14360356 2.40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 
14393925 2.38 BMP6 Bone morphogenetic protein 6 
14387085 2.20 BMPR1B Bone morphogenetic protein receptor, type IB 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
 








14291033 7.87 IL6 Interleukin 6 (interferon, beta 2) 
14387651 5.40 CXCL10 Chemokine (C-X-C motif) ligand 10 
14305354 2.81 TACR1 Tachykinin receptor 1 
14281184 2.36 PTP4A1 Protein tyrosine phosphatase type IVA, member 1 
14257638 2.21 JAK2 Janus kinase 2 
14326966 2.09 PDPN Podoplanin 
14265178 
1.90 RPS19 Ribosomal protein S19 pseudogene 3; ribosomal 
protein S19 
14437994 
1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14310205 -1.80 LAMB1 Laminin, beta 1 
 








14378900 3.73 UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase) 
14337646 3.69 CTSC Cathepsin C 
14397988 3.51 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
14409755 2.42 CASP4 Caspase 4, apoptosis-related cysteine peptidase 
14390084 2.33 SENP7 SUMO1/sentrin specific peptidase 7 
14309451 2.27 CTSS Cathepsin S 
14440227 1.55 LGMN Legumain 
14265772 -1.51 CAPNS1 Calpain, small subunit 1 












14432035 2.96 S100A4 S100 calcium binding protein A4 
14437994 
1.67 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
14444308 -1.73 SOX9 SRY (sex determining region Y)-box 9 
14260690 
-1.87 NFATC1 Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 
14448168 -2.33 NOTCH1 NOTCH homolog 1, translocation-associated  
 
3.3.5 IPA 
The list of 591 genes was uploaded to the Ingenuity Pathway Analysis (IPA), and 
525 out of 591 genes were mapped. The top 10 up- and down-regulated mapped 
genes are listed in Table 3-25.  
Table 3-25 Top 10 up- and down-regulated mapped genes in IPA 
Fold-change up-regulated  Fold-change down-regulated  
Gene Symbol Gene Identity 
Fold-
change 
Gene Symbol Gene Identity 
Fold-
change 
ADAMDEC1 ADAM-like, decysin 1 16.43 CILP 




Actin, gamma 2, smooth 
muscle, enteric 
15.35 TNMD Tenomodulin -5.48 
ANGPTL1 Angiopoietin-like 1 7.93 GJB6 Gap junction protein, beta 6 -5.27 
IL6 Interleukin 6 7.87 DSC2 Desmocollin 2 -5.18 
SFRP2 
Secreted frizzled-related protein 
2 
7.11 LAMA2 Laminin, alpha 2 -5.16 





Complement component 4 




cyclic nucleotide-gated channel 
1 
-4.30 
CCL13 Chemokine ligand 13 6.40 LPPR5 
Lipid phosphate phosphatase-
related protein type 5-l 
-4.23 
RGS2 
Regulator of G-protein 
signalling 2 




5.78 FSTL4 Follistatin-like 4 -3.53 
 
Functional clustering showed 11 main categories using IPA, and they were endocrine 
system disorders, cellular movement, connective tissue disorders, inflammatory 




cardiovascular disease, humoral immune response, cardiovascular system 
development, and cell death and survival (Table 3-26). 
Table 3-26 Diseases and functions annotation 
Category 
Disease or Function 
Annotation 
Count p-value 
Endocrine System Disorders Diabetes mellitus 71 1.70E-11 
Cellular Movement Migration of cells 134 1.53E-09 
Connective Tissue Disorders Arthropathy 78 1.8E-08 
Inflammatory Disease Arthritis 83 1.43E-08 
Immune Cell Trafficking Leukocyte migration 79 4.05E-08 
Cancer Uterine tumor 315 3.60E-07 
Haematological System Development  Cell movement 122 5.32E-07 
Cardiovascular Disease Vascular disease 114 7.01E-07 
Humoral Immune Response Production of antibody 40 1.56E-06 
Cardiovascular System Development  Angiogenesis 94 1.79E-06 
Cell Death and Survival Cell death 125 2.39E-06 
 
Up-stream analysis by IPA identified the top 10 up-stream regulators, these ten 
molecules contribute to the up-regulation of the differentially expressed genes. They 
are IL-1B, IL-13, TGFβ1, DYSF, IFN-γ, TNF, LDLR, CSF2, NFκB, and NFE2L2, 
and they are summarized in Table 3-27 and Figure 3-7 (LDLR). 












IL1B Interleukin 1, β Cytokine Activated 3.274 3.55E-12 
IL13 Interleukin 13 Cytokine  0.697 3.95E-11 
TGFB1 Transforming growth 
factor β1 
Growth factor  0.930 1.91E-09 
DYSF Dysferlin  Other   1.98E-09 
IFN-γ Interferon γ Cytokine Activated 4.876 2.77E-08 
TNF Tumor necrosis factor Cytokine Activated 2.683 1.13E-07 
LDLR Low-density lipoprotein 
receptor 
Complex Activated 3.006 1.68E-07 
CSF2 Colony stimulating 
factor 2 
Cytokine Activated 3.024 7.64E-07 
NFκB  nuclear factor kappa-
light-chain-enhancer of 
activated B cells 
Complex Activated 3.387 8.63E-07 








In Figure 3-7 (LDLR), only 4 downstream targets (down-regulation: MMP14, 
MMP16; up-regulation: IL6, CCL5 in MMVD) of LDLR were inconsistent with the 
published experimental findings (yellow interrupted arrow lines). 
 
Figure 3-7 Example for one of the activated up-stream regulators, LDLR. The gene in the centre 





Canonical Pathway Analysis 
In total, 33 canonical pathways passed the p-value cut-off in IPA (Table 3-28). Three 
functions identified that appeared biologically relevant to myxomatous mitral valve 
disease were caveolar-mediated endocytosis signalling, remodelling of epithelial 
adherens junctions and endothelin-1 signalling. Schematic representations of these 
three functions are shown in Figure 3-8, Figure 3-9, and Figure 3-10. 
Table 3-28: Thirty three canonical pathways identified by IPA, cutoff –log(p-value) = 1.5 
Ingenuity Canonical Pathways -log(p-value) Ratio 
Communication between Innate and Adaptive Immune Cells 3.88E00 8.04E-02 
Agranulocyte Adhesion and Diapedesis 3.63E00 7.81E-02 
TREM1 Signalling 3.38E00 1.07E-01 
Glucocorticoid Receptor Signalling 3.29E00 6.35E-02 
Role of NFAT in Regulation of the Immune Response 3.19E00 7E-02 
Complement System 3.10E00 1.43E-01 
Pathogenesis of Multiple Sclerosis 2.82E00 3E-01 
Granulocyte Adhesion and Diapedesis 2.79E00 7.14E-02 
Systemic Lupus Erythematosus Signalling 2.62E00 5.08E-02 
fMLP Signalling in Neutrophils 2.58E00 7.58E-02 
Role of Hypercytokinemia/hyperchemokinemia in the 
Pathogenesis of Influenza 
2.58E00 1.09E-01 
Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 2.49E00 8E-02 
Dendritic Cell Maturation 2.46E00 5.69E-02 
Graft-versus-Host Disease Signalling 2.43E00 9.8E-02 
Role of Pattern Recognition Receptors in Recognition of 
Bacteria and Viruses 
2.06E00 7.34E-02 
CD28 Signalling in T Helper Cells 2.05E00 6.62E-02 
NRF2-mediated Oxidative Stress Response 1.96E00 6.15E-02 
Caveolar-mediated Endocytosis Signalling 1.93E00 8.24E-02 
Adenine and Adenosine Salvage III 1.91E00 1.18E-01 
Purine Ribonucleosides Degradation to Ribose-1-phosphate 1.91E00 1E-01 
Pregnenolone Biosynthesis 1.91E00 1.54E-01 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 
1.85E00 7.55E-02 
Remodelling of Epithelial Adherens Junctions 1.83E00 8.57E-02 
γ-linolenate Biosynthesis II (Animals) 1.8E00 1.25E-01 
PI3K Signalling in B Lymphocytes 1.67E00 6.29E-02 
cAMP-mediated signalling 1.63E00 5.75E-02 
HIF1α Signalling 1.62E00 7.14E-02 
Endothelin-1 Signalling 1.61E00 5.73E-02 
Crosstalk between Dendritic Cells and Natural Killer Cells 1.6E00 5.66E-02 
B Cell Development 1.58E00 8.33E-02 
Cdc42 Signalling 1.55E00 4.3E-02 





IL-4 Signalling 1.54E00 7.5E-02 
RhoGDI Signalling 1.52E00 5.45E-02 
 
 
Figure 3-8 Diagram illustrating caveolar mediated endocytosis signalling. Genes are coded as 







Figure 3-9 Diagram illustrating endothelin-1 signalling. Genes are coded as red (up-regulation) 






Figure 3-10 Diagram illustrating remodelling of epithelial adherens junctions. Genes are coded 

















IPA identified 16 categories under “toxicity” which contributes to a certain 
pathology based on the literature or experimental reports. Significant cardiac related 
toxic functions were cardiac hypertrophy, cardiac necrosis/cell death, oxidative stress, 
and cardiac dysfunction Table 3-29. A number of categories relating to renal function 
were also found, and could be expected to contribute to cardiovascular dysfunction. 
Table 3-29 Ingenuity toxicity list identified by IPA 
Toxicity List -log(p-value) Ratio 
Cardiac Hypertrophy 3.78E00 7.07E-02 
Increases Renal Proliferation 3.73E00 1.07E-01 
Persistent Renal Ischemia-Reperfusion Injury  3.64E00 2E-01 
Increases Liver Damage 2.79E00 1.01E-01 
Acute Renal Failure Panel 2.57E00 1.13E-01 
Cardiac Necrosis/Cell Death 2.23E00 6.45E-02 
Oxidative Stress 2.2E00 1.05E-01 
Long-term Renal Injury Pro-oxidative Response Panel  2.08E00 2.31E-01 
NRF2-mediated Oxidative Stress Response 1.92E00 5.56E-02 
Decreases Depolarization of Mitochondria and 
Mitochondrial Membrane 
1.58E00 1.5E-01 
Increases Cardiac Dysfunction 1.55E00 1.08E-01 
Hepatic Fibrosis 1.4E00 7.29E-02 
Renal Proximal Tubule Toxicity Biomarker Panel 1.35E00 1.11E-01 
Increases Renal Damage 1.33E00 7.25E-02 








The gene networking analysis was conducted based on the diseases and functions 
annotations in accordance with the fold-change for each gene identified by 
microarray. The three most significant and biologically relevant networks were 
identified and overlaid with the diseases/functions annotations and canonical 
pathways; they were cardiovascular system development and function (Figure 3-11), 
cellular movement (Figure 3-12), and cell-to-cell signalling (Figure 3-13).  
The number under each shape is the fold-change. Shapes in red colour mean 
increased expression while shapes in green colour mean decreased expression. 
 
 
Diseases and functions Genes 
Abnormal morphology of mitral valve NFATC1 
Abnormal morphology of cardiovascular system NFATC1, PPDX1, RBPJ, NOTCH1, ZMIZ1 
Abnormal morphology of cardiac valve NFATC1, ZMIZ1 
Morphogenesis of endocardium RBPJ 
Morphogenesis of atrioventricular valve NOTCH1 
Morphogenesis of heart NOTCH1, RBPJ, ZMIZ1 
Looping morphogenesis of heart NOTCH1, RBPJ 
Differentiation of endocardial cells NFATC1 
Differentiation of endothelial cells NFATC1, RBPJ, NOTCH1 
Development of mesenchymal cells NOTCH1 
  
Canonical Pathway  Genes 
Regulation of the epithelial-mesenchymal transition pathway Secretase γ, RBPJ, NFκB1, NOTCH1, CSL-
HIF-1A 
NOTCH signalling Secretase γ, RBPJ, NOTCH1, CSL-HIF-1A 
Figure 3-11 Gene network for cardiovascular system development and function identified by 







Diseases and functions  Gene 
Cell movement of fibroblast SKAP2, WASF2, ANGPT1, ENPP2 
Familial thoracic aortic aneurism MYH11 
Endothelial cell development ANGPTL1, ANGPT1 
Cell movement of endothelial cells ANGPT1, ENPP2 
Injury of endothelial cells ANGPT1 
  
Canonical Pathway  Gene 
Integrin Signalling Arp2/3, Talin, calpain, Akt, integrin, 
JINK1/2, Lfa-1 
Figure 3-12 Gene network for cellular movement and connective tissue development identified 







Diseases and functions  Gene 
Adhesion of fibroblast cell lines TNMD, TENC1 
Adhesion of vascular endothelial cells ITGB1, SELE 
Association of extracellular matrix ITGB1 
Attachment of smooth muscle cells ITGB1 
Binding of vascular endothelial cells ITGB1, SELE 
Morphogenesis of endothelial tube PDPN 
Basement membrane disruption NID1, Laminin 
Figure 3-13 Gene network for cell-to-cell signalling and tissue development identified by IPA. 





3.3.6 BioLayout Express3D 
BioLayout Express3D is a network analysis tool that clusters genes based on 
coexpression patterns. In the graph (Figure 3-14), every node represents an annotated 
or un-annotated transcript. All clustered nodes are joined by edges (when the Pearson 
correlation coefficient between two transcripts was over 0.94), and weighted based 
on the correlations between similar expression patterns. Nodal clustering was based 
on the MCL method (Figure 3-14).  
 
Figure 3-14 Two major groups of clusters were identified in BioLayout Express 3D. Cluster 1 and 
6 were genes with higher expression level in MMVD compared to controls, whereas Cluster 2, 3, 
4, 5 were genes with lower expression level in MMVD compared to controls. 
The two major clusters (1 and 2) with highest numbers of genes have distinct 
expression patterns, where cluster 1 showed relatively high expression in 
myxomatous mitral valves and cluster 2 showed relatively low expression in 
myxomatous mitral valves (Figure 3-15). One diseased valve sample (MMVD024) 
had a similar expression pattern to controls in cluster 1, 2, and 3. Genes with higher 
expression level in control group can be found in cluster 3, 4, and 5. In cluster 4, 
control02 was found exceptionally high compared to other samples in the control 





Figure 3-15 Mean signal intensity for main clusters (1 to 6) on two plots. Y axis- average 
intensity for the cluster. The plot on the left shows two clusters (1 and 6) of genes that have 
relatively higher expression level in MMVD, whereas the plot on the right shows 4 clusters (2, 3, 
4, and 5) of genes that have relatively lower expression level in MMVD. In the three major 
clusters (1, 2, and 3), MMVD024 was identified as an outlier, which also showed in the PCA plot 
(Figure 3-3).  
Further data mining for the genes associated with EndoMT can be found in Table 
3-30. Genes underlined in the Table were not in the 591 genes identified by the 
initial microarray analysis. 
Table 3-30 Summary of the Biolayout Express3D findings and genes associated with EndoMT in 
each cluster 
Cluster Expression Pattern 
Genes associated with 
EndoMT 
Annotation  
Cluster 1 ↑MMVD, ↓Control  
HAS2, SNAI1, CTSS, 
TAGLN, BMP6, BMPR1B, 
BMPR2, CTNNB1, RBPJ1 
69% (2420/3504) 
Cluster 2 ↓MMVD, ↑Control  
NOTCH1, NOTCH2, NID1, 
NFATC1, NFATC2 
54% (1137/2091) 
Cluster 3 ↓MMVD, ↑Control  CDH5 31% (342/1114) 
Cluster 4 ↑Control02 No gene 34% (120/357) 
Cluster 5 ↑Control01 LAMA2 70% (144/207) 




3.3.7 Transcriptomic Data Mining Based on Signal Intensity 
Annotation clustering analysis of differentially expressed genes by gene ontology 
platforms provided insight into the functional aspects of MMVD, and the most 
biologically relevant functions identified were 1) inflammatory response, 2) cellular 
movement, 3) cardiovascular development, 4) extracellular matrix organization, 5) 
epithelial to mesenchymal transition. Genes associated with these five categories 
were sub-categorized with their signal intensity values (this value was converted 
from the digital pixels on the array) for further analysis and the detail is shown in 
3.3.7.1 to 3.3.7.17. Down- or up-regulation of genes presented in this section were 
based on microarray analysis. Mining the data on their signal intensities provides 
extra insight into the trend and pattern of gene expression. 
3.3.7.1 Collagens 
The signal intensity for all collagen mRNA is shown in Figure 3-16. Briefly, the 
signal intensities for genes encoding subunits of collagen I, III, V, VI, XII, and XIV 
were higher than 1,000, but intensity for COL15A1 and COL16A1 was low. The 








Figure 3-16 Signal intensity for collagens: (A) Genes encoding Collagen type I to type VII, and 
(B) Genes encoding collagen type IX to XXVIII. ↓ down-regulated (p < 0.05) 
3.3.7.2 ADAMTS 
ADAMTS is a family of peptidases. A homologous sub-family of ADAMTSL 
(ADAMTS-like) proteins which lack enzymatic activity was also included. The 
signal intensity values for ADAMTS and ADAMTSL were all below 1,000, and the 
three significantly decreased genes were ADAMTS2, ADAMTS19, and 
ADAMTSL4 (Figure 3-17). 
 





3.3.7.3 Proteoglycans and Glycosaminoglycans 
The transcripts for proteoglycans and glycosaminoglycans had the highest signal 
intensity values among all the transcripts in the microarray. In general, lumican and 
versican had the highest signal intensity value (> 10,000), and the signal intensities 
for biglycan, decorin, asporin, fibromodulin, prolargin, keratocan, osteoglycin, and 
chondroadherin were between 3,000 and 10,000 (Figure 3-18). The two significantly 
down-regulated genes were KERA (keratocan) and CHAD (chondroadherin). 
 
Figure 3-18 Signal intensity for PGs and GAGs. ↓ down-regulated (p < 0.05). Chondroitin 
sulphate proteoglycan 4 (CSPG4) 
3.3.7.4 MMPs and TIMPs 
MMPs and tissue inhibitors of metalloproteinases (TIMPs) were categorized into one 
group. The signal intensity for TIMPs was higher (TIMP1 > 1,000, TIMP2 and 
TIMP3 > 4,000) than for MMPs. (Figure 3-19).  
MMP2 had the highest signal intensity value (> 4,000) among all the MMPs. 
MMP14 (p < 0.001) and MMP16 (p < 0.01) were significantly down-regulated, and 






Figure 3-19 Signal intensity for TIMPs and MMPs. ↓ down-regulated, ↑ up-regulated. 
3.3.7.5 Basement membrane (BM) components 
Nidogen1 (NID1, p < 0.01), laminin2 (LAMA2, p < 0.001), and laminin4 (LAMA4, 






Figure 3-20 signal intensity for basement membrane components. ↓ down-regulated. 
3.3.7.6 Cathepsins 
Cathepsin K (CTSK) had the highest signal intensity value (> 5,000) for this 
category (Figure 3-21). Expression of cathepsin S (CTSS) (> 3,000) and Cathepsin C 
(CTSC) (< 1,000) were both significantly higher in CKCS than control.  
 
Figure 3-21 Signal intensity for cathepsins. ↑ up-regulated (p < 0.05) 
3.3.7.7 Integrins 
The top three highest signal intensity (> 2,000) values for members of the integrin 
family were integrin α FG-GAP repeat containing 1 (ITFG1), integrin α5 (ITGA5), 
and integrin β1 (ITGB1) (Figure 3-22). ITFG1 and ITGB1 were significantly up-




integrin α1 (ITGA1), integrin α8 (ITGA8) and integrin β1-like (ITGBL1), whereas 
integrin β4 (ITGB4) was the only significantly down-regulated gene in CKCSs. 
 
Figure 3-22 Signal intensity for integrins. ↓ down-regulated (p < 0.05), ↑ up-regulated (p < 0.05) 
3.3.7.8 Claudins and Occludin 
Claudin 1 (CLDN1), claudin 11 (CLDN11), and claudin 12 (CLDN12) had higher 
signal intensities compared with other claudins. Interestingly, CLDN1 was 
significantly up-regulated while CLDN11 was significantly down-regulated in 





Figure 3-23 Signal intensity for claudins and occludin. ↓ down-regulated (p < 0.05), ↑ up-
regulated (p < 0.05) 
3.3.7.9 Cadherins 
Cadherin (CDH) expression was high in signal intensity (> 1000), and CDH2, 
CDH5, CDH11, CDH13, and CDH23 were the highest cadherins expressed in both 
groups (Figure 3-24). CDH13 was the most expressed cadherin (> 3,000). CDH2, 
CDH5, CDH11, and CDH23 had similar expression levels (1,000 ~ 2,000). 
 





3.3.7.10 Fibrillins, Periostin, Fibronectin, and Fibulins 
Signal intensities for periostin (PTN), fibronectin (FN), and fibulin1 (FBLN1) were 
generally high (> 5,000), and expression level for fibrillin (FBN1) and fibulin5 
(FBLN5) were between 3,000 and 5,000 (Figure 3-25).  
 
Figure 3-25 Signal intensity for fibrillins, periostin, fibronectin, and fibulins. 
3.3.7.11 Others 
In this category, cartilage intermediate layer protein (CILP), elastin (ELN), 
hyaluronic acid synthases (HAS), tenascin (TNC), filamin (FLN), and hyaluronan 
and proteoglycan link protein (HAPLN) were included. Expression of HAPLN1 had 
the highest expression (> 2,500), and CILP, HAS2, TNC, and FLNA had moderate 
expression (> 1,000) (Figure 3-26). Two significantly down-regulated genes were 





Figure 3-26 Signal intensity for CILP, ELN, Has, TNC, FLN, HAPLN, ↓ down-regulated (p < 
0.05), ↑ up-regulated (p < 0.05). 
3.3.7.12 Nitric oxide synthases and endothelins 
Signal intensity for all three nitric oxide synthases and the three endothelins was low 
(< 500) (Figure 3-27). Nitric oxide synthase 1 (NOS1, neural NOS, nNOS) and nitric 
oxide synthase 3 (NOS3, endothelial NOS, eNOS) were similar in signal intensity.  
 





3.3.7.13 Caveolins, PECAM-1, selectin, ICAM-1, and VCAM-1 
Signal intensities for caveolin1 (CAV1), caveolin (CAV2), platelet endothelial 
adhesion molecule-1 (PECAM1), and vascular cell adhesion molecule-1 (VCAM1) 
were high (> 1,000), whereas caveolin3 (CAV3), selectin (SELE), and intercellular 
cell adhesion molecule-1 (ICAM1) had low intensities (< 500) (Figure 3-28). Only 
SELE had significantly higher expression level in CKCSs. 
 
Figure 3-28 Signal intensity for CAVs, PECAM, SELE, ICAM1, and VCAM1. ↑ up-regulated (p 
< 0.05) 
3.3.7.14 NOTCH and SNAI1 
Signals for NOTCH2, recombination signal binding protein for immunoglobulin 
kappa J region (RBPJ) and SNAI2 (Slug) were medium to high (1,000~2,500), and 
signal for NOTCH1 and SNAI1 were low (<500) (Figure 3-29). There was lower 





Figure 3-29 Signal intensity for NOTCH, RBPJ, and SNAI1. ↓ down-regulated (p < 0.05), ↑ up-
regulated (p < 0.05). 
3.3.7.15 Catenins, VEGFs, and NFATcs 
Signal intensity for β-catenin (CTNNB1) was strong (>2,000). Expression of nuclear 
factor of activated T-cells, cytoplasmic 1 (NFATC1) and NFATC3 was moderate to 
low (500 ~ 1500). NFATC1 was significantly down-regulated in CKCS. Expression 
of vascular endothelial growth factors were low (> 500), and there was no difference 
between two groups (Figure 3-30). 
 





3.3.7.16 TGF-β and TGF-β Superfamily 
Expression of members of the transforming growth factor β family was variable but 
not different between affected and normal dogs (Figure 3-31). The highest signal 
intensity was for TGFβI (transforming growth factor induced) (> 3,000), following 
by TGFβ receptors (TGFβR3, TGFβR2, and TGFβR1) and TGFβ (TGFβ2 and 
TGFβ3). TGFβ1 had the lowest expression. Endoglin (ENG) also showed high signal 
intensity (> 3,000).  
 
Figure 3-31 Signal intensity for TGF-βs, TGF-β receptors, and endoglin 
Bone morphogenic proteins (BMPs) are also members of the TGF-β superfamily. 
Highest signal intensity was seen with bone morphogenic protein receptors 
(BMPR1A and BMPR2), and BMPs (BMP2, BMP4, BMP5, and BMP6) with 
BMPR1B having low to moderate expression (500 ~ 1,000) (Figure 3-32). BMP6 
and BMPR1B were the only two significantly up-regulated genes in CKCSs, and the 





Figure 3-32 Signal intensity for BMPs and BMP receptors. ↑ up-regulated (p < 0.05). 
3.3.7.17 Actins, Myosins and Smooth Muscle Cell Markers 
Signal intensity for most actins, myosins and SM22 (smooth muscle cell marker, 
transgelin, TAGLN) was in general high (> 2,000) except α1 actin (ACTA1) and 
TAGLN3 (Figure 3-33). There was significantly increased expression of γ2 actin 
(ACTG2) and TAGLN1. 
 
Figure 3-33 Signal intensity for actin and SM22 (transgelin, TAGLN). ↑ up-regulated (p < 0.05) 
Genes associated with myosins overall had a low expression pattern (< 1,000) 
compared with actins (> 2,000) (Figure 3-34). Only myosin heavy chain 7 (MYH7), 








Figure 3-34 Signal intensity for myosin heavy chain genes. ↑ up-regulated (p < 0.05). 
3.3.8 Final Categorization and Prioritization of Microarray Results 
The gene list contained 591 differentially expressed genes which were analysed 
using the three major Gene ontology platforms (ToppFun, DAVID, and IPA), and the 
combined summarized results are shown in Table 3-31. The annotations that were 
biologically relevant to MMVD were selected and combined into the final functions 
list, and included inflammatory response, cellular movement, cardiovascular 
development, extracellular matrix organization, and epithelial to mesenchymal 
transition.  
Table 3-31 Functions and diseases annotation identified by different platforms 
Platform Functions and Diseases 
ToppFun 
1. Inflammation and immune response 
2. Cellular adhesion and movement 
3. Cardiovascular development 
4. Extracellular matrix organization 
5. Osteogenesis 
6. Epithelial proliferation 
DAVID 
1. Inflammatory response 
2. Cell adhesion 
3. Vasculature development 




5. Collagen metabolic process 
6. Epithelial to mesenchymal transition 
IPA 
1. Endocrine system disorders 
2. Connective tissue disorders 
3. Inflammatory disease 
4. Cancer 
5. Cardiovascular system development 
6. Cell death and survival 
Finalized 
1. Inflammatory response 
2. Cellular movement 
3. Cardiovascular development 
4. Extracellular matrix organization 
5. Epithelial to mesenchymal transition 
 
IPA alone also allowed prediction of upstream regulators, toxicity, and canonical 
pathways by analyzing fold-changes of the imported gene list. The finalized result 
are summarized in Table 3-32. 
 
Table 3-32 Identified upstream regulators, toxicity, and canonical pathways 
IPA Description 
Upstream regulator IL1B, IL13, TGFB1, LDL 
Toxicity 1. Cardiac Hypertrophy 
2. Cardiac Necrosis/Cell Death 
3. Oxidative Stress 
4. Increases Cardiac Dysfunction 
Canonical Pathway 1. Caveolar-mediated endocytosis signalling 
2. Endothelin-1 signalling  




The genes showing significant signal differences between affected and unaffected 






Table 3-33 Significant results from signal intensity analysis 
Category Gene, direction of change and intensity level  
Collagen COL6A3↓(H) 
ADAMTS ADAMTS2↓(M), ADAMTS19↓(M), 
ADAMTSL4↓(M) 
PGs and GAGs KERA↓(H), CHAD↓(H) 
MMP and TIMP MMP12↑(M), MMP14↓(M), MMP16↓(M) 
BM NID1↓(H), LAMA2↓(L), CTSS↑(H) 
Cathepsin CTSC↑(M), CTSS↑(H) 
Integrin ITFG1↑(H), ITGA↑(M), ITGA8↑(M), ITGB1↑(H), 
ITGB4↓(M), ITGBL1↑(M) 
Claudin and occludin CLDN1↑(M), CLDN11↓(H) 
Others CILP↓(H), HAS2↑(M), HAPLN1↓(H) 
CAV, PECAM, ICAM, SELE, 
and VCAM 
SELE↑(L) 
NOTCH and SNAI1 NOTCH1↓(L), RBPJ↑(H) 
Catenin, VEGF, and NFATc NFATC1↓(M) 
TGF-β superfamily ENG↓(H), BMPR1B↑(L), BMP6↑(M) 
Actin, myosin, and SM22 ACTG2↑(H), TAGLN↑(H) 
↑ up-regulated, ↓ down-regulated, H = high signal intensity, M = medium signal 







The array used for transcriptional profiling in this study was the Affymetrix Canine 




and predicted canine genes) were designed according to the updated genome 
information from canFam2. The specific design of 26 unique 25-mer probes for each 
transcript allowed the highest coverage yet and the potential for future updates on 
currently unannotated transcripts. This also yielded accurate detection of the 
transcribed genome and provided higher resolution compared with classical 3’-biased 
microarrays. Oyama et al first reported the transcriptional profile of canine MMVD 
in 2006 using the first generation of the array (Affymetrix GeneChip Canine Genome 
1.0). 106 In that study, up-regulation of HTR2B and TGF-β superfamily molecules 
including endoglin and BMP6 highlighted the potential role of the serotonin-TGF-β 
signalling pathway in MMVD, which may play a role in VIC activation and ECM 
remodelling. 106  
For human MMVD there have been three transcriptomic studies so far (two 
published, and one abstract). Hulin et al identified the down-regulation of 
metallothioneins-1 and -2 (MT1/2) and ADAMTS family members. In cultured cells 
in the same study knocking out MT1/2, TGF-β2 was up-regulated, which then down-
regulated ADAMTS19 resulting in excessive versican deposition. 115 The other two 
studies both identified increased expression of extracellular component genes 
(collagen, proteoglycans and MMPs) and ECM associated transcriptional factors 
(BMPs), with activation of valve interstitial cells by BMP4 in a culture system. 114 
These findings suggest an important role for TGF-β and TGF-β superfamily 
signalling in controlling cellular activation and ECM remodelling in human mitral 
valves. In the current study expression of genes associated with collagen and 
proteoglycan was generally down-regulated (COL6A3, KERA, CHAD) or 
unchanged whereas in human MMVD they were all up-regulated (COL1A1, 
COL3A1, decorin, biglycan, versican, and lumican). 114 Another interesting 
difference between the dog and human  is the absence of up-regulation of HTR2B in 
any of the human transcriptomic studies. This might suggest species-specific 
mechanisms for MMVD and that the two diseases differ at least at the transcriptome 
level. The up-regulation of collagen and proteoglycan expression in human MMVD 
may also explain why calcific and fibrotic lesions are rarely seen in severe canine 




The microarray results (Appendix 9.1) confirmed the previous findings (Table 3-25) 
in dogs for up-regulation of HTR2B (5.783-fold increase) and BMP6 (2.378-fold 
increase) 106, but found no differences in the expression of TGF-βs or TGF-β 
receptors. Because of the complexity of regulation of the TGF-β superfamily, this 
result does not rule out involvement in control of valve cell differentiation and ECM 
turnover during valve development, valve remodelling and disease. 59,63 The gene 
ontology analysis in the current study found similar biological functions for the 
differentially expressed gene sets as has been previously reported, including genes 
involved in cell signalling, inflammation, extracellular matrix, immunity, cell 
defence, and metabolism, but additional novel functions, including cellular 
movement and epithelial to mesenchymal transition, were also identified. 106 The 
specific findings in the transcriptome of interest to MMVD are discussed in detail in 
the following sections.  
TGF-β and TGF-β superfamily 
Transforming growth factor β plays a key role in development, and diseases such as 
cancer, fibrosis, and calcification. 125 There are three isoforms of TGF-β: TGF-β1, 
TGF-β2, and TGF-β3, and TGF-β signalling through SMAD pathway triggers 
myofibroblastic differentiation of valve interstitial cells and increases expression of 
SMAD-targeted genes associated with extracellular matrix such as COL1A1, 
COL3A1, COL6A1, COL6A3, elastin, and TIMP1. 126,127 
In the current study none of genes encoding the TGF-βs and TGF-β receptors were 
differentially expressed in MMVD. TGFB1 had the lowest (signal intensity 200) 
expression level and was considered as background noise suggesting extremely low 
or no expression. Expression of TGFB2 and TGFB3 was moderate (signal intensity = 
1,000) but more variable in MMVD. Expression of TGF-β receptors (TGFBR1, 
TGFBR2, and TGFBR3) was high (signal intensity > 1,000). Consistent expression 
of TGF-β genes suggested there is continual biological effect of TGF-β2 and TGF-
β3, which is not surprising. This homeostasis maintained by TGF-β may be 
associated with ECM turnover, cell survival, and differentiation; although no sign of 
myofibroblastic differentiation was present in the normal mitral valve. 52,61 TGF-β 




TGF-β downstream genes such as COL1A1, COL3A1, and TIMP1 were not 
differentially expressed, suggesting there was no excessive up-regulation of the 
target genes. In contrast, human myxomatous mitral valves were found to show 
higher transcriptional level of all isoforms of TGF-β, and TGF-β downstream genes 
(COL1A1, COL3A1 and elastin) were also up-regulated, suggesting activation of 
fibrosis. 125 Interestingly, Aupperle et al have also observed an increased expression 
(by immunohistochemistry) of TGF-β1 and TGF-β3 in the subendothelial stroma 
cells (proposed to be activated myofibroblasts) in canine myxomatous valves, but 
with minimal expression of TGF-β2 in both normal and myxomatous valves. 61 Post-
transcriptional modification might be the reason that the expression of TGF-βs in the 
current study conflicts with these IHC (immunohistochemistry) results.  
Low-density lipoprotein 
The plasticity of valve cells implies an adaptive and homeostatic potential to the 
dynamically changing macro- and micro-environment. The upstream regulators 
analysis identified a positive association between LDLR and the downstream genes 
(17 out of 23), which predicted an activation of LDL signalling. One canine lipid 
profiling study identified an increased LDL-cholesterol concentration (mean = 
145.7mg/dL) for the aging group (>7 years old) compared with young adult group 
(3.1 to 7 years old, cholesterol-LDL = 117.2 mg/dL), and this coincided with the 
MMVD prevalence in dogs. 7,12,15,128 It is not particularly surprising since control 
mitral valves were sampled from young adult dogs and diseased mitral valves were 
collected from elderly dogs. Moreover, CKCS has been recently identified as a breed 
predisposed to chronic fibrosing pancreatitis, and the abnormal lipid metabolism 
leading to intermittent LDL surge may be one of the contributing factors to the early 
onset of MMVD. 129,130  
It is generally believed that the degenerative pathways of mitral and aortic valve 
were shared and controlled by BMPs and TGFβ signalling 131, and it has been 
reported that coronary calcification and aortic valve calcification progress more 
rapidly in subjects with levels of LDL >130 mg/dL. 131 Together, LDL could be a 
potential factor contributing to MMVD in normal aging group and the early-onset 






Three canonical pathways deemed to be of potential interest to MMVD were 
identified, and included caveolar mediated endocytosis, endothelin-1 signalling, and 
remodelling of epithelial adherens junction. The remodelling of epithelial adherens 
junctions will be discussed together with EndoMT later.  
Caveolae are lipid raft invaginations of the plasma membrane found in high numbers 
in endothelial cells, fibroblasts, smooth muscle cells, and adipocytes. They are 
believed to be involved in regulation of endothelial cell growth, endocytosis, and cell 
migration by internalizing important signalling molecules, such as TGF-β receptors, 
tyrosine kinase receptor, and endothelial nitric oxide synthase. 132 Due to their 
endosomal degradation of TGF-β receptors, caveolae are suggested to play an 
important role in reducing TGF-β induced fibroblast activation, leading to excess 
deposition of associated ECM in fibrotic disorders. 133 Down-regulation of this 
pathway (section 3.3.5) could mean increased TGF-β signalling. In migrating cells, 
focal adhesion is regulated by integrin-caveolae interaction, and the increased 
expression of integrin β1 (ITGB1, 1.519-fold increase) in the current study might 
suggest a change in cell polarity or directional migration through caveolae signalling 
in valve endothelial and interstitial cells. 134 Nevertheless, expression levels of 
caveolin1 (CAV1) and CAV2 were high (signal intensity > 2,000) in CKCSs and 
controls. 
Endothelins (ET-1 encoded by EDN1, ET-2, encoded by EDN2, and ET-3 encoded 
by EDN5) are potent vasoconstrictor peptides synthesized from endothelium 
throughout the whole body and they have mitogenic effect on fibroblasts, smooth 
muscle cells, and endothelial cells. 135 ET-1 is the main isoform acting through ETA-
R (endothelin receptor A, vasoconstriction) and ETB-R (endothelin receptor B, NO 
release) to maintain normal cardiovascular physiology. 136 It has been suggested that 
ET-1 modulates extracellular matrix remodelling in MMVD, since the expression of 
ET receptor is positively associated with canine MMVD severity and ET receptors 
are highly expressed in the stroma and endothelium of the myxomatous leaflet tips. 69 




EDNRB) and nitric oxide synthase (nNOS, iNOS, eNOS) was low (signal intensity < 
500), and statistically there was no difference. Whether there is localized activation 
of endothelin signalling or not remains unknown. Further work is required to 
quantify and localize endothelin and eNOS expression in normal and affected valves. 
Finally, the low signal intensity of ET receptors coincides with the report by 
Pedersen et al, which found low levels and localized expression of endothelin 
receptor RNA both in diseased and normal mitral valves. Unfortunately, expression 
patterns of the ETA-R (vasocontriction) and ETB-R (vasodilation) could not be 
differentiated in their study. 69 
Inflammation 
In general, there was evidence of an increased inflammatory response in the 
myxomatous mitral valves transcriptome, with increased expression of inflammatory 
cytokines, and these result are in agreement with the previous finding. 106 However, 
adhesion molecules expressed by endothelium (VCAM-1 and ICAM1) were not 
changed. The novel finding from the current study was the over-expression of toll-
like receptors (TLRs) in CKCSs. In the gene networking analysis, two molecules 
central to the inflammation network were identified by IPA; toll-like receptor 4 
(TLR4) and interleukin 18 (IL-18). Other up-regulated molecules associated with 
inflammation and immunity included interleukin 6 (IL-6), toll-like receptor 1 
(TLR1), and toll-like receptor 8 (TLR8). The TLRs are the first line of defence 
against microbial infection and modulate innate and adaptive immunity. Moreover, 
TLRs can also recognize endogenous ligands (heat shock protein 70, fibronectin, 
hyaluronic acid, heparan sulfate, and hyaluronan), and may play a protective role in 
ischemic injury in heart and wound healing in skin. 137 However, in MMVD there is 
no evidence of inflammatory cell infiltration, and this was confirmed in the 
myxomatous mitral valves from CKCSs 52. Pathological changes in myxomatous 
mitral valves are characterized by deposition of glycosaminoglycans, fragmentation 
of collagen bundles and elastic fibres. Taken together, excess breakdown of the ECM 
components in the mitral valve might be the endogenous factor that triggers TLR 
receptors signalling, which then further contributes to ECM remodelling and 




mitral regurgitation alone could trigger leaflet remodelling leading to an 
inflammatory response. Recently, IL-6 has been shown capable of triggering 
EndoMT in the embryonic and adult aortic valve endothelium suggestive of an 
important role during valve development. 139 The continuous mechanical assault 
might initiate the developmental signal in adult valve endothelial cells, which could 
play a role in the pathogenic remodelling of valve tissues. 
Collagens 
There are 28 different types of collagen found in vertebrates. 140 Genes encoding 
subunits of all collagens except collagen VIII were screened in this study. In general, 
genes for collagen type I, III, IV, V, VI, XII, and XIV subunits were highly 
expressed (signal intensity 1,000 ~ 4,000) both in the diseased and normal mitral 
valves, and very minimum expression of collagen XV and XVI subunits was also 
found in the diseased and normal mitral valves. The only significantly down-
regulated collagen gene was COL6A3. COL6A3 is a network-forming collagen 
expressed in developing the endocardial cushion and adult atrioventricular valves, 
and is thought to provide tensile strength to the surrounding tissues. 141,142 Lower 
expression of COL6A3 suggests disorganization of force-resistant collagen bundle 
formation in MMVD, and this could result in weakening of the mitral valve leaflet.  
ADAMTS and ADAMTSL 
ADAMTS family consists of 19 ECM metalloproteases. ADAMTS1, ADAMTS5, 
ADAMTS9 are reported to be expressed in the developing heart where they control 
atrioventricular endocardial cushion formation, trabeculation, and outflow tract 
remodelling.143,144  
ECM degradation by ADAMTS also plays an important role in connective tissue 
formation, cancer, coagulation, arthritis, angiogenesis and cell migration. 145 In the 
current study there were 20 ADAMTS and 4 ADAMTSL genes identified in the 
canine microarray. The expression of all ADMATS and ADAMTSL family genes 
was generally low (signal intensity < 500), except for ADAMTS2, ADAMTS9, and 
ADAMTSL4 (ADAMTS-like 4), which were all significantly down-regulated in the 
diseased valves. ADAMTS2 is responsible for maturation of pro-collagen and 




cancer, and arthritis. 146 ADAMTS9 is one of the three ADAMTS expressed in the 
developing heart. 147,148 Haploinsufficient animal models of ADAMTS9 exhibit 
excessive versican deposition in myocardium and valves, and myxomatous 
degeneration is also noted in mitral valves. 147 This suggests lower expression of 
ADAMTS2 and ADAMTS9 in canine myxomatous mitral valves results in an 
inactive collagen turnover state with excessive extracellular matrix accumulation.  
ADAMTSL4, which lacks the disintegrin-like domain, is thought to be catalytically 
inactive. However, ADAMTSL4 has been identified in distinct human genetic 
disorders including thrombotic thrombocytopenic purpura and acromelic dysplasia, 
and mutation of ADAMTSL4 results in ectopia lentis, which is also caused by 
mutation in FBN1 (Marfan Syndrome). 146 One study has also identified that 
ADAMTSL4 binds fibrillin microfibrils and stimulates microfibril biogenesis. 145,146 
Diffuse expression of ADAMTSL4 in the fibrillar extracellular matrix region in 
ocular tissue also indicates its regulatory role for fibrillin-1. 145 Taken together data 
from these and the current study suggest lower expression of ADAMTSL4 in 
MMVD may contribute to decreased elastic fibre formation and leaflet elasticity.  
MMPs and TIMPs 
Matrix metalloproteinases are zinc-dependent endopeptidases, and can be roughly 
divided into 6 groups: (1) collagenases (MMP1, MMP8, MMP13), (2) gelatinases 
(MMP2, MMP9), (3) stromelysins (MMP3, MMP10, MMP11), (4) matrilysins 
(MMP7, MMP26), (5) enamelysin (MMP20), (6) membrane-type MMPs (MMP14, 
MMP15, MMP16, MMP17, MMP24, MMP25). Other unclassified MMPs include 
MMP19, MMP21, MMP23A, MMP23B, MMP27, and MMP28. The MMPs are 
inhibited by specific endogenous tissue inhibitors of metalloproteinases (TIMPs), 
which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and 
TIMP4. 149 The expression pattern of MMPs and TIMPs has been studied both in 
human and canine mitral valves (normal and myxomatous). However, only 6 MMPs 
(1, 2, 3, 9, 13, and 14) were covered in previous studies, and the results were variable 
probably due to use of a variety of methods (immunohistochemistry, PCR, and 




The latest canine microarray used in this study had the widest coverage of 22 MMPs 
(of a total 25 MMPs) and 4 TIMPs. While mRNA level does not necessarily equate 
to final protein concentration (post-translational modification and other proteasome 
mechanisms), generally speaking low or no genomic expression could mean low or 
no protein translated, but high genomic expression does not always mean high 
protein expression. Finally, the quantified signal intensity value for each MMP and 
TIMP can be an indicator for their genomic expression level, and this was not 
provided in the report by Oyama. 106 The signal intensity for MMPs and TIMPs in 
comparison to previous reports is summarized in Table 3-34. The expression of 
MMP1 was negligible, but most other studies identified up-regulation of MMP1 in 
myxomatous valves (PCR and IHC). The only consistent findings were expression 
for MMP9 and TIMP3, where MMP9 showed no expression and TIMP3 had higher 
expression. It is also important to note that MMP2 (gelatinase) was the highest MMP 






Table 3-34 Expression of MMPs and TIMPs, comparison data 
 Lu (present study) Aupperle 50 Aupperle 150 Disatian 104 Obayashi 151 Oyama 106 
Rabkin 
Human 56 




 MMVD Control       
MMP1 62 61 ND ↑ ↑ ↑  ↑ 
MMP2 3950 5139 ↓ ±  ND ± ↑ 
MMP3 145 323    ↑   
MMP7 31 30       
MMP8 36 47       
MMP9 23 21 ND ±  ND ± ↑ 
MMP11 130 167       
MMP12 283↑ 79       
MMP13 23 27   ↑  ± ↑ 
MMP14 702↓ 1090 ↑ ↑     
MMP15 104 122       
MMP16 92↓ 249       
MMP17 139 154       
MMP19 761 775       
MMP20 33 32       
MMP21 89 65       
MMP23B 337 321       
MMP24 59 61       
MMP25 52 54       
MMP26 18 17       
MMP27 16 18       
MMP28 324 355       
TIMP1 1362 1385     ↑  
TIMP2 4614 6115 ↑ ↑     
TIMP3 8497 7665 ↑ ↑     
TIMP4 260 193 ND ↑     
ND: not detectable, ↑: higher expression, ↓:lower expression, ±: no change 
 
Cathepsins 
Cathepsins (CTS) are proteases (collagenases) and classification of cathepsins is 
based on their structure and catalytic activity. They are serine proteases: Cathepsin A 
(CTSA) and G (CTSG); cysteine proteases: Cathepsin B (CTSB), C (CTSC), F 
(CTSF), H (CTSH), K (CTSK), L1 (CTSL1), L2 (CTSL2), L3 (CTSL3), O (CTSO), 
S (CTSS), W (CTSW) and Z (CTSZ); aspartyl proteases: Cathepsin D (CTSD) and E 
(CTSE). 152 Probes against transcripts encoding all cathepsins (except CTSG) were 
screened in the canine microarray. The highly expressed cathepsins were CTSK 




3,000), CTSB (signal intensity > 3,000), CTSH (signal intensity > 1,000), and CTSC 
(signal intensity > 1000). The most potent collagenase is CTSK, and its expression 
was high in MMVD and controls. 152,153 Cathepsin S  was another highly and 
differentially expressed cathepsin (2.27 fold-increased, p<0.001), and CTSS also has 
collagenolytic, elastinolytic and basement membrane cleavage (nidogen and laminin 
as substrates) activity. 152,154 Elevated CTSS expression in MMVD suggested a 
higher than normal enzymatic activity contributing to greater extracellular matrix 
degradation and basement membrane instability. Unlike the conflicting results for 
MMP expression, the findings on cathepsins (mRNA level) match the observation 
(protein level) in human myxomatous mitral valves, where CTSK and CTSS were 
also highly expressed in activated myofibroblasts. 56 The stimulatory factors and 
substrates of CTSS and CTSK are shown in Table 3-35. 
 
Table 3-35 Stimulatory factors and substrates of cathepsin S and K 155 
Cathepsins Stimulatory Factors Substrates 
Cathepsin K Angiotensin II, IL-1β, TNF-α, IFN-γ Elastin, collagen 
Cathepsin S Angiotensin II, IL-1β, IFN-γ, VEGF, 
bFGF, H2O2 
Elastin, collagen, 
fibronectin, laminin, nidogen 
 
Basement membrane components 
The basement membrane is a continuous specialized protein sheet underlying 
endothelial cells throughout the cardiovascular system, and is mainly composed of 
intertwined networks of laminin, nidogen, collagen type IV and HSPG2. The main 
function of the basement membrane is to structurally support endothelial cells and 
separate them from tissue compartments. Disruption of basement membrane results 
in vascular bedding instability. It is also known that different combinations of 
isoforms of laminin, HSPG2, and nidogen in the basement membrane structure result 
in different functions. In fact, dynamic regulation of a single basement membrane 
molecule can have influence on endothelial cell proliferation, migration, and 




In the gene network down-regulated genes associated with basement membrane, 
including laminin beta 1 (LAMB1), LAMA2, NID1, coupled with increased 
expression of Cathepsin S (CTSS) were identified in canine MMVD. Increased 
expression of cathepsin K and cathepsin S has been reported in human MMVD, and 
cyclic strain has been also shown to be associated cathepsin K expression in sheep 
mitral valves. 36,56 Since endothelial cells are suggested to be responsible for 
synthesis and deposition of basement membrane components, the current results 
might imply established endothelial damage and dysfunction due to mechanical 
stress and aging or valve endothelial cells locally dismantling basement membranes 
and acquiring a mesenchymal phenotype (EndoMT). 158,159  
In myxomatous mitral valves, marked endothelium denudation and exposure of 
basement membrane is found in severely affected mitral valves. 49 Collagen 6A3 
(2.46-fold decreased) also serves as an anchorage between basement membrane and 
interstitial matrices, and both endothelial and interstitial cells are capable of collagen 
VI synthesis. Decreased production of collagen VI suggests detachment of 
endothelial and interstitial cells from the basement membrane. 157 In myxomatous 
mitral valves, breakdown of NID1, laminin, collagen and elastin by CTSS (2.27-fold 
increased) impairs basement membrane integrity and stability. 154 Instability of the 
basement membrane in MV allows endothelial cell migration or EndoMT.  
Surprisingly, laminin expression in canine MMVD not only localized in the sub-
endothelium, but also marginally presented at the periphery of myxomatous region. 
48 The ectopic expression of basement membrane components may suggest an on-
going re-organization of endothelial-interstitial matrix network. 
Proteoglycan, HAS2, HAPLN1, CILP 
Proteoglycans (PGs) are composed of a core protein with one or more covalently 
attached GAGs. Classification of PGs can be based on the nature of their GAG 
chains, HA (hyaluronan), CS (chondroitin sulfate), DS (dermatan sulfate), HS 
(heparan sulfate) and KS (keratan sulfate) or size. Certain members are considered as 
"small leucine-rich proteoglycan family" (SLRP) such as decorin, biglycan, 
fibromodulin, and lumican. PGs are a major component of the extracellular matrix 




resistance to compression and tension. PGs are also involved in many biological 
functions such as cell migration, differentiation, proliferation, and signalling. 160 In 
early atrioventricular valve development, PGs and GAGs are the main components. 
70  
PGs (signal intensity) in normal and myxomatous mitral valves were the highest for 
any of the expressed transcripts. Lumican and versican were the top two PGs (signal 
intensity > 10,000), following by biglycan, decorin, and prolargin (signal intensity > 
5,000). CHAD and KERA were the only significantly down-regulated PG genes. 
Chondroadherin is a leucine-rich repeat protein which mediates adhesion of isolated 
cells (mainly chondrocytes) using integrin α2β1 and interacts with extracellular 
matrix. 161 Degradation of CHAD has been observed in scoliotic intervertebral discs, 
and has been suggested to play role in cartilage homeostasis and degeneration. 162 
Keratocan is a SLRP abundant in cornea and plays a pivotal role in organising 
extracelluar matrix assembly accounting for corneal transparency. 163 Grossly 
myxomatous mitral valves lose transparency as the disease develops, and down-
regulation of KERA in MMVD might explain these findings. There is no information 
on CHAD and KERA expression in normal and myxomatous mitral valves, but in a 
proteomic study the SLRPs decorin and biglycan were found up-regulated in early-
stage MMVD, but down-regulated in the late stage disease 164 In human MMVD, 
biglycan (protein), decorin (both mRNA and protein), and versican (protein) were 
found more abundantly expressed in myxomatous mitral valves compared with 
normal. 165,166 In the canine transcriptome there was no change in expression of the 
major PGs lumican, versican, decorin, and biglycan suggesting that cellular and 
structural changes in end-stage MMVD had no direct effect on PG genes expression. 
The variation of PG expression from different studies may suggest post-
transcriptional and translational modification of PG mRNA and proteins. 
 
Adhesion molecules 
The expression of cell adhesion molecules (CAMs) such as ICAM-1, PECAM-1 
(CD31), E-selectin (SELE), and VCAM-1 by endothelial cells has been shown to 




stimulated by inflammatory cytokines such as interleukins, TNF-α, and IFN-γ. 167,168 
In MMVD there is no inflammatory cell infiltration reported and this has been 
confirmed in this study. 12 Interestingly, increased expression of inflammatory 
cytokines with absence of inflammatory cells in canine MMVD are likely to be  
canine-specific as these are not reported in any human MMVD transcriptomic 
studies. 106,114,115 In the signal intensity analysis, ICAM-1, PECAM-1, E-selectin and 
VCAM-1 were screened. The expression of PECAM-1 was the highest (signal 
intensity > 3,000), and there was higher expression of SELE in MMVD valves. One 
study has also shown strong expression of E-selectin as well as VCAM-1 in 
myxomatous mitral valve. 168 
There are two layers of endothelial cells covering the atrial and ventricular sides of 
mitral valves. Between every endothelial cell, vascular endothelial cadherin (VE-
cadherin) is the major component of adherens junction, and it binds via its 
cytoplasmic domain to cytoskeletal proteins. Its functions include controlling closure 
and opening of the cell-cell endothelial adherens junctions, cell motility, and 
maintaining vascular permeability and integrity. VE-cadherin also plays a role in 
cell-cell signal transduction through intracellular partners such as p120, β-catenin, 
and plakoglobin. 167 The two major cadherins expressed by vascular endothelial cells 
are VE-cadherin (CDH5, CD144) and neuronal cadherin (N-cadherin, CDH2). 167 In 
the current microarray data, high expression of four cadherins was identified, 
including CDH13 (T-cadherin, heart, signal intensity > 3,000), CDH11 (OB-
cadherin, osteoblast, signal intensity > 2,000), CDH5 (VE-cadherin, vascular 
endothelial, signal intensity > 1,000), and CDH2 (N-cadherin, neural, signal intensity 
> 500). Unlike VE-cadherin and N-cadherin, where their localization is limited to the 
cell junction controlling intercellular adhesion, T-cadherin is equally distributed over 
the entire cell surface or concentrated at the leading edges of migrating cells, and this 
lack of transmembrane domain may suggest its role as migratory molecules rather 
than a true adhesion molecule. 169 Experimentally overexpression of T-cadherin in 
endothelial cells and smooth muscle cells promotes spontaneous cell migration, 
formation of stress fibres, and phenotype alteration from quiescent to pro-migratory. 
170 In cardiovascular disease, higher expression of H-cadherin has been found in 




receptor, which signals through ERK1/2 and promotes cell proliferation and 
migration. 171  
Phosphorylation and partial internalization of VE-cadherin weakens the intercellular 
junctions, and reduces endothelium permeability. However, down-regulation of VE-
cadherin through NOTCH-SNAI1 or TGF-β signalling permits endothelial migration 
and EndoMT (Figure 3-35). 86 In the current study, NOTCH1 was down-regulated, 
but the transcriptional factor RBPJK up-regulated in the transcriptome suggesting 





Figure 3-35 Model for NOTCH and TGF-β Superfamily Signalling in EndoMT. NOTCH 
signalling raises the level of TGF-β2. TGF-β2 also increases the activity of the transcription 
factor SNAI1. Increased SNAI1 expression results in down-regulation of VE-cadherin. Down-
regulation of VE-cadherin may be the initial event in the activation of EndoMT. NOTCH 





Cadherin-11 (CDH11) is a cell-cell adhesion protein mainly expressed at the junction 
between the mesenchyme and the osteoblasts, and it also participates in 
mesenchymal-to-osteochondral differentiation. 172 CDH11 has been showed to be 
expressed in endocardial cushion (both endocardial and mesenchymal cells) during 
valve development, and the expression becomes more restricted to endothelial cells 
in late valve remodelling. 172 In an aortic valve interstitial cell model, Hutchson has 
demonstrated myofibroblastic differentiation (increased α-SMA expression) of aVIC 
along with up-regulation of CDH11 by TGF-β1. In the same study, calcified aortic 
valve leaflets also showed increased co-expression of α-SMA and CDH11 in lesion 
sites.173 Compared with human aortic calcification, high but unchanged expression of 
CDH11 in canine MMVD may suggest an uninterrupted stimulation which maintains 
baseline osteochondral phenotype of valve interstitial cells.  
Fibronectin is a multi-domain glycoprotein, and is found in extracellular matrix and 
basement membrane. Fibronectin binds to collagen I, II, and III, and interacts with 
hyaluronan and heparan sulphate, which strengthens the fibrillar adhesion to cells. In 
addition, fibronectin also plays an important role in cell adhesion and migration. 174–
176 Functions of fibronectin in valve tissue remain largely unknown. In a wounding 
model (porcine mitral valve interstitial cells), there was expression of fibronectin at 
the wound edge by valve interstitial cells and this was associated with prominent 
fibrillar adhesions composed of α5β1 integrin (ITGA5 and ITGB1), suggesting its 
role in cell migration. 176 Realignment of extracellular fibronectin fibrils was also 
demonstrated to be associated with myofibroblast activation by TGF-β. 127 
Expression of fibronectin has been reported in canine normal (sub-endothelium and 
fibrosa) and myxomatous mitral valves (sub-endothelium and periphery of 
myxomatous areas). 48 Fibronectin mRNA level was unchanged in the present study 
and its association with myofibroblast activation in myxomatous mitral valves 
remains to be elucidated. 
EndoMT 
In heart development, EMT (epithelial-to-mesenchymal transition) plays a key role 
in endocardial cushion formation (Type I), whereas in adulthood, EMT plays a role 




subcategory of EMT, where cells switch from an endothelial to mesenchymal 
phenotype during the early stages of valvulogenesis and in myocardial fibrosis. In the 
transcriptomic profiling, an expression pattern suggestive of EndoMT was 
recognised, and this included differential expression of genes associated with 
basement membrane components, mesenchymal differentiation, and NOTCH 
signalling (Table 3-36). Briefly, there was a phenotypic transition into a 
mesenchymal phenotype in MMVD, which was represented as increased expression 
of mesenchymal markers, such as SM22 (TAGLN), and γ-SMA (ACTG2). The 
mesenchymal transition might be triggered by up-regulation of TGF-β superfamily 
members and their receptors (BMP6 and BMPR1). With the decreased expression of 
basement membrane components (NID1 and LAMA2) and increased expression of 
basement membrane lytic enzyme (CTSS), basement membrane disruption would 
permit migration of transitioned endothelial cells. The up-regulation of hyaluronic 
acid synthase 2 (HAS2) would allow production of the hyaluronic acid rich sub-
endothelial matrix necessary for EndoMT. This process will be discussed more detail 
in Chapter 5. 
Table 3-36. Differentially expressed genes associated with EndoMT. 
Category  Gene Fold- p-value Signal intensity 
  Change  Control MMVD 
Basement  Nidogen 1, NID1 -3.08 0.0004 1645 467 
membrane Laminin 2, LAMA2 -5.15 0.0011 365 69 
 Cathepsin S, CTSS 2.26 0.0001 1405 3310 
Mesenchymal  Myosin heavy chain 11, MYH11 4.93 0.0050 80 438 
Differentiation Transgelin, TAGLN, SM22 2.39 0.0042 1635 3994 
 Smooth muscle actin γ, ACTG2 15.35 0.0031 73 1473 
TGF-β & 
superfamily 
Bone morphogenic protein 6, 
BMP6 
2.38 0.0006 293 755 
Signalling Bone morphogenic protein 
receptor 1 B, BMPR1B 
2.20 0.0038 197 424 
 β-catenin, CTNNB1 1.38 0.0037 1866 2642 
 Hyaluronic acid synthase 2, 
HAS2 
2.18 0.0001 417 934 
NOTCH  NOTCH1 -2.33 0.0001 545 247 
Signalling RBPJ 1.60 0.0034 1401 2312 
 NFATC1 -1.87 0.0036 908 517 







There are several limitations to this study. Mitral valve tissues collected for diseased 
and control group have distinct age difference where MMVD valves were sampled 
from old dogs and control valves were sampled from young dogs. In addition, control 
mitral valves (Beagles) and diseased mitral valves (CKCSs) were collected from two 
breeds. Though breed-specific pathogenesis may exist, studies in Chapter 2 suggest 
that similar cellular changes and pathology could be found among different breeds.  
The total RNA was extracted from a heterogeneous population of cells from normal 
and myxomatous mitral valves, and the pooling of mRNA from cells with different 
phenotypes may decrease the expression variation of one gene; RNA profiling was a 
snapshot at two time points (normal and end-stage disease) and the genomic map and 
the discovered gene sets might be a reflection of difference in the tissue functioning 
over time, rather than initiators of myxomatous degeneration (cause or effect). In 
silico analysis of gene-gene interaction are based on databases derived from 
published literature (different experimental settings such as different cells and tissues 
used for modelling), and the gene networks may not necessarily represent the real 
relationship between genes in MMVD. Epigenetic control over gene expression such 
as microRNAs silencing mRNA could always be a factor for post-transcriptional 
modification, such that the transcriptional level will not completely represent the 
amount of protein translated, and will not always be representative of the end 
biological function. However, low or no expression of mRNA generally means low 
or no expression of the protein. The exception would be that some proteins have long 
half-lives, and they may be present when mRNAs are absent. 
While this is the first breed-specific transcriptional profiling in canine MMVD, age-
matched diseased-free control samples are nearly impossible to obtain. Aging itself is 
an important factor in canine MMVD, and it is impossible to tell MMVD valves 
from elderly CKCS are genetically similar. Thus, low grade (Whitney) and age-
matched mitral valves from CKCS may serve a better control samples. Since ECM 
deposition and lamination in valve tissues are regulated by multiple genes in short 
time spans it would be necessary to investigate dynamic transcriptional control of 




MMVD. 82 Lastly, there were a number of unannotated canine transcripts in the data 
sets, but seasonal updates for annotations can allow future re-analysis. 
Microarray data can be influenced by the biological system of interest and technical 
artefacts. Traditional methodologies of microarray analysis focused on identifying 
statistical differences (FDR, fold-change, and p-value) between groups of samples, 
and manipulating the cutoff setting can greatly affect the final gene list for data 
mining. BioLayout Express3D shows inter-individual variability which would 
influence averaged expression values and traditional fold-change values. This is 
consistent with the PCA result which placed one MMVD value sample close to 
control samples (3.3.2). Analysis through signal intensity value gave an impression 
of expression level, which allowed identification of a trend in genes of interest. 
However, there was no significant difference between normal and MMVD valves for 
some of the genes associated with EndoMT. This could be attributed to the 
variability of the samples which resulted in high standard deviation. The intragroup 
variability of the myxomatous valves could also be due to the different stages of 
degeneration, and these could not be identified grossly. Having evaluated the role of 
variability in reducing the power to detect significant differences, there were many 
differences that were not significant that warrant further investigation as they may be 
false negatives resulting from the lack of power. 
In conclusion, the characterization of MMVD identified by transcriptomic profiling 
and analysis included inflammation, cell movement, development, extracellular 
matrix organization and EMT. LDL signalling was also identified as an un-expected 
upstream regulator of differentially expressed genes. Two canonical pathways 
associated with endothelial functions identified were alveolar-mediated endocytosis 
and endothelin signalling, supporting a role for the endothelium in MMVD. Signal 
intensity analysis identified genes involved in extracellular matrix components, 
EndoMT, and valve development. There were patterns of gene expression consistent 
with weakening of ECM networking, disruption of basement membranes, increased 
cell migration potential, active endothelial differentiation and myofibroblastic 





4 Chapter 4 Analysis of Gene Expression in MMVD by 
Quantitative Polymerase Chain Reaction (Q-PCR) 
4.1 Introduction 
Q-PCR has been favourably used as a technique to validate microarray data for a 
decade in numerous high-throughput transcriptomic studies. 177 One study showed 
marked quantitative concordance between Q-PCR and microarray when the 
candidate genes are high in signal intensity (spot intensity) and with low variability. 
178 This is considered as “high-quality” microarray data and rarely requires 
validation. However, a major drawback of microarrays is the narrow dynamic range 
for differentiating the genes with weak signals due to background noise interference, 
whereas Q-PCR has wider dynamic range and is capable of detecting differential 
expression in less abundant genes. 178 In the same study, it was also suggested that up 
to 21% of genes in this category may be false negatives determined by microarray. 
This could also vary from sample to sample such as RNAs extracted from cell 
culture and tissue. 
In this study, the aim was to validate microarray data from different groups of signal 
intensities that had been determined as differentially expressed by microarray. Two 
groups of genes were selected for Q-PCR. Group A were genes selected based on 
their signal intensity for validation. Group B were genes known to be involved in 
EndoMT which showed a trend of expression pattern in their signal intensities, but 
there was no statistical support for differential expression. In group A, a total of 15 
candidate genes, which were initially identified by microarray analysis (out of total 
possible list of 5397 genes) were selected for validation, and were sub-divided into 







Table 4-1 Classification of candidate genes for Q-PCR assays 
Group Criteria Gene 
Group A1 
signal intensity for MMVD and 
control both < 512 
LAMA2, MYH11, MMP12, 
ANGPT1 
Group A2 
signal intensity for MMVD and 
control both ≥ 512 
ENG, CHAD, KERA, SOX9 
Group A3 
signal intensity for MMVD and 
control; one ≥ 512 and one < 512 
COL6A3, HTR2B, BMP6, 
ADAMTS19, ACTG2 
Group B 
EndoMT associated gene 
not identified as differentially 
expressed by microarray 
NOTCH1, HAS2, ACTA2, 
CDH5, SNAI1 
4.2 Material and Methods 
4.2.1 First-strand cDNA synthesis for Q-PCR 
For each sample (3 controls and 3 MMVD RNA samples used for microarray 
analysis), 4 to 5 µg of total RNA was used for first-strand cDNA synthesis for Q-
PCR. Total RNA, 1 µl of oligo (dT)20 (Invitrogen), 1µl of 10mM dNTP MIX (10 
mM each dATP, dGTP, dCTP and dTTP at neutral pH) (Invitrogen) and distilled 
water (to 13µl total volume) were added to a nuclease-free micro-centrifuge tube. 
The sample was heated at 65˚C for 5 minutes and incubated on ice for 1 minute. The 
content then was collected by a short centrifugation, and mixed with 4µl of 5x first-
strand buffer (Invitrogen), 1µl of 0.1 M DTT (Dithiothreitol) (Invitrogen), 1 µl of 
RNaseOUT Recombinant RNase Inhibitor (Invitrogen), and 1 µl of SuperScript III 
RT (200 units/µl) (Invitrogen) were added to the micro-centrifuge tube. The content 
was mixed by gentle pipetting and incubated at 50˚C for 45 minutes, followed by 
heat inactivation at 70˚C for 15 minutes. The cDNA was used as a template for 






Roche Universal Probe Library system (Roche Applied Science) in combination with 
the Roche Probe Master (Roche Applied Science) was used for Q-PCR. Six RNA 
samples used for microarray were validated by Q-PCR. Assays for 15 differentially 
expressed genes, 3 genes of interest (ACTA2, CDH5, and SNAI1 which were not 
differentially expressed) and one reference gene (Table 4-2) were designed as 
previously reported. 179 
Table 4-2 Primer Sequences for Microarray Data Validation by Q-PCR 
Gene Name Forward Primer Reverse Primer 
Probe 
No. 
Microarray validation   
LAMA2 5’ccgcattgagctgacagtag3’ 5’caaactggttgaggccatct3’ 38 
ENG 5’ggtgctcaagaaagacctcatc3’ 5’gcaggacaaactggtcatctc3’ 30 
COL6A3 5’aaggaagcttcagcacaaaga3’ 5’tgaactagaagccaaccttgc3’ 39 
HTR2B 5’ggtctggattacaaacagaatcg3’ 5’tccctgttgctcaccagtct3’ 6 
MYH11 5’atgcagctggccaagaag3’ 5’tctgagcaatttcatcatcgag3’ 81 
MMP12 5’ccaatttgagttttgatgctgt3’ 5’cactgttctttggactctctgga3’ 22 
BMP6 5’tctccagcgcctcagattac3’ 5’tggaagctcacatacagctca3’ 4 
ANGPT1 5’aggaaacgaaaagcagaactaca3’ 5’atcagcaccatgtaagatcagg3’ 18 
CHAD 5’ccagtctttcggcagatacc3’ 5’acatgtttcagtgtggtcacg3’ 20 
ADAMTS19 5’tcaaccctgcaatgagaaga3’ 5’cgtatcactcggcagtacaca3’ 14 
ACTG2 5’ggtcatcaccattggcaac3’ 5’tgaatcccagcagactccat3’ 11 
SOX9 5’ ccaacgccatcttcaagg3’ 5’ ggagtgcacctcgctcat3’ 63 
KERA 5’ gactatgcatgactttgactgtcc3’ 5’tttcacagtataaagcagtagggaaa3’ 29 
HAS2 5’aggtgtcgggggagatgt3’ 5’aaaagccatccagtatctcaca3’c 12 
NOTCH1 5’gccaacaaagacatgcagaa3’ 5’cttggcggtctcatagctg3’ 63 
Genes of interest (EndoMT)   
ACTA2 5’cggctactcctttgtgacg3’ 5’cgtggccatctcgttctc3’ 81 
CDH5 5’tgcatcctcaccatcacagt3’ 5’agctgctcgtggatctcg3’ 4 
SNAI1 5’caagatgcacatccgaagc3’ 5’agcaggaaaacggcttctc3’ 66 
Reference Gene   




Probe and Primer Design 
For the candidate genes, corresponding canine cDNA sequences of the transcripts 
were found at Ensembl. 180 Briefly, the sequence was copied into Word (Office. 
Microsoft). Parentheses ([]) were inserted to represent introns in the sequence. The 
modified sequence was then copied into Assay Design Centre (Roche Applied 
Science) and the function of intron spanning assay strategy was enabled. Since 
canine is not a specified species in the Roche system, “Other Organism” was 
selected. Once all the parameters were correctly indicated, the primers were 
designed. The rules for assay designing were 1) closer to 5’ end, 2) intron crossing, 
3) sequence double-checked (BLAST). 181 The primers designed for microarray 
validation were LAMA2, ENG, COL6A3, HTR2B, MYH11, MMP12, BMP-6, 
ANGPT1, CHAD, ADAMTS19, ACTG2, SOX9, KERA, HAS2, NOTCH1, ACTA2 
, CDH5, SNAI1, and the endogenous control gene MRPS25 was used for 
normalization. Primers (MWG Biotech) and probes (Universal Probe Library, Roche 
Diagnostics) were synthesized using locked nucleic acids with the 5′-end labelled 
with a reporter fluorescein dye (FAM, 6-carboxy fluorescein) and 3′-end labelled 
with a dark quencher dye. 
Q-PCR Assay Set-up 
Primers were dissolved in the suggested volume of water to create a concentration of 
100 pmol/µl. Q-PCR assays were performed in triplicate in 96-well plates with one 
no-template-control (RNase-free water) for each sample. Occasionally Q-PCR 
reactions were performed in duplicate with one no-template-control due to the 
limited sample volume. For each well, the reaction mix consisted of 0.1 µl sequence 
specific probe (Universal Probe Library, Roche), 0.2 µl primers (100 pmol/ µl), 5 µl 
of 2x master mix (Roche Diagnostics), and 4.7 µl of first strand cDNA (200 – 400 
ng/ µl). After reaction mix and the cDNA were separately pipetted into the 
designated wells (Table 4-3) the plate was sealed with adhesive PCR film (Thermo 
Scientific) and wrapped with tin foil to protect it from light. The plate was then 
vortexed for sufficient mixing of the reagents and centrifuged at 15,000 rpm 
(Eppendorf Centrifuge 5810R with plate holder) for 5 minutes at 4°C. The plate then 




Diagnostics). The amplification was programmed and performed according to a 
standard PCR cycle (Table 4-4). 
Table 4-3 Plate design for Q-PCR 














































*For each well, 5.3µl reaction mix (RM) and 4.7 µl cDNA made up 10µl reaction 
volume. NTC, no template control. 
 
Table 4-4 Standard protocol for Q-PCR 
Action Temperature Time Cycle 
Pre-incubation 95°C 10 minute  
Amplification 
95°C 10 second 
45 60°C 30 second 
72°C 1 second 
Cooling 40°C 30 second 1 
 
The result for each well was presented as crossing point (C) and threshold value at a 
constant level of fluorescent signal. Q-PCR data were analysed using LightCycler 
480 Basic Software (Roche Diagnostics). The endogenous control (MRPS25) was 
used for normalization, and the relative expression level was calculated following the 
∆Ct Method (the comparative Ct). Mann–Whitney U test was used for statistical 
analysis on the ∆Ct values between diseased group and control group.  
The equation for calculating relative expression (R): 
 
R = 2-[Ct sample – Ct control] 





Theoretically, for the comparative Ct method to be valid, the efficiency of the target 
amplification (genes of interest) and the efficiency of the endogenous control 
(reference gene) amplification should be approximately equal. Therefore, efficiency 
tests for all primers were performed. Briefly, cDNA samples were serially diluted to 
create a sequence of [1], [1:10], and [1:100] for the standard curve, and the plate for 
Q-PCR was allocated as shown in Table 4-5. In general, the acceptable value for 
efficiency rate should be within 90% to 110%. Examples of the efficiency rate (E) 
calculation for MRPS25 are shown in Table 4-6 and Figure 4-1. 
Table 4-5 Plate design for primers efficiency rate test 
Primer 1 Primer 2 Primer 3 Primer 4 
1 1 1 1 1 1 1 1 1 1 1 1 
1:10 1:10 1:10 1:10 1:10 1:10 1:10 1:10 1:10 1:10 1:10 1:10 
1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 
 
Table 4-6 Q-PCR Cp value and input concentration for MRPS25 
Name log(Con.) Cp Con. 
MRPS25 0 23.88 1 
MRPS25 0 23.91 1 
MRPS25 0 23.98 1 
MRPS25 -1 27.08 0.1 
MRPS25 -1 27.20 0.1 
MRPS25 -1 27.13 0.1 
MRPS25 -2 30.52 0.01 
MRPS25 -2 30.25 0.01 
MRPS25 -2 30.31 0.01 
*Con. = concentration 
 
 
Y axis = Cp value 
X axis = cDNA input (dilution) 
SLOPE = -3.21833 
POWER = (10,-1/SLOPE)) = 2.045 
E = 100*(POWER-1) = 104.51 





4.2.3 Statistical Analysis 
Considering the very small sample size in this study (control n=3, disease n=3), 
normality testing was not conducted and non-parametric tests provided no power. 
Student’s t-test was used to compare the relative expression (R) between the two 
groups. P-value less than 0.05 was considered significant. 
 
4.3 Results 
4.3.1 Primer Efficiency Rates 
Efficiency rates for primers were determined prior to PCR reaction, and are 
summarized in Table 4-7. For 16 of 19 primers (including the house-keeping gene: 
MRPS25) efficiency rates were between 90% and 110%. However, there were three 
primers (MYH11 = 89.79%, KERA = 116.31%, and HAS2 = 128.48%) that were not 
within the ideal range (Figure 4-2). 
 
Table 4-7 Efficiency rate for primers  
Gene Name Probe No. Efficiency Rate  Gene Name Probe No. Efficiency Rate  
LAMA2 38 96.45 ACTG2 11 93.92 
ENG 30 95.36 SOX9 63 108.19 
COL6A3 39 99.52 KERA 29 116.31 
HTR2B 6 95.10 HAS2 12 128.48 
MYH11 81 89.79 NOTCH1 63 103.76 
MMP12 22 93.86 ACTA2 81 102.00 
BMP6 4 96.06 CDH5 4 109.31 
ANGPT1 18 97.10 SNAI1 66 93.06 
CHAD 20 100.22 MRPS25 15 104.51 





Figure 4-2 Primer efficiency rate for 19 designed primers. The primers for MYH11, KERA, and 
HAS2 are out of ideal range (90% - 110%) 
4.3.2 Microarray Data Validation by Q-PCR 
Microarray data validation was conducted by Q-PCR assays for 15 differentially 
expressed genes. Although there were differences in the magnitude of expression 
level, the trends of expression for each gene were generally in agreement with the 
microarray result (Figure 4-3). Thirteen genes (LAMA2, ENG, COL6A3, HTR2B, 
MYH11, MMP12, BMP6, ANGPT1, CHAD, ADAMTS19, ACTG2, KERA, and 
NOTCH1) were significantly and differentially expressed and did not conflict with 
the microarray result (Table 4-8). However, there was no difference for the 
expression of SOX9 (p = 0.41) and HAS2 (p = 0.15) in the Q-PCR assay, conflicting 





Figure 4-3 Fold changes for differentially expressed genes determined by microarray and 
validation by Q-PCR. ns = not significant. 
 








LAMA2 -5.15 -13.18 ± 1.35 0.0005 
ENG -1.52 -1.98 ± 1.13 0.0033 
COL6A3 -2.47 -5.72 ± 1.17 0.0004 
HTR2B 5.78 2.87 ± 1.39 0.0170 
MYH11 4.93 15.03 ± 2.62 0.0151 
MMP12 3.82 3.01 ± 1.07 0.0021 
BMP6 2.38 4.57 ± 1.50 0.0116 
ANGPT1 3.65 2.93 ± 1.52 0.0218 
CHAD -3.17 -7.04 ± 1.81 0.0048 
ADAMTS19 -4.52 -9.52 ± 1.76 0.0023 
ACTG2 15.35 15.87 ± 2.25 0.0053 
SOX9 -1.73 -1.66 ± 2.54 0.4186 
KERA -2.29 -6.61 ± 1.47 0.0012 
HAS2 2.18 4.96 ± 2.14 0.1539 
NOTCH1 -2.33 -4.12 ± 0.55 0.0001 




4.3.3 Q-PCR for Genes Related to EndoMT 
Q-PCR assays for three genes (ACTA2, CDH5, and SNAI1) were found to be 
differentially expressed (0.01 < p < 0.05) between MMVD and control samples, with 
ACTA2 and SNAI1 up-regulated, and CDH5 down-regulated in myxomatous mitral 
valves (Table 4-9). The expression patterns for these 3 genes were also in agreement 
with their microarray signal strengths. 
 
Table 4-9 Microarray validation by Q-PCR (ACTA2, CDH5, and SNAI1) 




ACTA2 10.66 ± 1.23 0.027 329 1857 
CDH5 -2.59 ± 0.70 0.029 1630 877 
SNAI1 4.80 ± 0.31 0.045 162 419 
Data presented as Mean ± standard deviation 
 
4.4 Discussion 
Overall, Q-PCR provided consistent result in the trend (up- or down-regulated) of 
gene expression in all candidate genes in Group A and Group B, but 2 genes (SOX9 
and HAS2) in Group A showed no evidence of differential expression (p > 0.05). 
In Group A, all the candidate genes belonging to A1 (low-low signal intensity) were 
in agreement with the microarray data, and this suggests robust data can be obtained 
even when genes have weak signal strengths (< 512) and high intragroup variability. 
However, SOX9 in Group A2 and HAS2 in Group A3 were found to have no 
difference in gene expression, and these findings were most likely due to primer 
efficiency issues, in which the primer for SOX9 was 108.19% (<110%, borderline) 
and HAS2 was 128.48% (>110%, overly exceeding optimal limit). No additional 
samples were available to allow further Q-PCR assays under better primers design. 




(high-high) and A3 (high-low or low-high) where the signal intensities between 
control and diseased groups were clear, it is reasonable to give priority to the 
microarray findings over the Q-PCR results.  
In Group B, the trends for expression of 3 genes (ACTA2, CDH5, and SNAI1) 
associated with EndoMT were determined by looking at their individual signal 
intensities. However, they were not classified as differentially expressed genes by 
microarray due to their high intragroup signal strength variability (Figure 3-33, 3-24, 
3-29 respectively). Q-PCR results suggested that the three genes were significantly 
differentially expressed (at 0.01 < p < 0.05) comparing MMVD and control mitral 
valves. The reason why these genes were not discovered in the microarray may be 
due to the limited dynamic range of microarray analysis. Due to the large number of 
test conducted, it can be argued the p-value < 0.05 was not sufficiently stringent to 
claim significance using Q-PCR platform, and all three genes should have not be 
described as differentially expressed (Table 4-9). It is less biased to analyse the raw 
genomic expression profile (3.3.6 and 3.3.7) as a trend by platforms such as 
BioLayout Express3D rather than on processed fold-change. To discover the accurate 
genomic expression of these genes, recruiting more samples in both groups and 
repeating Q-PCR assays with better designed primers is required.  
The genomic expression at transcriptional level is not always equal to the 
translational level (protein) due to post-transcriptional modification mechanisms 
such as miRNAs silencing, and the fold-change difference on RNA expression does 
not necessarily represent true difference biological function in vivo. It is necessary to 
conduct protein quantification to validate if these mRNAs were translated into 
protein. Finally, since both microarray and Western Blotting are screening global 
mRNA and protein concentration from a heterogeneous cell population in mitral 
valves, performing immunohistochemistry (localization and qualitative study) would 
provide valuable information. 
One challenge that limited the experimental design is the small sample size of the 
mitral valve tissues collect from small breed dogs. Generally, anterior mitral valve 
leaflet was mainly used for RNA extraction (microarray and Q-PCR), and posterior 




found all over the two leaflets, it would be ideal to collect tissues for RNA isolation, 






5 Chapter 5 Reactivation of developmental pathways in 
Canine Myxomatous Mitral Valve Disease 
5.1 Introduction 
Johannes Holtfreter in the 1920s and Elizabeth Hay in the 1960s, and many others, 
identified epithelial-to-mesenchymal transition (EMT; Type 1) as being fundamental 
to embryo formation and differentiation. EMT, and its reverse MET, explains a 
process of cell phenotypic plasticity that not only allows organ development, but also 
may have a role in disease pathogenesis. 182 More recently the recognition of the role 
of EMT (Type 2 inflammatory) in conditions such as chronic fibrosis (renal, skin, 
cardiac, lung etc) and tumour malignancy (Type 3) not only helps to explain disease 
pathogenesis, but also identifies potential therapeutic targets. 1 The analogous 
process of EMT in heart valve development is EndoMT. The valve endothelium is a 
specialised form of squamous epithelium and can give rise to the analogous forms of 
the three types of EMT described above. In early valve development, endothelial 
cells lining the primitive heart tube at the sites close to where the atrio-ventricular 
(A-V) canal and outflow tract develop undergo EndoMT and invade the cardiac jelly 
and form the endocardial cushions. The A-V cushion eventually contributes to 
development of the mitral and tricuspid valves and is derived predominantly through 
EndoMT. The initiation of EndoMT is closely regulated by several growth factor-
mediated signalling pathways including VEGF, TGF-β, BMP and NOTCH. 65 The 
mesenchymal cells that form VICs then contribute the extra-cellular matrix of the 
developing valve through to adulthood. In the adult valve it is presumed that VICs 
are predominantly quiescent or contributing to low level life-long valve remodelling, 
but during MMVD the VICs become activated, produce catabolic enzymes and 
contribute to matrix destruction and mechanical valve failure. 48,56,114,183 The exact 
mechanism by which these cellular changes occur is unknown, but one possible 
explanation is that it is a re-manifestation of EndoMT; a situation where 
developmental biology pathways designed to make the valve in the first place are 




Important to valve formation from the endocardial cushion is the presence of cardiac 
jelly, which is mainly composed of the glycosaminoglycan hyaluronan (HA; 
hyaluronic acid) and is initially produced from the adjacent myocardium through the 
activity of HAS2. 80,83 The accumulation of HA causes expansion of the extracellular 
space and the HA-rich environment favours migration of transformed endothelial 
cells, and induces PI3K and ErbB2/3 signalling that promotes cell proliferation. In 
cultured embryos, disruption of HA synthesis prevents endocardial cushion 
formation. 85 
On the cellular level, endocardial endothelial cells undergo phenotypic transition by 
losing endothelial phenotype markers such as platelet endothelial cell adhesion 
molecule (PECAM-1, CD31), and VE-cadherin and begin to express the 
mesenchymal marker α-SMA. Their migratory ability is also obtained by losing cell-
to-cell contact (loss of VE-cadherin) and secreting matrix metalloproteinases 
(MMPs, collagenases) which degrade the endocardial basal lamina. At the 
endocardial cushion, EndoMT contributes to the mesenchymal cells by the migration 
of the transformed endothelial cells into the underlying HA and chondroitin sulfate-
rich cardiac jelly. 
There is also evidence from other diseases that EMT can contribute to disease 
pathogenesis. Chronic fibrotic conditions and cancer are the best examples, and in 
the case of cardiovascular disease, at least in mouse models of myocardial fibrosis, 
EMT and EndoMT have both been implicated. This is not necessarily surprising 
considering 1/3 of cardiac fibroblasts in mouse myocardium are of endothelial origin. 
2 In the case of myocardial fibrosis the process appears to be driven by the TGF-β 
signalling pathway, which is also up-regulated in human MMVD although this was 
not observed in the current study of canine MMVD (Chapter 3). 61,184 
Myxomatous degeneration results in destruction of the valve fibrosa and expansion 
of the spongiosa. In the advanced stages of the disease the distal leaflet lacks 
structure and the stroma primarily consists of glycosaminoglycans. 51 To that extent 
the valve structure somewhat resembles embryonic mesenchyme. At the same time 
there is evidence of endothelial cell loss and activation with accumulation of α-SMA 




complex developmental signalling pathways to MMVD pathogenesis has been 
recently suggested. 65 Since osteogenesis and chondrogenesis can be identified in 
aortic and mitral valves this would be further evidence that development signalling 
pathways are activated in different chronic valvulopathies. 65,185,186 Suggested 
possible candidate signalling pathways include BMP-Sox9, Wnt and NOTCH. 65  
In the chapter 3 and 4, differentially expressed genes indicating myofibroblastic 
differentiation, basement membrane disruption, and remodelling of endothelial 
adherens junctions were identified. The biological functions of these genes might 
suggest potential EndoMT in MMVD. However, data are limited to the 
transcriptional level and the cellular and tissue distributions of the encoded proteins 
are unknown. This study investigated evidence of EndoMT in MMVD by localizing 
expression of key EndoMT markers including α-SMA, CDH5, SNAI1, and HAS2. 
 
5.2 Material and Methods 
5.2.1 Tissue Sample 
Myxomatous (n=14) and normal (n=12) mitral valves were collected from a 
population of mixed breed and age dogs, and Cavalier King Charles Spaniels 
presented to the Hospital for Small Animals, Royal (Dick) School of Veterinary 
Studies, the University of Edinburgh or from Beagles from Charles River 
Laboratories, Tranent, UK. The mitral valve tissue collection followed the same 











Table 5-1 Detail information of mitral valve samples 





Myxomatous Mitral Valve n=14     
2010/01 CKCS 7y Male 3 Severe 
2009/59 CKCS 10y Unknown 4 Severe 
2009/51 CKCS Unknown Male 3 Severe 
2009/50 CKCS 11y Female 3 Severe 
2009/41 CKCS 10y Male 3 Severe 
2009/33 CKCS Unknown Unknown 4 Severe 
2011/01 CKCS 10y Female 3 Severe 
2009/07 CKCS Unknown Unknown 3 Severe 
2011/02 CKCS 13y Female 3 Severe 
2010/07 Labrador Retriever 6y Male 2 Mild 
2010/10 Terrier X 9y Male 2 Mild 
2011/33 Border Collie 5y Male 2 Mild 
2012/17 Mongrel 3y Female 3 Severe 
2012/23 Mongrel 4y Male 1 Mild 
Control Mitral Valve n=12     
2013/02 Beagle 1y Female 0 Normal 
2013/01 Beagle 1y Female 0 Normal 
2013/03 Beagle 1y Unknown 0 Normal 
2012/03 Beagle 1y Unknown 0 Normal 
2012/07 Beagle 1y Unknown 0 Normal 
2013/04 Beagle 1y Female 0 Normal 
2013/08 Beagle 1y Male 0 Normal 
U82 Beagle 5y Female 0 Normal 
2011/29 Mongrel 5y Male 0 Normal 
2012/22 Mongrel 2y Unknown 0 Normal 
2011/15 Mongrel 1y Female 0 Normal 
2011/16 Mongrel 1y Male 0 Normal 
 
5.2.2 Immunohistochemistry 
Please refer to 2.2.3. Antibodies used in this chapter are summarized in Table 5-2. 
Table 5-2 Antibodies and working concentration used in this study 
Name Clonality IHC Made Cat. No. 
Primary Antibody     
α-SMA Ms monoclonal 1:400 Sigma A2547 
CDH5 Rb polyclonal 1:50 Abcam Ab33168 
HAS2 Rb polyclonal 1:50 Abcam Ab168816 
SNAI1 Rb polyclonal 1:200 Santa Cruz A1509 
Secondary Antibody     
Alexafluor 488 Goat anti-Ms IgG (H+L) 1:100 Invitrogen A10667 
Alexafluor 568 Goat anti-Rb IgG (H+L) 1:100 Invitrogen A11011 
Biotinylated Antibody Goat anti-Rb IgG (H+L) 1:1000 Vector BA-1000 





For each dog, a minimum of four sections were examined for each antibody. Positive 
controls included canine skin and duodenum, and for negative controls the primary 
antibody was omitted.  
 
5.2.3 Image capture and Statistical analysis 
Images were taken using a light microscope with fluorescent filters (Leica-DMLB). 
Tile-scanning was performed using a Zeiss LSM-710 confocal microscope. Semi-
quantitative analysis of staining was graded as: 0, no staining; 1 mild <30% of cells; 
2 marked between 30% and 60% of cells; 3 diffuse and strong >60%. MMVD valves 
and controls were blindly graded at distal and middle portion (negligible 
myxomatous changes) as shown in Figure 5-1. The Mann-Whitney test was used to 
compare the semi-quantitative value between the two groups. P-value less than 0.05 
is considered significant. Qualitative and semi-quantitative assessment was carried 
out on the NovaRed stained (2.2.3) sections (HAS2). Fluorescent double-labelled 
sections (α-SMA/CDH5, α-SMA/HAS2, and α-SMA/SNAI1) were examined 
qualitatively.  
 














5.3.1 Spatial and Temporal Distribution of Activated 
Myofibroblasts in MMVD and Normal MV 
All tile scanning images were orientated in a similar way, with atrial side upward and 
edge of the mitral valve leaflet towards left (Figure 5-2).  
 
Figure 5-2 Orientation of the confocal microscopy images. M = myxomatous region 
In the normal mitral valves no α-SMA positive cells were observed at the leaflet tip. 
However, in most normal mitral valves, there was a single layer of myofibroblasts in 
the mid-zone at the atrial side of the leaflet, and no α-SMA staining was noted on the 





Figure 5-3 Photomicrograph of a full length mitral valve leaflet from a healthy dog. Tile 
scanning image from confocal microscopy. (Top) Immunofluorescence staining for α-SMA 
(green). (Bottom) Image merged with DAPI nucleic counterstaining (blue). Myocytes were 
positive for α-SMA, and there was a single layer of myofibroblasts at the mid atrial surface. 
Scale bar = 500µm 
Bundles of myocytes at the basal part of the leaflet were also positive for α-SMA. 
Occasionally, there was a small number of α-SMA positive myocytes extending to 
the middle portion through spongiosa layer (Figure 5-4). Small linear clusters of 





Figure 5-4 Tile scanning image of a normal mitral valve. (Top) Immunofluorescence staining for 
α-SMA (green). (Bottom) Image merged with DAPI (blue). Aggregation of myofibroblasts were 
seen in the mid portion at the atrial surface. Scale bar = 500µm. 
In the mildly affected valves, nodular thickening changes were noted at the distal-
zone with additional linear clusters of myofibroblasts aggregating adjacent to the 
sub-endothelium. In the distal myxomatous regions, the myofibroblast clusters were 
seen on both atrial and ventricular sides, and there was an extension (connection) 
between sub-endothelial myofibroblast clusters and stroma myofibroblast clusters 
(Figure 5-5 and Figure 5-6). 
In the mid zone, where there was no obvious pathology, myofibroblast clusters were 
also seen at the atrial side as a single linear layer. Myocytes bundles at the proximal 
portion were also positive for α-SMA (see comment above). Due to section folding, 
occasionally antibody was trapped and resulted in artefact signal of α-SMA staining 





Figure 5-5 Tile scanning image of a mildly affected mitral valve. (Top) Immunofluorescence 
staining for α-SMA (green). (Bottom) Image merged with DAPI (blue). Single layer of 
myofibroblasts was observed in the mid portion at atrial surface. The artefact (antibody 
trapped owing to section folding) of α-SMA staining indicated by white arrow was found in the 
mid-portion. Scale bar = 500µm. 
 
Figure 5-6 Tile scanning image of a mildly affected mitral valve. (Top) Immunofluorescence 




myofibroblasts was observed in the middle and distal portions at atrial surface. However, no 
pathological changes were observed in the middle portion. Small numbers of myofibroblast 
clusters were also noted in the distal myxomatous region. Scale bar = 500µm. 
 
Figure 5-7 Tile scanning image of a mildly affected mitral valve. (Top) Immunofluorescence 
staining for α-SMA (green). (Bottom) Image merged with DAPI (blue). From basal to distal 
portion, linear clusters of myofibroblasts were evenly distributed along the atrial side of the 
leaflet. At the myxomatous region, whorl-like pattern of myofibroblast localization can be seen 
(white arrow). Scale bar = 500µm. 
 
In one mildly affected MMVD valve, at the junction (neck) of myxomatous and 
normal MV structure, there were high numbers of myofibroblasts aggregating in the 





Figure 5-8 Tile scanning image of a mildly affected mitral valve. (Top) Immunofluorescence 
staining for α-SMA (green). (Bottom) Image merged with DAPI (blue).  At the mid portion, 
single layer of myofibroblasts was found in the mid atrial surface of the leaflet (no myxomatous 
pathology). At the distal end, linear clusters of myofibroblasts were found at the sub-
endothelium and myxomatous stroma. In this mitral valve, higher cellularity of myofibroblasts 
were noted at the distal end atrial surface. Interestingly, at the junction (neck) of myxomatous 
and normal MV structure, there were high numbers of myofibroblasts aggregating (white 
arrow) in the stroma (spongiosa layer). Scale bar = 500µm. 
In the severely affected valves, whorl-like aggregations of myofibroblasts were seen 
in the expanded distal-zone stroma (Figure 5-9), and a marked increase in cell 
numbers was also noted. Furthermore, myofibroblast clusters were found localized at 
atrial and ventricular sides and they were restricted to the edge of the leaflet and 
myxomatous stroma. Surprisingly, there were no noticeable changes in the structure 








Figure 5-9 Tile scanning image of a severely affected mitral valve. (Top) Immunofluorescence 
staining for α-SMA (green). (Bottom) Image merged with DAPI (blue). Large numbers of 
myofibroblasts were found in the myxomatous stroma in a whorl-like pattern. At the junction of 
myxomatous and normal mitral valve structure, linear clusters of myofibroblasts were noted at 












Figure 5-10 Tile scanning image of a severely affected mitral valve. (Top) Immunofluorescence 
staining for α-SMA (green). (Bottom) Image merged with DAPI (blue). Large numbers of 












5.3.2 HAS2 Expression in Normal and Myxomatous Mitral Valves 
In normal mitral valves, there was a clear and continuous expression of HAS2 in 
endothelial cells predominantly at the atrialis side. Sparse expression of HAS2 was 
present in the spongiosa (Figure 5-11A and C). In contrast, HAS2 expression in the 
myxomatous mitral valve free edge was diffuse and a similar expression pattern of 
HAS2 was seen in the mid-zone (Figure 5-11B and D). Semi-quantitative analysis 
showed that expression of HAS2 at the free edge of the myxomatous mitral valves 
was significantly higher than the normal mitral valves, but there was no difference in 
the mid-zone of normal and myxomatous mitral valves (Figure 5-12). 
A B  
C D  
Figure 5-11(A)(C) Normal mitral valve. (B)(D) Myxomatous mitral valve. (A) In normal mitral 
valve mid-portion, HAS2 was expressed by interstitial cells in the spongiosa and endothelial cells 
at atrial and ventricular surface. Minimum amount of HAS2 was expressed in fibrosa layer. (B) 
In myxomatous mitral valve mid-portion, HAS2 expression was similar to normal mitral valve. 
Loose collagen bundles were seen in the fibrosa layer. (C) In the distal end of normal mitral 
valve, HAS2 was also expressed by endothelial cells at the valve surface, and a few interstitial 
cells were also positive for HAS2. (D) In the distal end of myxomatous mitral valve, HAS2 was 






Figure 5-12 Semi-quantitative analysis of HAS2 immunohistochemistry. The expression of 
HAS2 was higher in the distal portion of the myxomatous mitral valves compared with normal 
mitral valves. There was no difference in HAS2 expression in the middle portion of the 
myxomatous and normal mitral valves. Difference were assessed using the Mann-Whitney test. 
 
 
5.3.3 Myofibroblastic Expression of HAS2 in Myxomatous Mitral 
Valve 
In normal mitral valves, localized expression of HAS2 was observed in the 
endothelium and spongiosa. Most HAS2 positive interstitial and endothelial cells 
were not associated with α-SMA stained cells, but a few HAS2 positive endothelial 






Figure 5-13 Photomicrograph of 
immunofluorescence staining for HAS2 
(red). Atrial endothelial cells were 
expressing HAS2. Canine normal mitral 
valve. Scale bar = 50µm. 
Figure 5-14 Photomicrograph of double-
immunofluorescence staining for HAS2 
(red) and α-SMA (green). Atrial sub-
endothelial cells were positive for α-SMA. 
Interstitial cells in the spongiosa layer were 
also positive for HAS2. Canine normal 




Figure 5-15 Photomicrograph of double-immunofluorescence staining for HAS2 (red) and 
α-SMA (green). The mitral valve atrial endothelial cells were co-expressing HAS2 and α-






Figure 5-16 Photomicrograph of double-
immunofluorescence staining for HAS2 
(red) and α-SMA (green), and nuclei 
counterstained with DAPI. Mitral valve 
endothelial cells at the atrial surface were 
positive for HAS2 but negative for α-
SMA. Myofibroblasts (α-SMA positive 
cells) adjacent to the atrial endothelial 
cells were not associated with HAS2 
expression. Canine normal mitral valve. 







In myxomatous mitral valves, there was a close correlation between HAS2 
expression and myofibroblasts as confirmed by double-staining for HAS2 and α-
SMA (Figure 5-17, Figure 5-18, Figure 5-19, and Figure 5-20). Furthermore, co-
expression of HAS2 and α-SMA in endothelial cells was also noted in the region 







Figure 5-17 Photomicrograph of double-immunofluorescence staining for HAS2 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. At distal end, there was whorl-like 
aggregation of myofibroblasts (α-SMA staining) in the overtly myxomatous region, and the 
expression pattern of HAS2 was closely associated with α-SMA expression. Canine 











Figure 5-18 Photomicrograph of double-
immunofluorescence staining for HAS2 
(red) and α-SMA (green), and nuclei 
counterstained with DAPI. At distal end, 
co-expression of HAS2 and α-SMA in 
myofibroblasts clusters was also noted. 
Canine myxomatous mitral valve. Scale bar 
= 50µm. 
Figure 5-19 Photomicrograph of double-
immunofluorescence staining for HAS2 
(red) and α-SMA (green), and nuclei 
counterstained with DAPI. HAS2 was 
expressed by the interstitial cells in the 
spongiosa and myofibroblasts clusters. 









Figure 5-20 Photomicrograph of double-
immunofluorescence staining for HAS2 
(red) and α-SMA (green), and nuclei 
counterstained with DAPI. Endothelial 
cells at the mitral valve surface were 
positive for HAS2, and few of them were 
also expressing α-SMA. Two clusters of 
myofibroblasts were found in these 
regions, and they are morphologically 
different. The myofibroblast cluster 
deep in the stroma was highly associated 
HAS2 expression (white arrow), 
whereas the myofibroblasts cluster 
adjacent to the endothelial layer was 
partially positive for HAS2 (white 
hollow arrow). Canine myxomatous 









   
Figure 5-21 Photomicrograph of double-immunofluorescence staining for HAS2 (red) and α-
SMA (green), and nuclei counterstained with DAPI. This image was taken from a 
myxomatous-free and non-myofibroblasts dominated area. Co-expression of HAS2 and α-
SMA was observed in the elongated and spindle-shape cells near the mitral valve surface. 
Canine myxomatous mitral valve. Scale bar = 25µm. 
 
 
5.3.4 SNAI1 Expression Pattern in Myofibroblast Clusters in 
Myxomatous Mitral Valves 
In the normal mitral valve, expression of SNAI1 was minimal and localized to the 
endothelium (Figure 5-22).  
  
Figure 5-22 Photomicrograph of double-immunofluorescence staining for SNAI1 (red) 
and α-SMA (green), and nuclei counterstained with DAPI. In a myofibroblast-free area, 
SNAI1 was only mildly expressed by few endothelial cells (white arrow). (Left) SNAI1 
expression was noted in the endothelium, but (Right) not all endothelial cells were 






In contrast, in myxomatous mitral valves, cells expressing SNAI1 were identified in 
the hyperplastic endothelium at the tip of the leaflet and the stroma of myxomatous 
regions (Figure 5-24, Figure 5-25, and Figure 5-26). Furthermore, SNAI1 positive 
cells found in myofibroblast clusters in myxomatous mitral valves were mainly α-
SMA negative (Figure 5-23, Figure 5-24, and Figure 5-25). 
 
 
Figure 5-23 Photomicrograph of double-
immunofluorescence staining for SNAI1 
(red) and α-SMA (green), and nuclei 
counterstained with DAPI. In the 
myxomatous area, myofibroblasts (α-
SMA positive) were elongated and 
spindle shape with polarity. However, 
SNAI1 positive cells in the myxomatous 
stroma were round shape, and they were 
mildly or not co-expressing α-SMA. 
Canine myxomatous  mitral valve. Scale 












Figure 5-24 Photomicrograph of double-
immunofluorescence staining for SNAI1 
(red), α-SMA (green), and nuclei 
counterstained with DAPI. In the 
myofibroblasts cluster, SNAI1 positive cells 
were also expressing α-SMA. These were 
mainly distributed along the endothelium, 
but a few SNAI1 positive cells were found 
in the stroma. Canine myxomatous  mitral 
valve. Scale bar = 25µm.  
Figure 5-25 Photomicrograph of double-
immunofluorescence staining for SNAI1 (red), 
and α-SMA (green), and nuclei counterstained 
with DAPI. Myofibroblasts were elongated in 
the linear clusters along the endothelial 
surface, but SNAI1 positive cells were 
polymorphic (mainly round shape, but few 
elongated shape). Co-expression of α-SMA and 
SNAI1 was only seen in few cells. Canine 






Figure 5-26 Photomicrograph of 
double-immunofluorescence 
staining for SNAI1 (red) and α-SMA 
(green), and nuclei counterstained 
with DAPI. Underneath the SNAI1 
positive endothelial cells, there was 
an elongated and spindle shape 
myofibroblast. Canine myxomatous 
mitral valve. Scale bar = 25µm. 
 
5.3.5 Co-expression of VE-Cadherin (CD144, CDH5) and α-SMA in 
Normal and Diseased Mitral Valve 
CDH5 was highly expressed in the endothelium of both normal and myxomatous 
mitral valves, and a few of these cells co-expressed CDH5 and α-SMA. However, 
low level expression of CDH5 by interstitial cells was also noted in the spongiosa 
layer in the normal mitral valve and in the overtly myxomatous region (Figure 5-27 
to Figure 5-32). 
 
Figure 5-27 Immuno-staining images of CDH5, canine normal mitral valve. The expression of 
CDH5 was mainly in endothelium, with a few interstitial cells in the spongiosa and dense 
collagen bundles also positive for CDH5 (left). In another normal mitral valve (right), 
expression of CDH5 was found in spindle shape interstitial in the stroma at the distal end of the 






Figure 5-28 Photomicrograph of a 
normal mitral valve with immuno-
staining for CDH5. Endothelial cells 
were positively stained for CDH5. 
Only few CDH5 positive cells were 
noted in the dense collagen bundles. 
Scale bar = 25 µm 
 
Figure 5-29 Photomicrograph of a 
normal mitral valve with immuno-
staining for CDH5. Spindle shape 
interstitial cells in the spongiosa and 
endothelium showed positive staining 
for CDH5. Scale bar = 50 µm 
 
Figure 5-30 Photomicrograph of a 
myxomatous mitral valve with 
immuno-staining for CDH5. 
Endothelial cells in the myxomatous 
mitral valve were also expressing 
CDH5. In the stroma with myxoid 
deposition, interstitial cells were also 





Figure 5-31 Photomicrograph of a 
myxomatous mitral valve with 
immuno-staining for CDH5. There 
was a strong CDH5 staining at the 
endothelium. Mild expression of 
CDH5 was also seen in interstitial 
cells at spongiosa layer. Scale bar = 
50 µm 
 
Figure 5-32 Photomicrograph of a 
myxomatous mitral valve with 
immuno-staining for CDH5. Whorl-
like clusters of spindle shape 
interstitial cells were partially CDH5 




α-SMA+ cells in normal mitral valves were always identified to lie underneath the 
CDH5+ endothelial cells, with some also co-expressing CDH5. In myxomatous 
mitral valves, α-SMA+ cells aggregated in a multiple layered pattern, and most of the 









Figure 5-33 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Endothelial cells on 
both atrial and ventricular side were CDH5 positive, and α-SMA positive 
myofibroblasts were only seen on the atrial sub-endothelium or sub-endothelial 









Figure 5-34 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Endothelial cells on 
atrial side were CDH5 positive. A monolayer of myofibroblasts was closely sub-
adjacent to the endothelial cells with one cell co-expressing CDH5 and α-SMA. 








Figure 5-35 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Endothelial cells on 
atrial side were CDH5 positive. A single myofibroblast was closely sub-adjacent 
to the endothelial cells, and there was a protrusion of cytoplasmic α-SMA (white 
arrow), suggesting migration (differentiation) of the atrial endothelial cells. Scale 








Figure 5-36 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Endothelial cells on 
atrial side were CDH5 positive. A single myofibroblast was closely sub-adjacent 
to the endothelial cells, and there was a protrusion of cytoplasmic α-SMA (white 
arrow), suggesting migration (differentiation) of the atrial endothelial cells. Scale 









Figure 5-37 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Atrial endothelial 
cells were CDH5 positive, and there were more CDH5 (+) spindle shape 
interstitial cells aggregating underneath the myofibroblast cluster. 
Myofibroblasts (α-SMA positive) were localized linearly sub-adjacent to the atrial 







Figure 5-38 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Normal canine mitral 
valve, middle portion. (Top left) α-SMA with DAPI. (Top Right) CDH5 with 
DAPI. (Bottom) Merged image of α-SMA, CDH5, and DAPI. Atrial endothelial 
cells were CDH5 positive, and there were more CDH5 (+) spindle shape 
interstitial cells aggregating underneath the myofibroblast cluster. 
Myofibroblasts (α-SMA positive) were localized linearly sub-adjacent to the atrial 








Figure 5-39 Photomicrograph of immunofluorescence images for CDH5 (red) and 
α-SMA (green), and nuclei counterstained with DAPI. Myxomatous canine mitral 
valve, mid portion. (Top left) α-SMA with DAPI (Top Right) CDH5 with DAPI 
(Bottom) Merged image of α-SMA, CDH5, and DAPI. Atrial endothelial cells and 
vessel endothelial cells were CDH5 positive, and a few endothelial cells were also 
co-expressing α-SMA. Linear clusters of myofibroblasts (α-SMA positive) were 
sub-adjacent to the endothelial cells, and the majority of the cells in the 
myofibroblast clusters were α-SMA+/CDH5-, with few cells that were positive for 








Figure 5-40 Photomicrograph of immunofluorescence images for CDH5 (red) and α-SMA 
(green), and nuclei counterstained with DAPI. Myxomatous canine mitral valve, distal-end. 
(Top left) α-SMA with DAPI. (Top Right) CDH5 with DAPI. (Bottom) Merged image of α-SMA, 
CDH5, and DAPI. There were no distinct CDH5+/α-SMA- endothelial cells at the surface of 
overtly myxomatous region, and only one CDH5+/ α-SMA- cell was noted in this field (white 
arrow). All sub-endothelial myofibroblasts (α-SMA+) clusters were spindle and elongated in 
shape with expression of CDH5. However, stroma myofibroblasts were not distributed in a 








Figure 5-41 Photomicrograph of immunofluorescence images for CDH5 (red) and α-SMA 
(green), and nuclei counterstained with DAPI. Myxomatous canine mitral valve, distal-end. 
(Top left) α-SMA with DAPI. (Top Right) CDH5 with DAPI. (Bottom) Merged image of α-SMA, 
CDH5, and DAPI. There were no distinct CDH5+/α-SMA- endothelial cells at the surface of 
overtly myxomatous region. The myofibroblasts clusters were evenly distributed in this field. 
Though the majority of myofibroblasts were the classic spindle shape, there were also round 
cells. Interestingly, there were more round shape α-SMA-/CDH5+ cells in the myofibroblast 








Figure 5-42 Photomicrograph of immunofluorescence images for CDH5 (red) and α-SMA 
(green), and nuclei counterstained with DAPI. Myxomatous canine mitral valve, distal-end. 
(Top left) α-SMA with DAPI. (Top Right) CDH5 with DAPI. (Bottom) Merged image of α-SMA, 
CDH5, and DAPI. Whorl-like pattern of myofibroblast clusters were seen at the overtly 
myxomatous area. In this section, most myofibroblasts were of spindle and elongated shape, and 
the differences in myofibroblasts direction between clusters at the surface (left) and stroma 








Figure 5-43 Photomicrograph of immunofluorescence images for CDH5 (red) and α-SMA 
(green), and nuclei counterstained with DAPI. Myxomatous canine mitral valve, distal-end. 
(Top left) α-SMA with DAPI. (Top Right) CDH5 with DAPI. (Bottom) Merged image of α-SMA, 
CDH5, and DAPI. In the myxomatous stroma, clusters of spindle shaped cells were a mixture of 








A summary of immunohistochemistry studies is presented in Table 5-3. 
Table 5-3 Summary of the findings by IHC. 
Markers MMVD Normal  
HAS2 
Increased expression at the edge 
of the leaflet, but no change in 
middle portion. Diffusely 
expressed in VECs and VICs. 
Expressed strongly at VECs and 
some VICs. 
HAS2 / α-SMA 
HAS2 co-expressed with α-
SMA in myofibroblast clusters 
(activated VICs) and some α-
SMA(-) VICs. 
HAS2 co-expressed only with 
small amount of activated VICs. 
α-SMA(+) cells were found 
adjacent to HAS2(+) VECs 
SNAI1 / α-SMA 
SNAI1 expression mainly found 
in round-shaped VICs in 
myofibroblast clusters, and not 
co-expressed with α-SMA 
No co-expression. SNAI1 
expression occasionally found 
in VECs. 
CDH5 / α-SMA 
CDH5 co-expressed with α-
SMA both in VICs and VECs. 
Strong CDH5 expression in 
VECs, but also found in VICs 
in spongiosa. Only a small 
amount of VECs co-expressed 







EndoMT in Mitral valve 
During valvulogenesis in the embryonic heart, growth factors such as TGF-βs, 
BMPs, epidermal growth factor, vascular endothelial growth factors, and NOTCH-
SNAI1 signalling trigger endocardial cushion endothelial cells to lose their cell-to-
cell adhesion molecules. At the same time increased expression of catabolic enzymes 
which dismantle the basement membrane allows migration of transformed 
endothelial cells into the hyaluronan-rich cardiac jelly. The transition of endothelial 
cells through losing endothelial cell phenotype and acquiring mesenchymal 
phenotype by expression of α-SMA is the process of EndoMT, a sub-class of EMT. 
1,86 In the previous chapters, transcriptomic profiling identified the key biological 
functions which suggest EndoMT is on-going in MMVD, and these included the 
inflammatory response, basement membrane disruption, and mesenchymal 
differentiation. 139  
 
Figure 5-44 NOTCH1 orchestrates a network of signalling pathways for EndoMT and heart 
valve formation. The figure was modified from 187. 
 
Figure 5-44 demonstrates the signalling pathways involved in EndoMT and their co-
ordination by NOTCH during valve development. In the atrioventricular canal 




NOTCH is able to promote non-invasive EndoMT in a Snail1 and TGF-β2–
dependent manner alone, but cannot initiate a complete invasive EndoMT. For 
complete invasion, BMP2 secreted from the adjacent myocardium is required to act 
in concert with NOTCH. BMP2 from the myocardium can induce EndoMT by 
maintaining SNAI1/2 activity in conjunction with NOTCH. 59,187 Surprisingly in the 
current study (Chapter 3) NOTCH expression was higher in normal mitral valves 
compared to myxomatous mitral valves, and this finding may suggest normal 
NOTCH expression may play a role in maintaining healthy mitral valve structure 
without of triggering EndoMT. The NOTCH-SNAI1 signalling pathway is described 
in more detail below. 
 
HAS2 Expression in Normal Mitral Valves 
In cardiac jelly biosynthesis of hyaluronan occurs at the plasma membrane by 
alternating addition of glucuronic acid and N-acetylglucosamine resulting in a 
polymer. This polymer may vary in length from 2000 to 25,000 disaccharides. There 
are three hyaluronan synthesizing enzymes found in vertebrates; Has1, 2 and 3, and 
HAS2 is highly expressed during heart development. 188 HAS2 has also been shown 
to be involved in endocardial cushion expansion and is considered the main source of 
hyaluronan production during valve formation and tissue regeneration. 98,189,190 The 
biological functions of hyaluronan have been comprehensively reviewed by Toole. 
191 The chains of hyaluronan are negatively charged and osmotically active, which 
attracts large amounts of salt and water. Once hyaluronan is deposited in the cardiac 
jelly or connective tissues it links to extracellular matrix and forms a strong 
meshwork that is resistant to biomechanical forces. 191 In the adult heart hyaluronan 
is mainly found in aortic and mitral valve leaflets. Alterations in hyaluronan and its 
localization are linked to aortic valve calcification and down-regulation of 
hyaluronan receptor for endocytosis (HARE), without change in hyaluronan-binding 
protein (HABP). This was discovered in human myxomatous mitral valves 
confirming an important role for hyaluronic acid during normal cardiac valve 
function and a role in disease. 166,192,193  
In the present study, in normal canine mitral valves HAS2 expression was mainly 




positive cells were found in the spongiosa layer (Figure 5-20). Endothelial 
expression of HAS2 in normal mitral valve may be due to mechanisms of valve 
homeostasis, remodelling and repair, and mechanical protection. Increased synthesis 
of hyaluronan forming along the leaflet surface acts as a cushion protecting 
underlying tissues against the shear stress created by blood flow. In atherosclerosis, 
hyaluronan is suggested to be atheroprotective and increased expression of HAS2 
under  shear stress conditions has also been demonstrated in an arterial pulsatile 
laminar flow model using human umbilical vein endothelial cells (HUVECs) which 
supports this hypothesis.194 In addition to being a structural component of the cardiac 
jelly, exogenous hyaluronan is able to induce EndoMT in endocardial cushion 
explants derived from HAS2-null hearts. 195 In ovarian tumour cells hyaluronan-
induced ErbB2 phosphorylation leads to β-catenin nuclear translocation, 
transcriptional activation, and increased cell migration. 188,196 In the spongiosa of 
normal mitral valves, a few spindle shape interstitial cells (α-SMA-) expressed HAS2 
(Figure 5-16), possibly indicating the presence of a pro-migratory phenotype of valve 
interstitial cells. If that is the case, this is likely to be triggered by TGF-β/BMP 
signalling through a MEKK3/ERK1/2/5-dependent cascade pathway. 93,197,198  
 
HAS2 Expression in Myofibroblasts 
In myxomatous mitral valves prominent myofibroblast (α-SMA+) clusters were 
identified at the edge of the mitral valves and in the stroma of the overtly 
myxomatous area (Figure 5-18). Myofibroblast clusters were generally co-expressing 
HAS2 with α-SMA. In lung fibrosis models  myofibroblast accumulation is also 
found at sites of tissue remodelling with associated increased collagen and 
hyaluronan production and over-expression of HAS2 by myofibroblast produces a 
more aggressive phenotype leading to severe lung fibrosis and death. 199 Therefore 
up-regulation of HAS2 with myofibroblastic differentiation in myxomatous mitral 
valves also suggests that an aggressive (productive) phenotype of interstitial cells 
with invasiveness exists. The identification of HAS2+/α-SMA- spongiosa interstitial 
cells in normal and myxomatous mitral valves might suggest myofibroblastic 
differentiation begins with HAS2 overexpression which facilitates TGF-β1 signalling 




Interestingly, α-SMA was also expressed by a few HAS2+ endothelial cells at the 
atrial side (Figure 5-15) of the normal mitral valves, indicating on-going EndoMT. 
 
SNAI1 Expression 
During embryonic development, members of the Snail family of zinc-finger 
transcription factors play essential roles in valvulogenesis. Induction of EndoMT is 
one of their best-known functions. From recent experimental findings SNAI1 has 
been suggested as a survival factor and inducer of cell movement, rather than solely 
as an inducer of EndoMT or cell fate (Figure 5-45). Many up-stream regulators of 
SNAI1 gene such as TGF-β, BMP, NOTCH, and WNT have been identified (Figure 
5-45). 201 
 
Figure 5-45 SNAI1 expression is associated with down-regulation of epithelial or endothelial 
markers and inhibition of proliferation, but promoting mesenchymal markers, cell survival and 
cell movement. Up-stream regulators of SNAI1. Modified from 201. 
 
In normal canine mitral valves there was a strong expression of Snail, but only seen 
in the endothelial cells and not interstitial cells. A possible explanation is that this 
may be associated with endothelial cell survival. 201 In myxomatous mitral valves 
SNAI1+ cells were found within the myofibroblast cluster towards the leaflet surface 
and in the stroma (Figure 5-23, 5-24, and 5-25). These SNAI1+ cells were mostly α-




spindle shape myofibroblasts. These SNAI1+/α-SMA- cells might be trans-
differentiated cells through partial EndoMT (acquiring migratory phenotype without 
expressing α-SMA) and originating from surface endothelial cells. 201  
Due to the SNAI1 expression, these differentiated cells not only obtain migratory 
phenotype, but show minimum proliferative activity. 201 SNAI1+ cells then trigger 
differentiation of surrounding VICs into aVIC through a paracrine mechanism, which 
was shown in a myocardium fibrosis model. 202 Interestingly, SNAI1+ transformed 
cells triggered the adjacent cardiac fibroblast activation through  paracrine secretion 
of connective tissue growth factor (CTGF), and activated cardiac fibroblasts showed 
higher extracellular matrix synthetic activity. 202 In canine myxomatous mitral valve 
disease, this paracrine mechanism could play a key role in VIC activation. 
Experimental studies in kidney fibrosis, myocardial infarction, and myxomatous 
mitral valve disease suggest myofibroblasts play a key role in extracellular matrix 
synthesis and deposition. 108–110 Myofibroblasts are identified as cells that are capable 
of tissue repair after damage by secreting extracellular matrix and can contract 
through α-SMA possibly contributing to valve mechanics. 58,203 The orchestration of 
secreted cytokines, such as TGF-β, by myofibroblasts plays a major role in tissue 
remodelling. 159 Several studies have examined myofibroblasts in MMVD but the 
origin of these cells remains unknown. In a kidney fibrosis model, it was predicted 
that 50% of the myofibroblasts are derived through proliferation from resident 
fibroblasts, 35 % differentiate from bone marrow-derived cells, 10 % arise from 
EndoMT, and 5 % through EMT. 204 In the mitral valve, whether or not there is 
similar proportion of myofibroblasts derived from EndoMT to that seen in kidney 
requires further investigation. 
In the high-resolution confocal microscopy tile-scanning there was a small number of 
myofibroblasts close to the atrial endothelium in the pathology-free mid portion of 
the normal valve (Figure 5-3 and 5-4). In contrast, a few myofibroblasts were present 
in the mid portion of myxomatous mitral valves, but present as numerous linear 
clusters along the surface, and at the edge of the myxomatous regions (Figure 5-7). 
Since Ki-67 expression was demonstrated in myxomatous mitral valve but absent 
from normal valves, (Chapter 2) there are three likely sources of myofibroblasts; 




different sources of VICs, the accumulation of activated myofibroblasts in MMVD 
might occur in response to a variety of unrelated stimuli, such as inflammatory 
cytokines, growth factors (e.g. TGF-β) and mechanical stress. 55,139,205 
In conclusion, immunohistochemistry was able to identify evidence of EndoMT in 
normal and myxomatous mitral valves. Expression (genes and proteins) of ACTA2 
(α-SMA), CDH5 (VE-cadherin), SNAI1 and HAS2 was investigated in MMVD and 
normal valves. Although both microarray and Q-PCR results showed no evidence 
(marginal p-value) of change in CDH5, ACTA2, SNAI1 expression, some evidence 
of EndoMT derived from IHC may support the hypothesis of EndoMT and the 
capacity for endothelial migration in MMVD pathogenesis. Of particular interest is 
the expression of HAS2 in myxoid stroma and close to the endothelium of diseased 
valves. It is the presence of HA that drives embryonic valve development and allows 
EndoMT to progress. Furthermore, there is co-expression of HAS2 with α-SMA in 
endothelial and interstitial cells, and this phenotype may suggest a more aggressive 
(productive) behaviour of myofibroblasts. VE-cadherin is clearly expressed in both 
normal and diseased valve endothelium, suggesting cell-to-cell contact has not been 
completely lost. Co-expression of VE-cadherin and α-SMA in normal (endothelial 
cells) and myxomatous mitral valves (stroma cells) also suggest that one source of 
origin of myofibroblasts is through EndoMT.  
Studies of MMVD have tended to examine the cellular and molecular events where 
there is end-stage disease and the series of events that have led to that situation are 
difficult to elucidate. One hypothesis derived from the present study as well as the 
literature, is that unidentified processes result in activation of a quiescent VIC 
population in the valve stroma to an activated phenotype and these cells then 
contribute to inappropriate remodelling of the valve. The trigger might be endothelial 
activation and/or damage which then results in activation of the TGF-β/5HT 
signalling pathway enabling VIC phenotypic transformation. EndoMT suggests an 
additional disease pathogenesis hypothesis whereby the α-SMA positive cells seen in 
MMVD partially originate from the resident VIC population (activation) or are 
differentiated endothelial cells (EndoMT). EndoMT events could be a consequence 
of endothelial damage and dysfunction of endothelial-interstitial signalling. 55 









6 Chapter 6 MicroRNA Expression in Canine Myxomatous 
Mitral Valves 
6.1 Introduction 
MicroRNAs (miRNA) are short (19-22 nucleotides), single-stranded, non-coding 
RNAs that specifically anneal with complementary sequences in mRNAs. Binding 
the designated mRNA, the microRNA silences the mRNA and suppresses protein 
expression. In general, one miRNA has multiple targets, and depending on its 
abundance, a miRNA can act as a fine-tuner of gene expression (orchestrating 
various pathways) or as an on/off switch. 206,207 These features highlight the great 
potential of miRNAs as therapeutic targets in many diseases. The most widely 
studied applications of miRNAs to date are predominantly cancer and cardiovascular 
disease, and this is based on miRNA expression profiling in animal models or 
samples from patients with cardiac disease. As  examples of therapeutic possibilities, 
anti-miR-21 (chemically engineered oligonucleotides) which inhibit activity of miR-
21 have been shown to have potential anti-fibrotic effects in lung and kidney fibrosis, 
a clinical trial of miRNA has been reported in treatment of hepatitis C infection and 
fibrosis- and hypertrophy-associated miR-29a has been recognized as a biomarker 
for hypertrophic cardiomyopathy (HCM) in human. 208,209,210,211 Nevertheless, more 
studies are needed to understand the biological function of miRNA. 
One of the challenges in miRNA research is target prediction, which is generally 
based on bioinformatics methods and databases such as Targetscan  or DIANA-
micro-T-CDS, and the data is sometimes overwhelming and requiring further and 
repeated data mining212,213,214. To date, there have been several miRNA profile data 
reports for canine cancer, but there is no miRNA profiling data available for 
myxomatous mitral valve in any species. This study  aims to investigate the miRNA 
transcriptomic expression pattern and identify potential functions in canine MMVD 
using miRNA target prediction platforms mentioned above along with the 
bioinformatics tool BioLayout Express3D. This will allow the expression profiling of 
miRNA based on the use of a correlation measure to define similarities between 




6.2 Material and Methods 
6.2.1 Microarray 
A list of differentially expressed miRNAs was manually separated from the total 
differentially expressed gene list initially generated in Chapter 3. For cutoff setting, 
fold-change ≥ 2 or ≤ -2, FDR < 0.05, and p-value < 0.05 were considered significant. 
6.2.2 miRNA Expression Validation 
Reverse Transcription (RT) PCR 
The cDNAs for TaqMan microRNA assays (cfa-miR-218-1, cfa-miR29c-1, and cfa-
miR-23b) were synthesized from the same RNA samples as used for microarray 
analysis (Chapter3) using the TaqMan MicroRNA Reverse Transcription primers and 
universal reverse transcription kit (Roche). Briefly, 1 µl of miRNA specific RT-
primer, 1 µl of dNTPs (Roche), and 100 ng to 2 µg of total RNA (1 – 5 µl) was 
added to a clean Eppendorf tube. Nuclease-free water was added to make up to 13 µl 
of final reaction volume. The sample was heated at 65˚C for 5 minutes followed by 1 
minute incubation on ice, after which 4 µl of 5x first-strand buffer (Roche), 1 µl of 
0.1M DTT, 1 µl RNase inhibitor (Roche), and 1 µl of SuperScript III (Roche) were 
added. The sample  was incubated at 50˚C for 45 minutes. Inactivation of the 
reaction was achieved by incubation at 75˚C for 15 minutes. Final 20 µl of cDNA 
samples were stored at -20˚C prior to use. 
Q-PCR  
The MicroRNA Q-PCR assays were performed in duplicate in 96-well plates with 
one no-template-control (RNase-free water) for each sample. For each well, the 
reaction mix consisted of 1µl ready-made mixture of miRNA-specific forward PCR 
primer, specific reverse PCR primer, and miRNA-specific MGB probe (Life 
technologies), 0.5 µl of 2x master mix (Roche Diagnostics), 0.75 µl of first strand 
cDNA, 5 µl of 2x universal PCR master mix (Roche), and 3.75 µl of nuclease-free 
water. After reaction mix and the cDNA were separately pippeted into the designated 
wells, the plate was sealed with PCR film (Thermo Scientific) and wrapped with tin 
foil to protect from light. The plate was then vortexed and centrifuged down at 




machine (LightCycler 480; Roche Diagnostics). The amplification was programmed 
and performed according to a standard PCR cycle (Table 6-2). Since cfa-miR-218 is 
encoded in intron12 and 15 of SLIT2, the SLIT2 gene was also assayed by the same 
Q-PCR method as described in 4.2.2. MRPS25 was also used as a reference gene in 
this study. Detail of the miRNA assays can be found in Table 6-1. 
Test for primer efficiency rate and calculation for relative gene expression were 
performed following same method described in 4.2.2. 
Table 6-1 Information for the miRNAs assays and the primers for SLIT2 
















Forward Primer Reverse Primer 
SLIT2 37 5’ cgcttctgccatttacagc 3’ 5’ cggagagggacaggctct 3’ 
MRPS25 15 5’tcttggggaagaacaaggaa3’ 5’agtgggctgggtgagaaag3’ 
 
Table 6-2 Programmed PCR cycles for miRNA assays 
Action Temperature Time Cycle 
Pre-incubation 95°C 10 minute  
Amplification 
95°C 10 second 
45 60°C 30 second 
72°C 1 second 









6.2.3 miRNA Target and Pathway prediction 
TargetScan 6.2 
The targets of individual differentially expressed miRNAs were analyzed in 
TargetScan 6.2. 212 The top 200 predicted targets were retrieved irrespective of site 
conservation (within primitive creature and preserved through evolution). For each 
predicted target of each miRNA, the sum of the context+ score for the sites to that 
miRNA was calculated as the total context+ score. Predicted targets of each miRNA 
family are sorted by total context+ score. The representative miRNA is the miRNA 
in its family with the most favorable (lowest) total context+ score. If more than one 
miRNA has the most favorable context+ score, the miRNA with the lowest number 
and/or letter is shown. Poorly conserved sites are given the same weight as conserved 
sites. Although only one miRNA is chosen as the representative miRNA, all the other 
miRNAs of the miRNA family are also predicted to target the same target gene at the 
same target site(s). Since overlapping sites cannot be occupied at the same time, 
some are removed to create a set of non-overlapping sites while maximizing the total 
context score. These non-overlapping sites are used to calculate the total context 
score. 215 
The six contributors to the context+ score were; site-type contribution, 3’ pairing 
contribution, local AU contribution, position contribution, TA (target site abundance) 
contribution, and SPS (see-pairing stability) contribution. 
DIANA-TOOLs 
DNA Intelligent Analysis (DIANA) DIANA-miRPath 2.0 is a miRNA pathway 
analysis web-server, and was used to predict the targets of miRNA clusters identified 
by BioLayout Express3D. Briefly, it utilized miRNA predicted targets and 
experimentally verified targets and combined these results with merging and meta-
analysis algorithms, performing hierarchical clustering of miRNAs and pathways 
based on their interaction. 216,217 
6.2.4 BioLayout Express3D 
Network analysis and visualization was conducted using BioLayout Express3D 




formatted in an excel file following the software manual instructions. 123 The 
network graph was then illustrated using a correlation threshold of r ≥ 0.9. Markov 
clustering algorithm (MCL) analysis was conducted at an inflation value 2.2 
(controlling granularity of clustering) according to recommendations. 123 Clusters of 
miRNA were exported and mined in DIANA-micro-T-CDS for miRNA pathway 
prediction. 
6.3 Results 
6.3.1 Overview of miRNA Expression 
In total, 302 miRNAs were profiled by the microarray (Affymetrix Canine Gene 1.0 
ST Array). There were only 29 miRNAs that were differentially expressed and all of 
them were down-regulated in MMVD (Table 6-3). 
Table 6-3 Differentially expressed miRNAs 
Transcript ID miRNA Fold-Change p-value Overlapping transcripts 
14273759 cfa-miR-340 -8.49 1.78E-05 
ENSCAFT00000038586; 
RNF130-201; intron 2 
14384476 cfa-let-7c -7.85 0.00149098 
ENSCAFT00000032603; 
exon 1 
14404220 cfa-miR-218-1 -6.82 0.000110552 
ENSCAFT00000044488; 
SLIT2-201; intron 12 
ENSCAFT00000026343; 
SLIT2-202; intron 15 
14337772 cfa-miR-708 -6.70 1.33E-05 
ENSCAFT00000048242; 
intron 1 
14296611 cfa-miR-30e -4.89 2.17E-06 
ENSCAFT00000004517; 
NFYC-201; intron 5 
14430582 cfa-miR-214 -4.82 1.34E-08 
ENSCAFT00000023557; 
DNM3-201; intron 13 
14341700 cfa-miR-15a -4.55 0.00303761 
ENSCAFT00000032594; 
exon 1 
14409053 cfa-miR-125b -4.39 0.000297807 
ENSCAFT00000032610; 
exon 1 
14294874 cfa-miR-2414 -4.39 3.30E-05 n/a 
14455304 cfa-miR-181b -4.28 9.06E-05 intergenic 
14458526 cfa-miR-532 -4.24 0.00139701 
ENSCAFT00000025340; 
CLCN5-201; intron 3 




FANCC-202; intron 12 











14263997 cfa-miR-let7e -3.39 4.31E-05 
ENSCAFT00000032552; 
exon 1 







14455306 cfa-miR-181a -3.05 0.000567175 Intergenic 
14384474 cfa-miR-99a -3.04 8.63E-05 Intergenic 
14278575 cfa-miR-32 -2.81 0.000116053 
ENSCAFT00000004537; 
TMEM245-201; intron 14 
14407894 cfa-miR-145 -2.69 0.00133843 Intergenic 
14452361 cfa-miR-454 -2.60 0.000893899 
ENSCAFT00000042908; 
SKA2-201; intron 1 




RFWD2-201; intron 18 




WDR82-201; intron 2 
14427963 cfa-miR-197 -2.45 0.001507 
ENSCAFT00000032599; 
exon 1 
14284320 cfa-miR-30c -2.41 0.000218963 
ENSCAFT00000004517; 
NFYC-201; intron 5 
14407896 cfa-miR-143 -2.40 0.00306725 Intergenic 
14275110 cfa-miR-872 -2.39 4.03E-05 
ENSCAFT00000002673; 
IFT74-201; intron 13 
14462818 cfa-miR-545 -2.05 0.00656767 Intergenic 
14409051 cfa-let-7a -2.02 0.00290226 Intergenic 
 
Signal intensity for miRNA 
The expression of all 29 miRNAs was generally low (signal intensity < 300) in 
myxomatous mitral valves, but comparatively high in normal mitral valves (signal 
intensity between 300 and 1,000). Again, when the signal intensity was lower than 
100, it was considered as no expression or background noise. The only highly 
expressed miRNA was cfa-miR-218, for which the signal intensity was around 1,000 





Figure 6-1 Signal intensity for 29 differentially expressed miRNAs 
6.3.2 Efficiency Rate for Primers 
The efficiency rates for miRNA specific primers, SLIT2, and MRPS25 are shown in 
Table 6-4.  
Table 6-4 Efficiency rate for miRNA specific primers, SLIT2, and MRPS25 
Assay Efficiency Rate %  Assay Probe No Efficiency Rate 
cfa-miR-23b 89.17 SLIT2 37 130 
cfa-miR-29c 93.68 MRPS25 15 104.51 





The efficiency rate of primers for cfa-miR-29c (93.68%), cfa-miR-218 (96.06%), and 
MRPS25 (104.51%) were within acceptable range (90-110%). The efficiency rate of 
the primer for cfa-miR-23b (89.17%) was borderline. The only value outside the 
acceptable range was the efficiency rate for SLIT2 (130%). (Figure 6-2) 
 
Figure 6-2 Efficiency rate for miRNA specific primers, SLIT2, and MRPS25 
 
6.3.3 miRNA Microarray Validation 
In general, the expression pattern of miRNAs and SLIT2 determined by Q-PCR was 
in agreement with the microarray findings, all of which were down-regulated in 
myxomatous mitral valves. Interestingly, very large fold-changes were noted for cfa-
miR-29c (46.26-fold decrease) and cfa-miR-218 (170.07-fold decrease) compared 
with results from the microarray. (Table 6-5 and Figure 6-3)  













cfa-miR-23b -4.14 -4.88 ± 1.70 0.043 92 22 
cfa-miR-29c -3.56 -46.26 ± 1.31 0.004 335 96 
cfa-miR-218 -6.82 -170.07 ± 1.62 0.002 1211 167 
SLIT2 unchanged -3.82 ± 2.23 0.057 4201 2019 





Figure 6-3 miRNA microarray data validation 
The signal intensity (from the microarray) of cfa-miR-23b, cfa-miR-29c, cfa-miR-
218, and SLIT2 are shown in Figure 6-4. Although SLIT2 expression was lower in 
MMVD it was not statistically significant. 
   
Figure 6-4 Signal intensity for cfa-miR-23b, cfa-miR-29c, cfa-miR-218, and SLIT2 
 
6.3.4 miRNA Target Prediction 
The targets of miRNAs were arranged according to the total context+ score (lower 




6-7. The complete targets of differentially expressed microRNAs are present in the 
Appendix 9.3. 













FGF2 -1.42 cfa-miR-195 BMP8A -0.6 cfa-miR-99a 
ADAMTS17 -1.06 cfa-miR-29b COL1A1 -0.59 cfa-miR-29a 
COL4A4 -0.99 cfa-miR-29a NOS1 -0.58 cfa-miR-15b 
SRGAP2 -0.95 cfa-miR-145 COL1A2 -0.58 cfa-miR-29a 
COL3A1 -0.93 cfa-miR-29b HS3ST2 -0.58 cfa-miR-99a 
COL4A5 -0.85 cfa-miR-29b ITGB8 -0.58 cfa-miR-145 
COL11A1 -0.85 cfa-miR-29a HTR7 -0.58 cfa-miR-197 
FBN1 -0.82 cfa-miR-29a COL7A1 -0.57 cfa-miR-29b 
ADAMTS2 -0.8 cfa-miR-29a SRGAP1 -0.57 cfa-miR-145 
GLCE -0.79 cfa-miR-218 HTR4 -0.56 cfa-miR-497 
ADAMTS5 -0.79 cfa-miR-197 COL4A1 -0.56 cfa-miR-29c 
ELN -0.78 cfa-miR-29b CSGALNACT2 -0.56 cfa-miR-29a 
COL9A1 -0.74 cfa-miR-29a HS3ST3B1 -0.56 cfa-miR-99a 
FNDC7 -0.69 cfa-miR-143 ACTC1 -0.55 cfa-miR-218 
COL5A3 -0.68 cfa-miR-29b HAS3 -0.55 cfa-miR-29b 
COL12A1 -0.65 cfa-miR-15a LRP6 -0.54 cfa-miR-15a 
CTSE -0.65 cfa-miR-29b MMP13 -0.54 cfa-miR-99a 
AFAP1L2 -0.65 cfa-miR-197 COL5A1 -0.53 cfa-miR-29a 
PCDH7 -0.64 cfa-miR-1843 VEGFA -0.53 cfa-miR-29a 
CRTAP -0.63 cfa-miR-125b CTSB -0.52 cfa-miR-214 
COL1A1 -0.61 cfa-miR-218 ITGAM -0.5 cfa-miR-197 
 














NOS1 -0.49 cfa-miR-761 COL14A1 -0.41 cfa-let-7g 
NF1 -0.49 cfa-miR-16 COL1A2 -0.41 cfa-let-7g 
ADAMTS14 -0.49 cfa-miR-29a ITGA4 -0.41 cfa-miR-708 
FGF12 -0.48 cfa-miR-218 FGF7 -0.41 cfa-miR-16 
IL16 -0.47 cfa-miR-214 CLDN12 -0.41 cfa-miR-15b 
ROBO1 -0.47 cfa-miR-29a ADAM21 -0.41 cfa-miR-32 
LAMA2 -0.47 cfa-miR-29a COL19A1 -0.4 cfa-miR-218 




ADAMTS15 -0.46 cfa-let-7j HTR1F -0.4 cfa-miR-532 
TNC -0.46 cfa-miR-218 ADAM12 -0.4 cfa-miR-301a 
CLDN12 -0.46 cfa-miR-23a CTNND1 -0.4 cfa-miR-197 
COL15A1 -0.46 cfa-miR-29b HTR2C -0.4 cfa-miR-197 
NOS1 -0.46 cfa-miR-103 HS6ST3 -0.39 cfa-miR-218 
COL3A1 -0.46 cfa-miR-1843 HSPA4 -0.39 cfa-miR-708 
HSPG2 -0.45 cfa-miR-497 ECE2 -0.39 cfa-miR-214 
HTR4 -0.45 cfa-miR-125b LDLR -0.39 cfa-miR-130b 
COL2A1 -0.44 cfa-miR-29b ACTC1 -0.39 cfa-miR-872 
ADAMTS18 -0.44 cfa-miR-29b IL6R -0.38 cfa-miR-218 
FGFR3 -0.44 cfa-miR-99a HAPLN1 -0.38 cfa-miR-218 
IL15 -0.44 cfa-miR-130a NOS3 -0.38 cfa-miR-214 
VEGFA -0.43 cfa-miR-16 VCAN -0.38 cfa-miR-23a 
COL6A3 -0.43 cfa-miR-29a HAS2 -0.38 cfa-miR-23a 
COL22A1 -0.43 cfa-miR-29a ADAMTSL3 -0.38 cfa-miR-32 
ITGA2 -0.43 cfa-miR-145 BGN -0.38 cfa-miR-25 
ECEL1 -0.42 cfa-miR-195 ITFG1 -0.38 cfa-miR-145 
IL12A -0.42 cfa-miR-23a ACTG1 -0.38 cfa-miR-145 
LRP6 -0.42 cfa-miR-29b ADAM28 -0.38 cfa-miR-454 
ITGAV -0.42 cfa-miR-32 ESAM -0.38 cfa-miR-1843 
ADAM23 -0.42 cfa-miR-25 ITGAL -0.38 cfa-miR-143 
LRP8 -0.42 cfa-miR-130a FGF9 -0.38 cfa-miR-143 
ADAMTS8 -0.41 cfa-let-7f    
 
6.3.5 BioLayout Express3D & DIANA miRPath Analysis 
Nodes representing miRNAs (probesets), with edges representing correlations 
between individual expression profiles above r≥0.95, and the colour of the nodes 
representing the cluster to which they have been assigned are shown in Figure 5-8. 
The figure shows 106 nodes and 11 major clusters. Most clusters to the left side of 
the figure were representing lower expression of miRNA in MMVD, and cluster 3 is 





Figure 6-5 Clustering of miRNAs based on their expression profiles, and KEGG pathways 
associated with each cluster. 
miRNAs in each cluster were imported into DIANA miRPath web-server for further 
data mining. The most significant and biological relevant KEGG (Kyoto 
Encyclopedia of Genes and Genomes) pathways were attributed to each cluster. 218 
Briefly, cluster 1 contained the highest number of miRNAs that were down-regulated 
in MMVD, and the significant KEGG pathways were associated with PI3K-Akt, 
focal adhesion, MAPK, Wnt, cytoskeleton regulation, ErbB, TGF-β, hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), GAGs biosynthesis, 
osteoclast differentiation, NOTCH, and VEGF. The satellite clusters (2, 4, 5, 6, 7, 8, 
9, 10, and 11) contained similar KEGG pathways, such as TGF- β, focal adhesion, 
and GAGs biosynthesis. 
 
6.4 Discussion 
In general, all 29 differentially expressed miRNAs were down-regulated. However, 
there were differences in signal intensities for each miRNA. miRNA-218 (>1,000) 




Moderate signal intensities (>300) could be seen for miR-30, miR-15, miR-29, miR-
2414, and miR-1843. Finally, two thirds of the miRNAs had low signal intensities 
(of < 150). Overall low signal intensity of miRNAs found in MMVD tissue may be 
due to the background noise or alternatively a truly low miRNA level, suggesting an 
inactive epigenetic control over genomic expression. On the other hand, higher 
miRNA expression in normal mitral valves may indicate a more stringent epigenetic 
regulation of genome activity. Active cellular changes and increased ECM 
biosynthesis in MMVD may be the result of dampened inhibitory activity of 
miRNAs, whereas in normal mitral valves higher level of miRNAs may play a 
critical role in silencing valve interstitial cells. The best example of such processes is 
where miR-29, which regulates numerous ECM-related transcripts, is a direct cause 
of fibrotic lesions in numerous tissues in knockout animal models. 207,211 
There are two genome-wide association studies (GWAS) for CKCS, but they present 
conflicting results18,19. However, one study identified 2 loci on chromosome 13 (1.58 
Mb region, Figure 6-6) and chromosome 14 (1.68 Mb region, Figure 6-7) 18,19 
Interestingly VPS13B (vacuolar protein sorting 13 homolog B) is the only protein-
coding transcript in the 1.58Mb region and cfa-mir-599 (unchanged) and cfa-mir-875 
(unchanged), are encoded by the VPS13B sequence in dogs, but not in humans. 
Mutations of VPS13B cause Cohen syndrome in humans (mental retardation, facial 
dysmorphism, microcephaly, early onset and progressive myopia, retinal dystrophy, 
truncal obesity with slender extremities, and joint laxity). This phenotype does not 
entirely resemble the global heritable diseases (MMVD, syringomyelia, fibrotic 
pancreatitis) seen in CKCSs. 219 Furthermore, critical transcription factors are 
targeted by these two miRNAs (Table 6-8), suggesting a potential epigenetic disorder 
might contribute to the heritable diseases of CKCSs.  
 
Figure 6-6 Chromosome 13, region between 1.52Mb and 1.64Mb. VPS13B is the only protein-




syndrome in humans. However, cfa-mir-599 and cfa-mir-875 are also transcribed from the 
VPS13B region, off the reverse strand. 
 
Figure 6-7 Chromosome 14, region between 1.55Mb and 1.75Mb. FAM71C is encoded near the 
susceptible 1.68Mb region, but there is no disease associated with FAM71C mutation. 
Table 6-8 Target prediction for cfa-miR-875 and cfa-miR-599 
cfa-miR-875 cfa-miR-599 
Target Gene Gene Description Target Gene Gene Description 
TGFB3 Transforming growth factor, 
beta 3 
PAFAH1B1 Platelet-activating factor 
acetylhydrolase 1b, regulatory 
subunit 1 
TOB2 Transducer of ErBb2 ANGPTL2 Angiopoietin-like 2 




In terms of cardiovascular biology, some miRNAs are associated with angiogenesis, 
metabolism, and inflammation, and pathophysiology of heart diseases. For example 
miR-29 acts as an anti-fibrotic regulator in myocardial fibrosis. 207,211,220 To date, 
there are nearly 2,000 human miRNAs (hsa-miR) and 502 canine miRNAs (cfa-miR) 
catalogued, and the numbers are constantly being added to. 221 The functions of these 
miRNAs remain largely unknown. In the canine microarray chip, the coverage of the 
cfa-miRNAs is around 60% (302/502), and only 29 cfa-miRNAs (all down-
regulated) passed the statistical cutoff. In the 1395 (non-coding and uncharacterized 
RNA, ncRNA) differentially expressed probe-sets, 10% (139/1395) were manually 
identified to be cfa-miRNAs (59) or transcript homologs (80) to other species, and 
the rest 90% (1256/1395) of the probe-sets were ncRNAs. Whether or not these 
ncRNAs also play roles in MMVD pathogenesis is uncertain, but understanding 
epigenetic regulation of genes provides a new perspective when considering the 




EndoMT is a complex phenomenon in which endothelial cells acquire a 
mesenchymal phenotype by expressing mesenchymal markers (α-SMA and Collagen 
I) instead of VE-cadherin. 222 In valvulogenesis, the formation of the atrioventricular 
endocardial cushion is dependent on the differentiation of endocardial cushion 
endothelial cells into mesenchymal cells that invade the cardiac jelly82,100. MiR-21 
has been implicated in cancer metastasis and is also involved in TGF-β–induced 
EndoMT via a PTEN/Akt-dependent pathway. 223 In endothelial cells, exposure to 
TGF-β directly up-regulates miR-21. 224 In the microarray results, both TGF-β and 
miR-21 were not differentially expressed in canine myxomatous mitral valves 
compared with normal valves, suggesting TGF-β and its down-stream miR-21 are 
not affected under diseased condition. However, in the previous chapter, evidence of 
EndoMT in normal and myxomatous mitral valves was found and this may indicate a 
constant effect of TGF-β maintaining cellular phenotype and valve homeostasis. In 
prostate, breast, lung, and colorectal cancer, miR-29 and miR-30 have been identified 
to be associated with metastatic progression, and both microRNAs have the same 
target, SNAI1, which is a key transcriptional factor that inhibits expression of E-
cadherin in EMT (or VE-cadherin in EndoMT). 225 Interestingly, miR-29 (-3.56 fold-
change) and miR-30 (-4.89 fold-change) were both found to be down-regulated in 
myxomatous mitral valves. The unchanged but high expression of TGF-β in mitral 
valves is likely a contributor to normal valve homeostasis and the control of EndoMT 
may be through epigenetic modifiers such as miR-29 and miR-30.  
In myxomatous mitral valves, one of the most striking findings in the miRNA 
screening was the down-regulation of miR-29b (-4.02 fold-change) considering its 
well-characterised role in inhibition of ECM deposition. The expression of miR-29 
tends to be high in fibroblasts (equivalent to VICs in mitral valves), and there are at 
least 16 confirmed ECM genes regulated by miR-29.226 The miR-29 family, 
including miR-29a, miR-29b, and miR-29c, are mainly homologous in sequence and 
expressed as two bicistronic (two short RNA sequence) clusters, and their critical 
role in cardiac fibrosis has been demonstrated using a myocardial infarction model. 
227 In the miRNA target prediction analysis, more than 20 miR-29-targeted genes 
were identified (canine specific) which were are highly relevant to MMVD. The 




collagens, ADAMTS family members, FBN1, ELN, CTSE, HAS3, proteoglycan 
(CSGALNACT2), and a basement membrane component (LAMA2). The other 
targets of miR-29 were VEGFA and ROBO, which regulate endothelial cell function 
and migration (Table 6-9).  
 
Table 6-9 Predicted Target Genes for cfa-miR-29 
cfa-miR-29 Target Genes 

















In the myocardial infarction model, down-regulation of miR-29 was identified with 
up-regulation of ECM-associated genes near the lesion sites, suggesting a healing or 
remodelling mechanism controlled by miR-29. 227 ECM-related genes were down-
regulated after introducing anti-miR-29 in the same study. 227 A recognised feature of 
MMVD pathology is loss of a laminated structure and excessive deposition of 
disorganized ECM making the weakened mitral valves unable to withstand 
mechanical forces under normal haemodynamic challenges. Lower levels of miR-29 
found in canine myxomatous mitral valves might suggest a higher level of ECM 
protein production and greater degree of tissue remodelling compared to normal 
mitral valves. A further interesting observation is that inhibition of miR-29 enhances 
the vascular integrity during aneurysm formation in a mouse Marfan syndrome 
model. 228 Taken together, the data suggests multi-faceted roles for miR-29 which 




MMVD, down-regulation of miR-29 may suggest a decreased inhibition of ECM 
production and enhanced remodelling. However, to what degree miR-29 can trigger 
structural repair and remodelling without causing fibrosis in MMVD would need 
investigation.  
For all the differentially expressed miRNAs, cfa-miR-218-1 had the highest signal 
intensity with the marked differences between control (mean = 1211) and MMVD 
(mean = 167). Furthermore, the level of SLIT2 (sequence encoding cfa-miR-218) 
also showed the same expression pattern (control mean = 4201 and MMVD mean = 
2019) confirming its important role as a post-transcriptional regulator in MMVD. 
Roundabout (ROBO) receptors (ROBO1 and ROBO2) and their ligands (SLIT) are 
key regulators of axon guidance and vascular sprouting, and Slit-Robo signalling 
also controls endothelial cell migration. 229 Since blood vessels and nerves are 
organized in identical patterns during embryonic development, it has been suggested 
that vessels and nerves share a similar set of pathways controlling cell migration and 
pathfinding. 230 MiR-218 is encoded within introns in the Slit genes (SLIT2 and 
Slit3) and directly represses the expression of Robo receptors (ROBO1 and ROBO2) 
and multiple proteoglycan biosynthetic components such as GLCE (glucuronic acid 
epimerase), HS3ST3B1, and HS6ST3. (Table 6-10) 229 Knockdown of miR-218 
results in deregulation of Slit-Robo signalling, abnormal endothelial cell migration, 





Figure 6-8 The SLIT2/3 genes give rise to both SLIT2/3 and miR-218. Slit proteins interact with 
the Robo1/2 receptors and miR-218 inhibits GLCE, which reduces production of HSPG leading 
to endothelial cell migration and patterning. The figure was modified from 229,231. 
In the target prediction analysis for cfa-miR-218 there were many ECM related 
targets such as COL1A1, COL19A1, TNC, and HAPLN1. The fibroblast growth 
factor (FGF12) and cardiac muscle actin (ACTC1) were also targeted by cfa-miR-
218. (Table 6-10)  
Table 6-10 cfa-miR-218 target prediction. 
Target Gene Gene Description 
Signal Intensity (Microarray) 
CKCS Control 
GLCE Heparan sulphate modification (C5 epimerization) 1169 1274 
COL1A1 Collagen, type I, alpha 1 1588 3423 
ACTC1 Actin, alpha, cardiac muscle 1 108 5786 
FGF12 Fibroblast growth factor 12 689 537 
TNC Tenascin C 666 1135 
COL19A1 Collagen, type XIX, alpha 1 24* 30* 
HS6ST3 Heparan sulphate modification (3-O and 6-O sulfation) n/a n/a 
HAPLN1 Hyaluronan and proteoglycan link protein 1 2007 3284 
SRGAP2 Interacts with Robo (regulation of actin dynamics) 260 407 
HS3ST3B1 Heparan sulphate modification (3-O sulfation) 79* 109* 
Robo1 Slit receptor 1521 1438 
Robo2 Slit receptor 53* 81* 




Tenascin C is a glycoprotein mainly expressed in ligaments and tendons, and TNC 
modulates adhesion of cells to fibronectin and can be classified as an anti-adhesive or 
adhesion-modulating extracellular matrix protein. 232 The expression of TNC is 
highly up-regulated during embryonic development (valvulogenesis) and in the adult, 
and TNC is transiently expressed during organogenesis, and is mostly absent or 
down-regulated in fully developed organs. However, under pathological conditions 
such as infection, inflammation, or tumourogenesis, expression of TNC reappears. 
233,234 In one unpublished study of normal porcine aortic and pulmonic valves, there 
was higher expression of TNC in the aortic valve and TNC was localized more on 
the aortic side of the valve compared to the ventricular side. 235 These differences in 
TNC distribution may suggest that TNC expression is associated with mechanical 
stress and remodelling status. In the canine microarray result, there was no difference 
of TNC expression between MMVD and control. However, post-transcriptional 
control of miR-218 may have effects on translation of TNC in tissue, and it is worth 
further investigation. 
Lastly, the main functions of cfa-miR-218 can be broadly summarized as Slit-Robo 
signalling, collagen and PG biosynthesis, matrix networking and fibroblast 
differentiation. Applying these biological functions to MMVD pathogenesis, down-
regulation of cfa-miR-218 (-6.82 fold-change) in MMVD may suggest there are 
aberrant SLIT-ROBO signalling and tenascin expression leading to endothelial 
dysfunction and cell migration, excessive and disorganized extracellular matrix 
production and  enhanced myofibroblastic differentiation.  
During heart valve development, the formation of the endocardial cushion arises 
from swelling of cardiac endothelium due to increased production of extracellular 
matrix (cardiac jelly). 80 The glycosaminoglycan hyaluronan is the major ECM 
component secreted by endocardial endothelial cells. Depletion of hyaluronan 
synthesis also leads to absence of endocardial cushions and a loss of endocardial 
cushion cellularization through EndoMT due to lack of a hyaluronan-augmented 
activation of ErbB2-ErbB3 receptor. 97,188,195,236 Hyaluronan production also results 
in expansion of the extracellular space by binding salt and water and induces PI3K 




synthase in cardiovascular tissues and is positively and negatively controlled by 
regulators such as BMP (+) and miR-23 (-). 189,197 In MMVD, cfa-miR-23 was 
significantly down-regulated (-4.14 fold-change) which would reduce degradation of 
HAS2 mRNA. This finding was consistent with the results in the previous chapter, 
where increased HAS2 expression was found co-localized with myofibroblast 
clusters at the myxomatous valve edge. Moreover, miR-23 also targets transcripts 
related to ECM (versican and HGSNAT), endothelial signalling (EDNRB), basement 
membrane (LAMC3) and fibroblast proliferation (FGF12) (Table 6-11). Whether or 
not miR-23 has effects on the final production of hyaluronan, migration of VICs (and 
VECs), and remodelling in MMVD requires further investigation. 
Table 6-11 cfa-miR-23 target prediction 
Target Gene Gene Description 
Signal Intensity (Microarray) 
CKCS Control 
CLDN12 Claudin 12 815 988 
VCAN Versican 9183 9023 
HAS2 Hyaluronic acid synthase 2 934 417 
EDNRB Endothelin receptor type B 402 206 
HGSNAT Heparan-alpha-glucosaminide N-acetyltransferase 670 801 
LAMC3 Laminin, gamma 3 258 319 
FGF12 Fibroblast growth factor 12 689 537 
 
In canine mitral valve tissues, the most dramatic difference between MMVD and 
controls was the expression of miR-218, with -6.82-fold (microarray) and -170-fold 
(Q-PCR) down-regulation in myxomatous mitral valves. Several heart specific 
miRNAs such as miR-208 have been identified to be positively associated with 
circulating and tissue miR-208 levels in acute myocardial infarction, and some (miR-
223 and miR-197) show negative association. 220,237 Therefore, it is especially 
important to understand whether the circulating miR-218 is also associated with the 
tissue level and disease severity. It is possible that miR-218 could be used as a 





7 Chapter 7 Discussion 
MMVD is the single most common cardiac disease in veterinary medicine, and 
understanding the temporal and dynamic changes on a cellular and genomic level is 
important. In this project, myxomatous mitral valves from CKCSs were 
histologically assessed and compared with mixed breed myxomatous mitral valves 
using standard cellular markers for VECs, VICs, and inflammatory cells. No 
difference could be identified in the end-stage myxomatous mitral valves of CKCS 
and other dogs, suggesting that regardless of the cause, end-stage myxomatous mitral 
valves present the same cellular changes in CKCS and non-CKCS. However, it is not 
known if these cellular changes are linked to ECM component turnover. 
A global transcriptomic profiling was conducted to investigate gene regulation in the 
end-stage myxomatous mitral valves from CKCSs and healthy adult beagles. With 
advanced bioinformatics and the latest gene network analysis platforms and using the 
updated canine microarray, the current study of myxomatous mitral valve 
transcriptome confirmed the key biological functions, such as serotonin signalling 
and inflammation, reported in a previous study 106, but also led to two novel findings; 
possible reactivation of developmental pathways associated with EndoMT and 
miRNA down-regulation. Furthermore, using BioLayout Express3D to analyse gene 
signal strength allowed identification of the expression trend irrespective of what was 
found using the fold-change method. Although there were some inconsistent findings 
comparing microarray analysis and Q-PCR assays, microarray raw data was valuable 
and informative. 
Following on from the microarray analysis tissue sections of mitral valves were 
probed with specific antibodies of interest to examine their expression pattern. This 
identified the novel finding of increased expression of HAS2, potentially mediated 
by developmental pathways (BMP and SNAI1) and EndoMT. Investigation of 
temporal and spatial distribution of aVICs provided further evidence of life-long 
valve remodelling (repair), presumably in response to changes of mechanical force 





Considering data from the published literature and the current transcriptomic data, a 
mechanistic pathophysiology of canine myxomatous mitral valve degeneration can 
be hypothesized. The conventional view is that changes and damage to the leaflet are 
restricted to the distal zone, but the current study found changes occurring in the 
mid-zone of normal valves, suggesting a more complex story with ongoing valve 
repair. 
 
7.1 A Model of MMVD: 
 
Figure 7-1 A normal working mitral valve with various mechanical forces during systole and 
diastole. 
Under normal loading conditions mitral valve leaflets and the subvalvular apparatus 
together function synergistically to maintain leak-free mitral coaptation during 
systole. The interface of the valve commissures receives direct shock at the closure 
of the two leaflets during systole. Tensile stress (stretch of chordae tendineae and 
annulus), flexure, and fluid shear stress during cardiac cycle also may contribute to 
valve damage. (Figure 7-1) 85 
Healthy endothelium forms tight surface junctions under SLIT2-Robo-miR218 
signalling, and HAS2 expression by VECs also provides cushioning against 
physiological shear stress. 188,189,194,195,236 Mechanical damage to mitral valve 
structure and denudation of VECs might be the result of long-term wear. 




endothelial progenitor cells (EPCs) or bone-marrow-derived EPC. 60,102,239,240 Repair 
and remodelling of stromal damage is thought to be mediated by EndoMT and 
paracrine VICs-activation mechanism. (Figure 7-2) 202 Based on evidence from the 
current transcriptomic study ECM residual products from ECM breakdown could 
serve as endogenous ligands for toll-like receptors (TLR), and TLR signalling 
triggers inflammation and inflammatory-mediated EndoMT. 137,241 However, the 
cellular changes in normal mitral valves are restricted to the middle-atrial portion 
based on histological findings. Nevertheless, structural changes have been noted in 
the mid-zone using SEM and while speculative it may be that mid-zone damage 
altering valve mechanics could contribute to development of the more readily 
observable and characteristic distal-zone changes. 242 The excessive production of 
disorganized ECM and initiation of nodular lesion formation at the valve tip may be 
due to onset of regurgitation as a consequence of structural changes deeper in the 












Figure 7-3 Mitral regurgitant jets in early MMVD. 
 
Figure 7-4 Severe mitral regurgitation in late MMVD. 
In late stage MMVD, VEC denudation at valve tip is evident, and there is likely to be 
endothelial dysfunction (Figure 7-4). 57 This is consistent with the findings in the 
transcriptomic study such as down-regulation of basement membrane and collagen 
anchorage genes (NID1, LAMA2, and COL6A3) and miRNA dysregulation (cfa-
miR-218, miR-23, and miR-29).With loss of miR-23 and miR-29 secretion by VECs 
this would trigger excessive production of ECM by sub-endothelial VICs. Increased 
HAS2 gene expression at the valve tip and down-regulation of endothelial specific 





7.2 Limitations of the Study 
In this project, end-stage myxomatous mitral valves from CKCSs were used to 
screen global genomic expression and to model general canine MMVD pathogenesis. 
It is possible that there were genetic factors contributing to the development of 
MMVD in the four CKCS valves, with unidentified mutations contributing to 
aberrant genomic regulation.  
What is not known is what determines the onset of MMVD. Several possible 
contributing factors such as platelet abnormality unique to CKCS and ECM genes 
associated with structural integrity have been identified, but there are likely to be 
more factors associated with canine MMVD such as abnormal epigenetic control of 
genes (for example, through miRNAs). This study demonstrates the major genomic 
profile differences between young healthy mitral valves from beagles and severely 
diseased valves from CKCSs. Since mitral valves are constantly challenged by 
continuous and dynamic biomechanical forces under complex haemodynamic 
conditions, it is important to better understand the most significant force (regurgitant 
shear stress) that contributes to mitral valve degeneration and how this might affect 
gene expression. 
Additional limitations of this study include the lack of age- and breed-matched 
controls, and restrictive information derived from a single-shot profile at a small 
sample size (n=4). Due to the diverse phenotype and uncharacterized genetic 
components associated with canine MMVD, it will be necessary to better 
differentiate MMVD phenotype between breeds and for different ages. Genomic 
profiling of mitral valves from all stages of MMVD with consistent age correlation is 
required in order to build up a temporal picture of changes of gene activity associated 
with disease progression. This topic will be covered by a further study building on 
the data already derived for aged dogs. 
The microarray analysis using different platforms of software provides diverse data 
mining methods and results. Because most databases of bioinformatic platforms are 
based on the published literature or experimental settings varying between different 
tissues, cell lines, and species, the exact biological functions discovered by gene 




processes found in canine MMVD. Q-PCR assays did show good agreement with the 
microarray analysis in terms of the gene expression pattern, but it is necessary to 
recruit a large number of samples in order to confirm significance. 
To overcome some of the limitations, parallel to this PhD project, canine MVEC 
clones and primary mitral VIC cultures have been expanded from healthy mitral 
valve and phenotypically characterised (not included in this thesis). Pure canine 
MVEC clones and MVIC culture will provide a species-specific in vitro model for 
cfa-miRNA examination and gene regulation for future studies. 
7.3 Summary 
1. Regardless of the early onset and rapid progression of MMVD seen in CKCS, 
there are no differences in general pathology and cellular changes 
(myofibroblastic differentiation) comparing CKCSs and non-CKCS MMVD. 
This still needs to be confirmed to be the same for extra-cellular matrix 
changes. This suggests that MMVD in CKCS might be representative of all 
canine breeds affected by MMVD and that CKCS MMVD can be regarded as 
a model for the disease in dogs. Furthermore, the heritable component of 
CKCS MMVD might be related to the age of onset and rapidity of 
progression not the eventual pathology outcome. 
2. The updated transcriptional profile of canine MMVD, with tissues from a 
single breed (CKCS) and using stringent thresholds, greatly improves insight 
into gene regulation of MMVD. The study confirmed that serotonin 
signalling (up-regulation of 5HTR2B) is present in MMVD pathogenesis as 
first reported by Oyama et al 106, and supports the application of efforts by 
other research groups investigating this signalling pathway in MMVD 
3. The top five biologically relevant functions identified by transcriptomics 
analysis to be altered were inflammatory response, cellular movement, 





4. Developmental genes and pathways governing EndoMT, such as NOTCH, 
and SNAI1 may be contributing factors to MMVD. This was detected by the 
combination of transcriptomics and in silico gene network analysis. 
5. Analysing signal intensities for each probe-set associated with ECM 
biosynthesis (Collagens, ADAMTS, MMPs, TIMPs, and PGs), there was 
strong evidence for decreased ECM turnover rate under diseased conditions, 
and this might be associated with the prominent myofibroblastic 
differentiation seen with the disease. 
6. Evidence of EndoMT was identified in normal and myxomatous mitral valves 
by examining co-expression of mesenchymal (α-SMA) and endothelial 
(CDH5) cell markers in the myxoid stroma and close to the endothelium. This 
suggests EndoMT is a primary contributor to disease pathogenesis or a 
confounding factor. 
7. Increased myofibroblastic expression of HAS2 in myxomatous mitral valves 
suggested an elevation in hyaluronan synthesis (not confirmed), and this is 
reminiscent of what is found in embryonic mesenchyme (cardiac jelly 
production) producing conditions that favour cell migration. 
8. The EndoMT and aberrant expression of NOTCH found in MMVD could be 
a consequence of endothelial damage and dysfunction of endothelial-
interstitial interaction. 
9. Around 60% (302/502) of cfa-miRNAs were profiled in the canine array, and 
all 29 differentially expressed cfa-miRNAs were down-regulated. Within 
these miRNAs, miR-218, miR-23, and miR-29 were the key post-
transcriptional regulators that could be implicated in MMVD considering 
their ECM-related targets.  
 
7.4 Future Plans 
1. The transcriptomic study was conducted on normal dogs and dogs with end-




matched mitral valve sample cohorts with different grades of myxomatous 
lesions should be investigated to generate a dynamic map of gene expression 
throughout the natural history of MMVD. 
2. The ADAMTS family genes have important functions controlling collagen 
formation and ECM turnover, and their expression has not been studied in 
canine MMVD. Several genes of the ADAMTS family were differentially 
expressed, and their expression pattern needs to be investigated in greater 
detail in normal and diseased valves. 
3. Surprisingly LDLR was identified as a positive up-stream regulator in canine 
MMVD. Since LDLR is considered a risk factor for human cardiovascular 
disease, it would be worth investigating LDLR function in a large cohort of 
MMVD (CKCS and non-CKCS) and normal dogs, and as a potential 
biomarker of disease. 
4. Although evidence of EndoMT has been identified in normal and 
myxomatous mitral valves, more work is needed to understand what is the 
role in MMVD and the factors that initiate and control EndoMT in both 
normal and diseased valves. 
5. Considering the large difference in cfa-miR-218 expression in myxomatous 
mitral valves and its high signal intensity in normal mitral valves, it would be 
interesting to look at circulating cfa-miR-218 in serum samples of a large 
cohort of MMVD and normal dogs to see if it might be a useful biomarker or 
prognostic indicator for canine MMVD. 
6. Full-spectrum cfa-miRNAs profiling on myxomatous mitral valves using 
RNA-seq (RNA sequencing, next generation sequencing) should be 
conducted.  
7. Localization of miRNAs (cfa-miR-218, cfa-miR-23, cfa-miR-29) by using in 
situ hybridization in normal and myxomatous mitral valves aids 
understanding their expression patterns and origins. 
8. The role of increased production of hyaluronan, as suggested by increased 




myofibroblastic differentiation (ACTA2) and valve remodelling (catabolic 
enzyme and ECM-related transcripts) requires further investigation, and this 
might be best achieved in a dynamic bioreactor  maintained cell culture 
system. 
 
In summary the present study has revealed a potential role for EndoMT in 
MMVD. Further investigation of changes in mitral valves throughout the life 
course and understanding of the regulators and modulators that bring about the 
disease state will assist in both treating the disease and breeding away from key 
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9.1 Up-regulated Genes 
Transcript 
ID 




14356140 ADAMDEC1 ADAM-like, decysin 1 16.43 0.0023638 
14279513 HSP70 Heat shock protein 70 15.76 2.20E-06 
14308629 ACTG2 Actin, gamma 2, smooth muscle, enteric 15.35 0.0030887 
14430334 ANGPTL1 Angiopoietin-like 1 7.93 0.0001341 
14291033 IL6 Interleukin 6 7.87 0.0048311 
14277604 CDKN2A p14ARF protein 7.53 0.0003567 
14298902 SFRP2 Secreted frizzled-related protein 2 7.11 0.0018832 
14409533 IL18 Interleukin 18 6.93 0.0029053 
14429457 C4BPA 
Complement component 4 binding 
protein, alpha 
6.74 0.0052239 
14452716 CCL13 Chemokine ligand 13 6.40 0.0036236 
14305101 IGKC Immunoglobulin kappa constant 5.87 0.0080731 
14401712 RGS2 Regulator of G-protein signalling 2 5.81 0.0012611 
14356695 HTR2B 5-hydroxytryptamine receptor 2B 5.78 0.0048892 
14409039 SNORD14B pSNORD14B-a snoRNA 5.75 0.003647 
14387651 CXCL10 chemokine ligand 10 5.40 0.0004294 
14324892 CD180 CD180 5.39 0.0050902 
14339519 MS4A7 
Membrane-spanning 4-domains, 
subfamily A, member 7 
5.29 0.0004264 
14402028 RGS4 Regulator of G-protein signalling 4 5.25 0.0037782 
14395863 HOXD8 Homeobox D8 4.95 0.00021 
14277060 CXCL14 Chemokine ligand 14 4.94 0.0013862 
14421671 MYH11 Myosin heavy chain 11 4.94 0.0050241 
14330446 DNAJB1 
DnaJ (Hsp40) homolog, subfamily B, 
member 1 
4.87 0.0011413 
14276379 IRGM Immunity-related GTPase family, M 4.76 0.0015678 
14389567 CSTA Cystatin A (stefin A) 4.66 0.0044598 
14364302 OLR1 
Oxidized low density lipoprotein 
(lectin-like) receptor 1 
4.64 0.0069276 
14346717 CPNE4 Copine IV 4.63 0.000963 
14399010 KCNE4 
Potassium voltage-gated channel, Isk-
related family 
4.31 0.0004064 
14296316 LOC100855494 Relaxin receptor 1-like 4.24 0.0077952 
14441121 MDGA2 
MAM domain containing 




phospholipase C, X domain containing 
3 
4.16 0.0049998 
14259926 BLVRB Biliverdin reductase B 4.04 0.0012035 





14433991 PTGS2 Prostaglandin-endoperoxide synthase 2 3.98 0.0013685 
14306037 FCGR1A 








Ubiquitin carboxyl-terminal esterase L1 
(ubiquitin thiolesterase) 
3.73 0.0019072 
14337646 CTSC Cathepsin C 3.69 0.0036112 
14387161 DAPP1 
Dual adaptor of phosphotyrosine and 3-
phosphoinositides 
3.68 0.0020442 
14265296 MIA Melanoma inhibitory activity 3.67 0.000295 
14298963 FGG Fibrinogen gamma chain 3.66 0.0033911 
14415876 C5H17orf61 
Chromosome 5 open reading frame, 
human C17orf61 
3.66 0.0008839 
14287764 ANGPT1 Angiopoietin 1 3.65 9.78E-05 
14308417 DNAH6 Dynein, axonemal, heavy chain 6 3.64 0.0014576 
14447242 EVI2B Ecotropic viral integration site 2B 3.61 0.0027801 
14301010 ENPP6 Ectonucleotide phosphodiesterase 6 3.59 0.0008702 
14457347 TLR8 Toll-like receptor 8 3.56 0.000581 
14335858 LOC100856456 Transcription factor jun-B-like 3.56 0.0062055 
14427829 LOC100855953 Leukocyte surface antigen CD53-like 3.55 0.0006372 
14376000 ARAP2 
ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 2 
3.51 4.32E-05 
14397988 CASP8 




Zinc finger and BTB domain containing 
11 
3.46 0.0011206 
14306097 LOC100855873 uncharacterized 3.38 9.18E-05 
14315779 RAB1B Member RAS oncogene family 3.36 0.0007053 
14297194 CYP4B1 
Cytochrome P450, family 4, subfamily 
B, polypeptide 1 
3.35 0.0070399 
14384937 KCNJ15 
Potassium inwardly-rectifying channel, 
subfamily J, member 15 
3.35 0.0012843 
14388813 EPHA3 EPH receptor A3 3.34 0.0016206 
14400997 FCGR3A 
Fc fragment of IgG, low affinity IIIa, 
receptor, CD16a 
3.32 0.0019346 
14279408 LST1 Leukocyte specific transcript 1 3.22 5.69E-05 
14302908 MSR1 Macrophage scavenger receptor 1 3.22 0.0030312 
14387182 BANK1 
B-cell scaffold protein with ankyrin 
repeats 1  
3.19 0.0004135 
14408542 CDH6 




Multidrug resistance-associated protein 
1-like 
3.15 0.0001173 
14269496 RPS27A Ribosomal protein S27a 3.12 0.0057618 
14393246 CLDN1 Claudin 1 3.07 0.0062876 
14257671 PDCD1LG2 Programmed cell death 1 ligand 2 3.04 0.0023886 





Chromosome X open reading frame, 
human CXorf21 
2.98 0.0010594 
14260050 GMFG Glia maturation factor, gamma 2.97 9.31E-05 
14432035 S100A4 S100 calcium binding protein A4 2.96 0.0011562 
14366798 C3AR1 Complement component 3a receptor 1 2.95 0.0035321 
14289740 IGJ 
Immunoglobulin J polypeptide, linker 





transporter, class I, type 8B, member 1 
2.92 0.0016777 
14375983 TLR1 Toll-like receptor 1 2.92 0.0015849 
14316910 SLC7A11 
Solute carrier family 7 (anionic amino 
acid transporter light chain, xc- system), 
member 11 
2.90 0.0003853 
14395737 LOC100669834 3-ketoacyl-CoA thiolase 2.90 0.0082638 
14458099 GPR34 G protein-coupled receptor 34 2.86 0.0012531 
14399254 STK17B Serine/threonine kinase 17b 2.84 0.0040246 
14336520 EMR1 
Egf-like module containing, mucin-like, 
hormone receptor-like 1 
2.83 0.0066345 
14266174 SCN1B 





ribonucleoprotein H2 (H') 
2.82 0.0001491 
14305354 TACR1 Tachykinin receptor 1 2.81 0.005963 
14401130 CD48 CD48 molecule 2.79 0.0001312 
14376548 ARSK Arylsulfatase family, member K 2.76 0.0004966 
14395111 LOC100856186 Histone H2B type 1-like 2.71 0.0069714 
14415921 LSMD1 LSM domain containing 1 2.71 0.0015234 
14330808 ACP5 Acid phosphatase 5, tartrate resistant 2.71 0.0032024 
14388619 CFI Complement factor I 2.67 0.0004298 
14430287 PLA2G4A 
Phospholipase A2, group IVA 
(cytosolic, calcium-dependent) 
2.67 6.15E-05 
14293112 SKAP2 Src kinase associated phosphoprotein 2 2.66 0.0033201 
14285991 NOV Nephroblastoma overexpressed gene 2.64 0.0001948 
14295395 PLXNC1 Plexin C1 2.64 0.0001755 
14417953 SLC2A5 
Solute carrier family 2 (facilitated 
glucose/fructose transporter), member 5 
2.64 0.0003722 
14438172 AKAP5 A kinase (PRKA) anchor protein 5 2.64 0.004823 
14277492 BNC2 Basonuclin 2 2.63 0.0005092 
14423410 GCLM 




Cat eye syndrome chromosome region, 
candidate 1 
2.61 0.0028325 
14444226 CD300C CD300c molecule 2.60 0.0061729 
14455870 MUSTN1 
Musculoskeletal, embryonic nuclear 
protein 1 
2.60 0.0026978 
14369941 SLC16A12 Solute carrier family 16, member 12 2.58 0.0030007 
14394611 F13A1 Coagulation factor XIII, A1 polypeptide 2.58 0.00097 












14364714 MRPL51 Mitochondrial ribosomal protein L51 2.56 0.000589 
14260868 SERPINB8 
Serpin peptidase inhibitor, clade B 
(ovalbumin), member 8 
2.56 0.0006415 
14306915 OSR1 Odd-skipped related 1 (Drosophila) 2.50 0.0027473 
14376453 FAM174A 
Family with sequence similarity 174, 
member A 
2.50 0.0001622 
14316336 FKBP2 FK506 binding protein 2 2.50 0.0007302 
14290617 LOC100855806 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-11-like 
2.50 5.55E-06 
14290717 DYNC1I1 




Procollagen C-endopeptidase enhancer 
2 
2.48 0.0050051 
14295006 RNASE8 Ribonuclease, RNase A family, 8 2.48 0.0001736 
14293512 LOC100856330 Transcription factor EC-like 2.48 0.0028158 
14311075 LPXN Leupaxin 2.47 0.0002508 
14404160 KCNMB1 
Potassium large conductance calcium-




Complement component 1, q 
subcomponent, C chain 
2.45 0.0034431 
14393476 PDCD10 Programmed cell death 10 2.45 0.0001784 
14300558 LSM1 
LSM1 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
2.45 7.82E-05 
14260509 PEPD Peptidase D 2.44 0.0012788 
14457934 CYBB Cytochrome b-245, beta polypeptide 2.44 0.0005148 
14262002 SOD2 Superoxide dismutase 2, mitochondrial 2.44 0.0055162 
14329923 LRRC25 Leucine rich repeat containing 25 2.43 0.0064751 
14282827 HLA-DMB 
Major histocompatibility complex, class 
II, DM beta 
2.42 0.0006325 
14409755 CASP4 
Caspase 4, apoptosis-related cysteine 
peptidase 
2.42 0.00462 
14414808 TAGLN Transgelin, smooth muscle protein 22-α 2.40 0.0042533 
14341081 LOC100855439 
Lymphatic vessel endothelial 
hyaluronan receptor 1 
2.40 0.0024844 
14360356 P2RX7 
Purinergic receptor P2X, ligand-gated 
ion channel, 7 
2.40 0.0080105 
14279411 AIF1 Allograft inflammatory factor 1 2.39 6.21E-05 
14423570 GBP7 Guanylate binding protein 7 2.39 0.0010409 
14463411 ACSL4 
Acyl-CoA synthetase long-chain family 
member 4 
2.38 0.0001702 
14393925 BMP6 Bone morphogenetic protein 6 2.38 0.0006752 
14293421 THAP5 THAP domain containing 5 2.38 0.0049522 
14388251 EIF4E 
Eukaryotic translation initiation factor 
4E, transcript variant 1 
2.38 3.06E-05 
14420727 LOC100856347 
Apoptosis-associated speck-like protein 





14394786 CCDC90A Coiled-coil domain containing 90A 2.37 0.0002194 
14397810 PLCL1 Phospholipase C-like 1 2.37 0.0011644 
14281184 PTP4A1 
Protein tyrosine phosphatase type IVA, 
member 1 
2.36 0.0027559 
14378086 LOC488754 UPF0235 protein C15orf40 homolog 2.36 0.0007535 
14368831 ACSL5 
Acyl-CoA synthetase long-chain family 
member 5 
2.36 0.0025964 
14349723 LOC100855575 Prefoldin subunit 4-like 2.35 0.0002414 
14276284 TLR4 Toll-like receptor 4 2.35 0.0007263 
14405830 KCNK1 
Potassium channel, subfamily K, 
member 1 
2.34 7.61E-06 
14282689 PBX2 Pre-B-cell leukemia homeobox 2 2.34 0.0006961 
14306306 PSMD4 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 4 
2.34 0.0010403 
14390084 SENP7 SUMO1/sentrin specific peptidase 7 2.33 0.0005753 
14424895 BUD31 BUD31 homolog (S. cerevisiae) 2.32 0.0001206 
14389549 CD86 CD86 2.31 0.0061988 
14339560 LOC100688295 HIG1 domain family member 1A-like 2.30 0.0009726 
14282987 MNF1 Mitochondrial nucleoid factor 1 2.30 0.0004498 
14425484 LOC607096 Integrin alpha-D-like 2.29 0.0082467 
14289182 COMMD8 COMM domain containing 8 2.29 0.0014787 
14455843 YKT6 Synaptobrevin homolog YKT6-like 2.29 0.0001039 
14370194 BLNK B-cell linker 2.29 0.007452 
14324913 TAF9 
TAF9 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor 
2.28 0.0007525 
14310860 LMO2 LIM domain only 2 (rhombotin-like 1) 2.28 0.0003799 
14366241 ARNTL2 
Aryl hydrocarbon receptor nuclear 
translocator-like 2 
2.28 0.0053733 
14437194 COCH Coagulation factor C homolog, cochlin 2.28 0.0033649 
14269495 LOC481020 Ribosomal protein S27a pseudogene 2.28 0.0002827 
14384036 HEXA Hexosaminidase A (alpha polypeptide) 2.27 8.53E-05 
14316455 RARRES3 Retinoic acid receptor responder 2.27 0.001159 
14309451 CTSS Cathepsin S 2.27 0.0001155 
14272857 PIGF 
Phosphatidylinositol glycan anchor 
biosynthesis, class F 
2.27 2.42E-05 
14268697 SLC41A2 Solute carrier family 41, member 2 2.26 0.0007109 
14452113 TMEM100 Transmembrane protein 100-like 2.26 0.0002165 
14424902 ARPC1B 




Ras-like protein family member 11A-
like 
2.24 0.0043578 
14464562 CLIC2 Chloride intracellular channel 2 2.24 0.0004549 
14261042 SEC11C SEC11 homolog C (S. cerevisiae) 2.23 0.0006212 
14324259 SRA1 Steroid receptor RNA activator 1 2.23 0.000316 
14459417 ARMCX3 Armadillo repeat containing, X-linked 3 2.22 0.0004459 
14380316 PLDN Pallidin homolog (mouse) 2.22 0.0007458 




14257638 JAK2 Janus kinase 2 2.21 8.78E-05 






14304046 EMILIN1 Elastin microfibril interfacer 1 2.20 0.0044554 
14269753 PLEK Pleckstrin 2.20 0.0009991 
14272109 CHST11 













ribonucleoprotein C (C1/C2), transcript 
variant 4 
2.20 0.0003674 
14333765 PDE12 Phosphodiesterase 12 2.20 0.0001047 
14430268 C7H1orf27 
Chromosome 7 open reading frame, 
human 
2.19 0.0079821 
14364180 HEBP1 Heme binding protein 1 2.19 0.0016488 
14458636 TSR2 
TSR2, 20S rRNA accumulation, 
homolog (S. cerevisiae) 
2.19 0.0001605 
14288059 HAS2 Hyaluronan synthase 2 2.18 0.0009851 
14274424 UQCRQ 
Ubiquinol-cytochrome c reductase, 
complex III subunit VII 
2.18 0.0031511 
14387277 AIMP1 
Aminoacyl tRNA synthetase complex-
interacting multifunctional protein 1 
2.18 0.0006014 
14296247 GUCY1B3 Guanylate cyclase 1, soluble, beta 3 2.17 0.000957 
14408225 CARD6 












General transcription factor IIA, 2, 
12kDa 
2.16 1.95E-05 
14434952 FBXO28 F-box protein 28 2.16 8.51E-06 
14309398 LOC100855771 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
2.15 7.47E-06 
14363362 TWF1 
Twinfilin, actin-binding protein, 
homolog 1 (Drosophila) 
2.14 8.38E-05 
14437560 LOC100856165 
Abhydrolase domain-containing protein 
12B-like 
2.14 0.0003549 
14255611 ABRACL ABRA C-terminal like 2.14 0.0004002 
14261673 NUP43 Nucleoporin 2.14 1.81E-05 
14439109 C8H14orf109 
Chromosome 8 open reading frame, 
human C14orf109 
2.14 0.0011247 
14279522 CFB Complement factor B 2.14 0.0028465 
14329619 CCR1 Chemokine receptor 1 2.14 0.0077394 
14314380 C18H11orf46 
Chromosome 18 open reading frame, 
human C11orf46 
2.14 0.000794 





















14447044 CCL5 Chemokine ligand 5 2.12 0.00276 
14375538 HAUS3 HAUS augmin-like complex, subunit 3 2.12 0.0003076 
14452355 LOC100856241 








Lymphocyte cytosolic protein 1 (L-
plastin) 
2.11 0.0054745 
14280111 CDKN1A Cyclin-dependent kinase inhibitor 1A 2.11 0.0064265 
14295451 SNRPF 
Small nuclear ribonucleoprotein 
polypeptide F 
2.11 2.02E-05 
14404409 HAVCR1 Hepatitis A virus cellular receptor 1 2.10 0.0075884 
14291509 DNAJB9 
DnaJ (Hsp40) homolog, subfamily B, 
member 9 
2.10 0.000596 
14255007 TXNL4A Thioredoxin-like 4A 2.10 0.0001545 
14387790 RASGEF1B RasGEF domain family, member 1B 2.10 0.0068825 
14457994 MID1IP1 MID1 interacting protein 1 2.09 0.0005058 





14294722 PRDX1 Peroxiredoxin 1 2.09 0.0008154 
14347364 P2RY12 
Purinergic receptor P2Y, G-protein 
coupled, 12 
2.09 0.0054882 
14326966 PDPN Podoplanin 2.09 0.000746 
14457450 LOC100856271 








Spleen focus forming virus (SFFV) 
proviral integration oncogene 
2.08 0.0041846 
14367224 LOC100682990 uncharacterized 2.08 0.0081128 
14302847 ERI1 Exoribonuclease 1 2.08 0.0003779 
14447759 LSM5 












Chromosome 18 open reading frame, 
human C11orf48 
2.07 0.0013839 
14375926 UGDH UDP-glucose 6-dehydrogenase 2.07 0.002583 





Potassium channel tetramerisation 
domain containing 16 
2.07 0.0019304 
14326126 RPS6KA1 Ribosomal protein S6 kinase 2.07 0.0039676 
14342436 ITGBL1 
Integrin, beta-like 1 (with EGF-like 
repeat domains) 
2.06 0.001201 
14393763 NQO2 NADPH dehydrogenase, quinone 2 2.06 9.50E-05 
14291222 CHN2 Chimerin 2 2.05 0.0017276 





14388094 HSD17B11 Hydroxysteroid dehydrogenase 11 2.05 0.0017765 
14374668 CHSY1 Chondroitin sulfate synthase 1 2.04 0.000203 
14437248 NPAS3 Neuronal PAS domain protein 3 2.04 0.0050785 
14326622 LOC612968 UPF0327 protein C1orf151-like 2.04 2.36E-07 
14376263 MFSD7 
Major facilitator superfamily domain 
containing 7 
2.04 0.0010188 
14323171 CREM cAMP responsive element modulator 2.03 0.0024523 
14460399 HTATSF1 HIV-1 Tat specific factor 1 2.03 2.65E-05 
14415665 PSMB6 
Proteasome (prosome, macropain) 
subunit, beta type, 6 
2.03 3.38E-05 
14457364 RAB9A 







14264356 FLT3LG Fms-related tyrosine kinase 3 ligand 2.02 0.0038599 
14282545 HSPA1L Heat shock 70kDa protein 1-like 2.02 0.0005714 
14459962 SLC25A5 
Solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide 
translocator), member 5 
2.02 0.0013401 
14310009 C18H7orf25 
Chromosome 18 open reading frame, 
human C7orf25 
2.02 0.0044332 
14353865 REEP4 Receptor accessory protein 4 2.02 0.001033 
14303184 CDKN2AIP CDKN2A interacting protein 2.02 0.0022166 
14373072 CYP7B1 
Cytochrome P450, family 7, subfamily 
B, polypeptide 1 
2.02 0.0070221 
14432045 S100A6 S100 calcium binding protein A6 2.01 0.0060007 
14434527 ATP1B1 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
2.01 0.0072442 
14444221 LOC100686047 CMRF35-like molecule-like 2.01 0.0018697 
14278898 POLE3 




Histidine triad nucleotide binding 
protein 1 
2.01 0.0030206 
14255629 GPR126 G protein-coupled receptor 126 2.00 0.0016917 
14260025 EID2 
EP300-interacting inhibitor of 
differentiation 2-like 
2.00 0.0011167 
14366159 FAR2 Fatty acyl CoA reductase 2 2.00 0.0012864 
14402106 DUSP12 Dual specificity phosphatase 12 1.91 0.0038568 





ATPase, H+ transporting, lysosomal 
9kDa, V0 subunit e1 
1.88 0.0002092 
14447839 GNG10 
Guanine nucleotide binding protein (G 
protein), gamma 10 
1.88 9.96E-05 
14442139 NPC2 Niemann-Pick disease, type C2 1.83 3.27E-05 
14350497 DSTN Destrin 1.82 0.0009115 
14340701 PRKCDBP Protein kinase C, delta binding protein 1.77 0.0003068 
14400410 SERPINE2 
Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator inhibitor 
type 1), member 2 
1.75 0.0008742 
14272245 SULT1C4 








Ribosomal protein L23 pseudogene on 
chromosome 7 
1.73 0.0004456 
14432910 PLXDC1 Plexin domain containing 1 1.73 0.0004456 
14397472 FRZB Frizzled-related protein 1.72 0.0027688 
14260028 RPS16 Ribosomal protein S16 1.71 0.0076111 
14390307 ATG3 Autophagy related 3 1.70 0.0002805 
14388746 SEC24D 




Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
1.67 0.0008835 
14342163 CLN5 Ceroid-lipofuscinosis, neuronal 5 1.66 0.0001417 
14343958 GAS6 Growth arrest-specific 6 1.66 0.0024621 
14445842 MIEN1 Migration and invasion enhancer 1 1.65 0.0038984 
14461000 VAMP7 Vesicle-associated membrane protein 7 1.65 0.0012581 
14445369 RAB5C RAB5C, member RAS oncogene family 1.64 0.0002226 
14275171 DNAJA1 
DnaJ (Hsp40) homolog, subfamily A, 
member 1 
1.62 0.0040381 
14458010 LOC100682978 Renin receptor-like 1.61 0.00107 
14292191 ATP6V1F 
ATPase, H+ transporting, lysosomal 






14344504 RPSA Ribosomal protein SA 1.60 0.0020778 
14379164 RBPJ 
Recombination signal binding protein 
for immunoglobulin kappa J region 
1.60 0.0034678 
14261577 FUCA2 Fucosidase, alpha-L- 2, plasma 1.58 0.0010007 
14350033 RPS21 Ribosomal protein S21 1.58 0.0041851 
14412087 RER1 
RER1 retention in endoplasmic 
reticulum 1 homolog (S. cerevisiae) 
1.58 0.0033288 
14303909 RAB10 RAB10, member RAS oncogene family 1.58 0.0003814 
14271471 RBX1 Ring-box 1, E3 ubiquitin protein ligase 1.57 0.0001233 
14446749 CLTC Clathrin, heavy chain (Hc) 1.57 0.0029127 
14333938 SPCS1 
Signal peptidase complex subunit 1 
homolog (S. cerevisiae) 
1.56 0.0010232 




14340406 FOLR2 Folate receptor 2 (foetal) 1.56 0.0031528 
14303474 RPS7 Ribosomal protein S7 1.55 0.0017809 
14398657 ARPC2 
Actin related protein 2/3 complex, 
subunit 2 
1.55 6.05E-05 
14379076 PGM2 Phosphoglucomutase 2 1.55 0.0027705 
14440227 LGMN Legumain 1.55 0.0012816 
14279695 DLA-DRA MHC class II DR alpha chain 1.54 0.007323 
14269713 ACTR2 




Phosphatidylinositol glycan anchor 
biosynthesis, class Y 
1.53 0.0045689 
14414061 STT3A 





Chromosome 20 open reading frame, 
human C19orf42 
1.52 0.000737 
14387670 SCARB2 Scavenger receptor class B, member 2 1.52 0.005629 
14319137 ITGB1 
Integrin beta-1 (fibronectin receptor, 
beta polypeptide, CD29) 
1.52 0.0010731 
14360089 TMED2 
Transmembrane emp24 domain 
trafficking protein 2 
1.52 6.32E-05 
14440261 DAD1 Defender against cell death 1 1.52 0.0034178 
14321748 PTP4A2 




Guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 3 
1.51 0.0011621 
14262925 ANXA1 Annexin A1 1.50 0.0045024 





9.2 Down-Regulated Genes 
Transcript 
ID 





U6 small nuclear 21 (RNU6-21), small 
nuclear RNA 
-9.41 0.0023737 
14274311 KIAA1024L KIAA1024-like -8.55 0.0017609 
14383643 CILP Cartilage intermediate layer protein, -6.20 0.0015588 
14459309 TNMD Tenomodulin -5.48 0.0045327 
14353342 GJB6 Gap junction protein, beta 6 -5.27 0.0033142 
14432404 DSC2 Desmocollin 2 -5.18 0.0056081 
14256801 LAMA2 Laminin, alpha 2 -5.16 0.0010771 
14293892 SNORA55 
H/ACA box 55 (SNORA55), small 
nucleolar RNA 
-4.98 0.0033681 
14404304 CCNJL Cyclin J-like -4.64 0.0006434 
14274287 ADAMTS19 
A disintegrin and metalloproteinase 
with thrombospondin motif 19 
-4.52 0.0046562 
14347367 IGSF10 
Immunoglobulin superfamily, member 
10 
-4.43 0.0039529 
14263948 ZNF267 Zinc finger protein 267 -4.36 0.0012417 
14404821 HCN1 
Potassium/sodium hyperpolarization-




Lipid phosphate phosphatase-related 
protein type 5-l 
-4.23 0.0003116 
14456802 RN5-8S 5.8S ribosomal RNA -4.11 0.0003119 
14440266 LOC606860 
Cytochrome c oxidase subunit 6C-like 
variant 2 
-3.84 0.0011047 
14351625 NNAT neuronatin, transcript variant 2 -3.77 0.0009186 
14384782 CBR1 Carbonyl reductase 1 -3.61 0.0003973 
14276971 FSTL4 Follistatin-like 4 -3.53 0.0022076 
14316083 CDC42EP2 




Eukaryotic translation initiation factor 1 
(EIF1) 
-3.33 0.0022232 
14416005 VAMP2 Vesicle-associated membrane protein 2 -3.32 5.29E-06 
14409018 SCN3B 
Sodium channel, voltage-gated, type III, 
beta subunit 
-3.26 0.0035518 
14279273 ATAT1 Alpha tubulin acetyltransferase 1 -3.24 0.0001465 
14408526 PDZD2 PDZ domain containing 2 -3.22 0.0020964 
14452015 CHAD Chondroadherin -3.17 0.0070053 
14334891 CILP2 cartilage intermediate layer protein 2 -3.11 0.0002831 
14266793 KIF5A Kinesin family member 5A -3.10 3.89E-05 
14330901 DOCK6 Dedicator of cytokinesis 6 -3.10 0.0001512 
14402587 NID1 Nidogen 1 -3.09 0.0004765 
14440633 ADCY4 Adenylate cyclase 4 -3.01 0.0009372 
14311489 MYBPC3 Myosin binding protein C, cardiac -3.00 0.0035104 




and two follistatin-like domains 2 
14328977 NICN1 Nicolin 1 -2.95 0.0008845 
14421559 SYT17 Synaptotagmin XVII -2.91 0.0020807 
14442940 MOK MOK protein kinase -2.90 9.29E-06 
14316459 LGALS12 Lectin, galactoside-binding, soluble, 12 -2.88 0.0026561 
14409246 MPZL2 Myelin protein zero-like 2 -2.88 0.0058972 
14464011 LOC100683463 Protein FAM127-like -2.87 0.0002329 
14392321 CLDN11 Claudin 11 -2.87 0.0026389 
14313855 PCLO Presynaptic cytomatrix protein -2.87 0.0027832 
14263819 LENG8 Leukocyte receptor cluster member 8 -2.87 0.0014422 
14457986 TSPAN7 Tetraspanin 7 -2.85 0.0011349 
14360243 MLXIP MLX interacting protein -2.85 0.0008552 
14441890 ZFP36L1 Zinc finger protein 36, C3H type-like 1 -2.84 0.0002014 
14403626 ZMIZ1 Zinc finger, MIZ-type containing 1 -2.84 0.0036372 
14325844 LOC100855498 Serine incorporator 2-like -2.82 0.0001817 
14450321 MAPT Microtubule-associated protein tau -2.81 0.0026711 
14424200 AUTS2 Autism susceptibility candidate 2 -2.78 0.0001845 
14277414 FREM1 FRAS1 related extracellular matrix 1 -2.69 0.0003133 
14264759 HIF3A 
Hypoxia inducible factor 3, alpha 
subunit 
-2.67 0.0012752 
14265052 ZNF283 Zinc finger protein 283 -2.67 0.0021741 
14415096 LOC100686634 uncharacterized -2.67 0.0004244 
14400025 IGFBP5 
Insulin-like growth factor binding 
protein 5 
-2.65 0.0002239 
14381604 RYR3 Ryanodine receptor 3 -2.64 0.0028378 
14455066 LOC100855805 Cyclin-dependent kinase 9-like -2.64 0.0003616 
14259800 ATP1A3 




DDB1- and CUL4-associated factor 16-
like 
-2.63 0.0008798 
14344644 CCBP2 Chemokine binding protein 2 -2.63 0.0006024 
14453155 FAM222B 
Family with sequence similarity 222, 
member B 
-2.63 5.18E-05 
14277894 CNTFR Ciliary neurotrophic factor receptor -2.60 0.0016514 
14460473 LOC100855971 Protein LDOC1-like -2.59 0.001504 
14378505 GRK4 G protein-coupled receptor kinase 4 -2.58 0.0011628 
14373535 MMP16 Matrix metallopeptidase 16 -2.58 0.0040699 
14460548 MAMLD1 Mastermind-like domain containing 1 -2.56 0.0004072 
14287635 LOC100684029 




PML-RARA regulated adaptor 
molecule 1 
-2.54 0.0020339 
14417429 MXRA8 Matrix-remodelling associated 8 -2.53 0.0011745 
14293539 CTTNBP2 Cortactin binding protein 2 -2.52 0.0069934 
14306182 ADAMTSL4 ADAMTS-like 4 -2.52 0.0001809 




14277190 GFRA3 GDNF family receptor alpha 3 -2.47 0.0083011 
14444488 TANC2 
Tetratricopeptide repeat, ankyrin repeat 
and coiled-coil containing 2 
-2.47 0.0013202 
14329816 SUGP2 SURP and G patch domain containing 2 -2.47 0.0005754 
14356848 COL6A3 Collagen, type VI, alpha 3 -2.47 0.0002998 
14321931 SRSF4 Serine/arginine-rich splicing factor 4 -2.46 0.0004164 
14263835 TTYH1 Tweety homolog 1 (Drosophila) -2.44 0.0003127 
14419301 FAM65A 
Family with sequence similarity 65, 
member A 
-2.44 0.0015519 
14305406 DQX1 DEAQ box RNA-dependent ATPase 1 -2.44 0.0004586 
14272457 NPAS2 Neuronal PAS domain protein 2 -2.44 0.0015415 
14398770 TTLL4 




Phosphoinositide-3-kinase, class 2, beta 
polypeptide 
-2.42 0.0022057 
14409363 SIK3 SIK family kinase 3 -2.42 2.16E-05 
14297622 SZT2 Seizure threshold 2 homolog (mouse) -2.42 0.0004458 
14367455 MICAL3 
Microtubule associated 
monooxygenase, calponin and LIM 
domain containing 3 
-2.41 1.11E-05 
14373768 TMEM232 Transmembrane protein 232 -2.41 0.001817 
14329911 ISYNA1 Inositol-3-phosphate synthase 1 -2.41 0.0003538 
14331738 RFX2 Regulatory factor X, 2 -2.40 0.0013869 
14403871 FAM193B 
Family with sequence similarity 193, 
member B 
-2.39 0.000138 
14282609 TNXB Tenascin XB -2.38 0.0009905 
14353345 GJB2 Gap junction protein, beta 2 -2.37 0.0052903 
14438313 PLEKHH1 
Pleckstrin homology domain 
containing, family H (with MyTH4 
domain) member 1 
-2.37 0.0018726 
14453076 SGK494 Serine/threonine-protein kinase SgK494 -2.37 0.0001657 
14419748 NSUN5 NOP2/Sun domain family, member 5 -2.36 0.0007726 
14377933 CRTC3 
CREB regulated transcription 
coactivator 3 
-2.33 0.0004378 
14448168 NOTCH1 NOTCH 1 -2.33 0.0001854 
14272455 LOC100855789 60S ribosomal protein L31-like -2.33 0.0003392 
14415042 SIK2 Salt-inducible kinase 2 -2.32 0.0002157 
14358930 LOC612180 Lambda chain V-I region BL2-like -2.32 4.61E-05 
14299531 HIPK2 
Homeodomain interacting protein 
kinase 2 
-2.32 0.0029422 
14356909 PER2 Period homolog 2 (Drosophila) -2.31 0.0001976 
14286551 KIAA1875 uncharacterized -2.31 0.0027602 
14298252 KERA Keratocan -2.29 0.0044131 
14403272 EIF4EBP2 
Eukaryotic translation initiation factor 
4E binding protein 2 
-2.28 0.0064816 
14368859 TCF7L2 
Transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
-2.28 0.0047273 




14320231 PCDHB6 Protocadherin beta 6 -2.27 0.0002363 
14400879 LOC100855882 




Receptor (G protein-coupled) activity 







14330891 TMEM205 Transmembrane protein 205 -2.26 0.0057389 
14270169 BAZ2A 
Bromodomain adjacent to zinc finger 
domain, 2A 
-2.25 0.0015751 
14304824 TMEM127 Transmembrane protein 127 -2.25 0.0011494 
14383583 RBPMS2 
RNA binding protein with multiple 
splicing 2 
-2.25 0.0014787 
14367330 RAD52 RAD52 homolog (S. cerevisiae) -2.24 0.0001395 
14444903 DCAKD 
Dephospho-CoA kinase domain 
containing 
-2.24 0.0020062 
14443984 WBP2 WW domain binding protein 2 -2.23 2.34E-05 
14279460 CSNK2B Casein kinase 2, beta polypeptide -2.23 0.0003457 
14449897 ITGB4 Integrin, beta 4 -2.23 0.0015219 
14458986 ITGB1BP2 




Protein tyrosine phosphatase type IVA, 
member 3 
-2.22 0.0030047 
14336449 ZNF414 Zinc finger protein 414 -2.22 0.0047063 
14281354 KCNQ5 
Potassium voltage-gated channel, KQT-
like subfamily, member 5 
-2.22 0.0014712 
14327169 PEX14 Peroxisomal biogenesis factor 14 -2.22 0.0005239 
14287353 SLC4A4 
Solute carrier family 4 (sodium 
bicarbonate cotransporter), member 4 
-2.21 0.000228 
14425883 CCDC101 Coiled-coil domain containing 101 -2.20 0.0051057 
14356360 FAM160B2 
Family with sequence similarity 160, 
member B2 
-2.20 0.0032004 
14259044 RASIP1 Ras interacting protein 1 -2.19 4.02E-05 
14360655 SLC24A6 




14334149 ALAS1 Aminolevulinate, delta-, synthase 1 -2.18 8.27E-05 
14312916 NXF1 Nuclear RNA export factor 1 -2.17 0.0012885 
14428916 RABGGTB 




Protein phosphatase 1, regulatory 
subunit 12B 
-2.17 0.0002056 
14280756 TMEM63B Transmembrane protein 63B -2.17 0.0008502 
14380057 STARD9 
StAR-related lipid transfer (START) 
domain containing 9 
-2.16 0.0003973 
14309367 MTMR11 Myotubularin related protein 11 -2.16 0.0014399 
14257931 MZF1 Myeloid zinc finger 1 -2.16 0.0014903 
14328985 AMT Aminomethyltransferase -2.16 0.0059803 













Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 
-2.13 0.0065708 
14263990 LOC611704 uncharacterized -2.13 0.001024 
14310307 ATXN7L1 Ataxin 7-like 1 -2.13 0.0011088 
14380678 LIPC Lipase, hepatic -2.13 0.0021006 
14406539 ZMYND17 Zinc finger, MYND-type containing 17 -2.12 0.0035858 
14339306 NAV2 Neuron navigator 2 -2.12 0.0052866 
14422144 SRL Sarcalumenin -2.12 0.0028729 
14403912 PDLIM7 PDZ and LIM domain 7 (enigma) -2.12 0.000384 
14281639 NT5E 5'-nucleotidase, ecto (CD73) -2.12 0.0068563 
14459376 DRP2 DRP2 // dystrophin related protein 2 -2.12 0.0004183 
14416031 CTC1 




Sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain 
-2.12 0.0046086 
14422322 SRRM2 Serine/arginine repetitive matrix 2 -2.11 0.0016852 
14387683 CCDC158 
Coiled-coil domain containing 158, 
transcript variant 1 
-2.11 0.0043208 
14401528 ELK4 
ELK4, ETS-domain protein (SRF 
accessory protein 1) 
-2.11 0.0014438 
14362060 SMPD4 
Sphingomyelin phosphodiesterase 4, 
neutral membrane (neutral 
sphingomyelinase-3) 
-2.10 0.0007038 






ATPase, Ca++ transporting, cardiac 
muscle, slow twitch 2 
-2.10 0.0040478 
14368535 AS3MT 
Arsenic (+3 oxidation state) 
methyltransferase 
-2.09 0.004156 
14306498 LOC483226 Methylosome protein 50-like -2.09 0.0010908 
14322014 WASF2 WAS protein family, member 2 -2.08 0.0019819 
14441993 MAP3K9 Mitogen-activated protein kinase 9 -2.08 0.0048941 
14321743 TMEM234 Transmembrane protein 234 -2.08 0.0009542 
14335775 NFIX 




Intraflagellar transport 172 homolog 
(Chlamydomonas) 
-2.08 0.0005102 
14362408 ATF7 Activating transcription factor 7 -2.07 0.0049196 
14420251 LOC608835 Proline-rich protein 3-like -2.07 0.0001469 
14365377 TENC1 
Tensin like C1 domain containing 
phosphatase 
-2.07 0.0030479 
14300209 LOC611426 uncharacterized -2.06 0.0001624 
14410241 BCL6B B-cell CLL/lymphoma 6, member B -2.06 0.0001833 




14319305 NEBL Nebulette -2.06 0.0008921 
14355659 CBR4 Carbonyl reductase 4 -2.05 0.0039953 
14418313 CRISPLD2 
Cysteine-rich secretory protein LCCL 
domain containing 2 
-2.04 0.0005238 
14453163 LOC100856195 Flotillin-2-like -2.04 0.0019161 
14453266 GIT1 
G protein-coupled receptor kinase 
interacting ArfGAP 1 
-2.03 0.0021455 
14421037 ATXN2L Ataxin 2-like -2.03 0.0017541 
14315712 BBS1 Bardet-Biedl syndrome 1 -2.01 7.08E-05 
14282289 LOC100856242 Nurim-like -2.01 0.0026293 
14399678 INO80D INO80 complex subunit D -2.01 0.0001585 
14319630 FAM171A1 




Growth regulation by estrogen in breast 
cancer 1 
-2.01 0.000169 
14422165 CREBBP CREB binding protein -2.01 0.0041639 
14356674 SP110 SP110 nuclear body protein -2.01 0.0023131 
14305965 BCL9 B-cell CLL/lymphoma 9 -2.01 0.0062644 
14294098 LSM10 U7 small nuclear RNA associated -2.00 0.0001365 
14360531 C26H12orf51 
Chromosome 26 open reading frame, 
human C12orf51 
-2.00 0.0008397 
14386568 FRAS1 Fraser syndrome 1 -2.00 0.0070327 
14300868 SORBS2 Sorbin and SH3 domain containing 2 -1.99 0.0043209 
14419763 RHBDD2 Rhomboid domain containing 2 -1.99 0.0015067 
14429473 CD55 CD55 -1.98 0.0017287 
14379046 KLF3 Kruppel-like factor 3 (basic) -1.98 1.23E-05 
14426693 MKL2 MKL/myocardin-like 2 -1.94 0.0016282 
14422375 RNPS1 
RNA binding protein S1, serine-rich 
domain 
-1.92 0.0006026 
14331498 CERS4 Ceramide synthase 4 -1.91 0.0029483 
14282384 DDX39B 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 39B 
-1.89 0.0028996 
14361544 SF3A1 Splicing factor 3a, subunit 1 -1.89 0.0010373 
14312690 SF1 Splicing factor 1 -1.87 0.0006843 
14260690 NFATC1 
Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 1 
-1.87 0.0036493 
14312494 SYVN1 




Protein tyrosine phosphatase, non-
receptor type 14 
-1.86 0.0008193 
14358363 SSH1 slingshot homolog 1 (Drosophila) -1.85 0.0008985 
14333287 LOC100856259 SET domain-containing protein 5-like -1.85 0.000861 
14256190 TULP4 Tubby like protein 4 -1.85 0.0055682 
14311164 SLC43A3 Solute carrier family 43, member 3 -1.85 0.0008504 
14431996 GATAD2B 
GATA zinc finger domain containing 
2B 
-1.81 0.0027215 
14310205 LAMB1 Laminin, beta 1 -1.80 0.0044402 




14269237 EPAS1 Endothelial PAS domain protein 1 -1.78 0.006405 
14406378 C10orf54 Chromosome 10 open reading frame 54 -1.76 0.0041549 
14264607 EMP3 Epithelial membrane protein 3 -1.76 0.0069596 
14437668 SAMD4A 




Pogo transposable element with ZNF 
domain-like 
-1.74 0.0016606 
14352781 PROSER1 Proline and serine rich 1 -1.74 0.0020732 
14458281 USP11 Ubiquitin specific peptidase 11 -1.74 0.0002903 
14390820 HEG1 HEG homolog 1 (zebrafish) -1.74 0.0013119 
14444308 SOX9 SRY (sex determining region Y)-box 9 -1.73 0.0048806 
14337814 GAB2 GRB2-associated binding protein 2 -1.72 0.0019492 
14288043 SNTB1 Syntrophin, beta 1 -1.72 0.0039552 
14431823 KCNN3 
Potassium intermediate/small 
conductance calcium-activated channel, 
subfamily N, member 3 
-1.72 0.0006795 
14335617 TECR Trans-2,3-enoyl-CoA reductase -1.71 0.0005928 
14383275 MYO1E Myosin IE -1.70 0.0069968 
14306172 ECM1 Extracellular matrix protein 1 -1.70 0.0011319 
14329375 MAP4 Microtubule-associated protein 4 -1.69 0.0007358 
14456137 LRRC37A2 
Leucine rich repeat containing 37, 
member A2 
-1.69 0.0071945 
14425853 YPEL3 Yippee-like 3 (Drosophila) -1.68 0.0009338 
14370464 GOT1 Glutamic-oxaloacetic transaminase 1 -1.67 0.007637 
14364247 CSDA Cold shock domain protein A -1.66 0.0021388 
14446155 NFE2L1 
Nuclear factor (erythroid-derived 2)-
like 1 
-1.66 0.0010265 





14271370 ACO2 Aconitase 2, mitochondrial -1.65 0.003443 
14287965 ENPP2 Ectonucleotide phosphodiesterase 2 -1.64 0.0071504 
14295467 ELK3 




Microtubule-associated protein, RP/EB 
family, member 2 
-1.63 0.0030262 
14319243 ARHGAP21 Rho GTPase activating protein 21 -1.62 0.0001376 
14360729 MED13L Mediator complex subunit 13-like -1.61 0.0080276 
14267946 CYB5R3 Cytochrome b5 reductase 3 -1.61 0.0013967 
14345683 TSC22D2 TSC22 domain family, member 2 -1.60 0.0065129 
14447314 TNFAIP1 
Tumor necrosis factor, alpha-induced 
protein 1 (endothelial) 
-1.60 0.0015703 
14322498 ECE1 Endothelin converting enzyme 1 -1.60 0.0070936 
14351034 PSMF1 
Proteasome (prosome, macropain) 
inhibitor subunit 1 
-1.60 0.0010511 
14261067 ZNF532 Zinc finger protein 532 -1.59 0.0052136 
14349213 SRSF6 Serine/arginine-rich splicing factor 6 -1.59 0.0006142 




14356006 DPYSL2 Dihydropyrimidinase-like 2 -1.58 0.0024522 
14434363 PRRC2C Proline-rich coiled-coil 2C -1.58 0.0013934 
14374483 ATP10A ATPase, class V, type 10A -1.56 0.0021843 
14401056 DEDD Death effector domain containing -1.56 0.0012595 
14318073 FAT4 
FAT tumor suppressor homolog 4 
(Drosophila) 
-1.56 0.0055227 
14361056 SPPL3 Signal peptide peptidase like 3 -1.56 0.0013294 
14299705 PTN Pleiotrophin -1.56 5.54E-05 
14435451 INTS3 Integrator complex subunit 3 -1.56 0.0047204 
14364103 LOC488929 WW domain-binding protein 11-like -1.56 1.34E-05 
14327602 VGLL4 Vestigial like 4 (Drosophila) -1.55 0.0006058 
14421705 KIAA0430 KIAA0430 ortholog -1.55 0.0033955 
14275482 LOC100856258 
Golgi-associated plant pathogenesis-
related protein 1-like 
-1.55 0.0075174 
14402043 DDR2 




TRAF-type zinc finger domain 
containing 1 
-1.54 2.87E-06 





14449024 ENG Endoglin -1.52 0.0031292 
14265772 CAPNS1 Calpain, small subunit 1 -1.51 0.0052279 
14462353 HUWE1 
UBA and WWE domain containing 1, 
E3 ubiquitin protein ligase 
-1.51 0.0008192 
14278691 LPAR1 Lysophosphatidic acid receptor 1 -1.51 0.0001846 
14390433 ZBTB20 




Transmembrane emp24 protein 






9.3 miRNAs Target Prediction 
9.3.1 miR-340 
Target Gene 














LRP1B 3 2 0 1 0 0 0 0 -0.26 cfa-miR-340 
ADAMTS18 1 0 0 1 6 1 1 4 -0.2 cfa-miR-340 
ADAM2 0 0 0 0 1 1 0 0 -0.19 cfa-miR-340 


















ADAMTS15 2 2 0 0 0 0 0 0 -0.46 cfa-let-7j 
ADAMTS8 1 1 0 0 0 0 0 0 -0.41 cfa-let-7f 
COL14A1 1 0 1 0 1 0 0 1 -0.41 cfa-let-7g 
COL1A2 1 1 0 0 0 0 0 0 -0.41 cfa-let-7g 
COL3A1 1 1 0 0 0 0 0 0 -0.34 cfa-let-7a 


















GLCE 3 3 0 0 0 0 0 0 -0.79 cfa-miR-218 
COL1A1 1 1 0 0 2 0 1 1 -0.61 cfa-miR-218 
ACTC1 0 0 0 0 3 1 2 0 -0.55 cfa-miR-218 
FGF12 3 1 2 0 1 0 0 1 -0.48 cfa-miR-218 
TNC 1 1 0 0 0 0 0 0 -0.46 cfa-miR-218 
COL19A1 0 0 0 0 1 1 0 0 -0.4 cfa-miR-218 
HS6ST3 1 1 0 0 1 0 1 0 -0.39 cfa-miR-218 
HAPLN1 2 1 1 0 0 0 0 0 -0.38 cfa-miR-218 
SRGAP2 1 1 0 0 0 0 0 0 -0.34 cfa-miR-218 


















ITGA4 0 0 0 0 1 1 0 0 -0.41 cfa-miR-708 






















FGF23 0 0 0 0 2 1 0 1 -0.35 cfa-miR-30e 
SNAI2 0 0 0 0 2 2 0 0 -0.33 cfa-miR-30e 
COL12A1 1 1 0 0 0 0 0 0 -0.32 cfa-miR-30e 
CAV1 1 1 0 0 0 0 0 0 -0.29 cfa-miR-30e 
HAS2 0 0 0 0 2 1 0 1 -0.29 cfa-miR-30e 
COL9A1 0 0 0 0 1 1 0 0 -0.27 cfa-miR-30e 
CLDN16 0 0 0 0 2 1 1 0 -0.26 cfa-miR-30e 
 
9.3.6 miR-214 / 761 
Target Gene 














CTSB 0 0 0 0 3 1 1 1 -0.52 cfa-miR-214 
NOS1 2 0 1 1 2 0 0 2 -0.49 cfa-miR-761 
IL16 0 0 0 0 3 1 1 1 -0.47 cfa-miR-214 
MMP11 0 0 0 0 3 0 3 0 -0.4 cfa-miR-761 
ECE2 0 0 0 0 3 0 3 0 -0.39 cfa-miR-214 
NOS3 0 0 0 0 1 1 0 0 -0.38 cfa-miR-214 
 
9.3.7 miR-15 / 16 / 195 / 497 
Target Gene 














FGF2 2 2 0 0 3 1 1 1 -1.42 cfa-miR-195 
COL12A1 3 0 3 0 0 0 0 0 -0.65 cfa-miR-15a 
NOS1 1 1 0 0 2 0 2 0 -0.58 cfa-miR-15b 
HTR4 1 1 0 0 2 0 2 0 -0.56 cfa-miR-497 
LRP6 2 0 2 0 2 0 1 1 -0.54 cfa-miR-15a 
NF1 1 1 0 0 1 0 1 0 -0.49 cfa-miR-16 
HSPG2 1 1 0 0 1 0 0 1 -0.45 cfa-miR-497 
VEGFA 1 1 0 0 0 0 0 0 -0.43 cfa-miR-16 
ECEL1 1 1 0 0 0 0 0 0 -0.42 cfa-miR-195 
FGF7 2 0 1 1 0 0 0 0 -0.41 cfa-miR-16 


















CRTAP 0 0 0 0 3 2 0 1 -0.63 cfa-miR-125b 





















HTR1F 0 0 0 0 2 1 1 0 -0.4 cfa-miR-532 
CDH10 0 0 0 0 1 1 0 0 -0.37 cfa-miR-532 
ADAMTS5 0 0 0 0 4 1 2 1 -0.37 cfa-miR-532 
TNN 0 0 0 0 1 1 0 0 -0.37 cfa-miR-532 
MMP13 0 0 0 0 1 1 0 0 -0.36 cfa-miR-532 
LRP6 1 0 1 0 1 0 1 0 -0.33 cfa-miR-532 


















CLDN12 1 1 0 0 1 1 0 0 -0.46 cfa-miR-23a 
IL12A 0 0 0 0 2 1 0 1 -0.42 cfa-miR-23a 
VCAN 1 1 0 0 1 0 1 0 -0.38 cfa-miR-23a 
HAS2 1 1 0 0 1 1 0 0 -0.38 cfa-miR-23a 
EDNRB 0 0 0 0 2 2 0 0 -0.36 cfa-miR-23a 
HGSNAT 0 0 0 0 2 0 1 1 -0.33 cfa-miR-23a 
LAMC3 0 0 0 0 1 1 0 0 -0.3 cfa-miR-23a 


















ADAMTS17 3 1 2 0 1 0 1 0 -1.06 cfa-miR-29b 
COL4A4 2 0 2 0 2 1 1 0 -0.99 cfa-miR-29a 
COL3A1 2 2 0 0 0 0 0 0 -0.93 cfa-miR-29b 
COL4A5 2 2 0 0 0 0 0 0 -0.85 cfa-miR-29b 
COL11A1 2 0 2 0 1 0 1 0 -0.85 cfa-miR-29a 
FBN1 2 1 1 0 1 0 0 1 -0.82 cfa-miR-29a 
ADAMTS2 2 1 1 0 3 0 2 1 -0.8 cfa-miR-29a 
ELN 3 2 1 0 0 0 0 0 -0.78 cfa-miR-29b 
COL9A1 1 1 0 0 1 0 1 0 -0.74 cfa-miR-29a 
COL5A3 3 1 2 0 0 0 0 0 -0.68 cfa-miR-29b 
CTSE 0 0 0 0 2 1 0 1 -0.65 cfa-miR-29b 
COL1A1 3 1 0 2 0 0 0 0 -0.59 cfa-miR-29a 
COL1A2 2 1 0 1 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA9 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHAC2 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHAC1 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA13 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA12 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA11 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA10 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA8 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA7 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 




PCDHA5 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA4 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA3 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA2 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
PCDHA1 1 1 0 0 0 0 0 0 -0.58 cfa-miR-29a 
COL7A1 2 1 1 0 0 0 0 0 -0.57 cfa-miR-29b 
COL4A1 2 1 0 1 0 0 0 0 -0.56 cfa-miR-29c 
CSGALNACT2 0 0 0 0 3 0 2 1 -0.56 cfa-miR-29a 
HAS3 3 1 2 0 1 0 1 0 -0.55 cfa-miR-29b 
COL5A1 3 2 1 0 0 0 0 0 -0.53 cfa-miR-29a 
VEGFA 1 1 0 0 0 0 0 0 -0.53 cfa-miR-29a 
ADAMTS14 2 2 0 0 1 0 1 0 -0.49 cfa-miR-29a 
ROBO1 1 1 0 0 0 0 0 0 -0.47 cfa-miR-29a 
LAMA2 1 1 0 0 0 0 0 0 -0.47 cfa-miR-29a 
COL15A1 1 1 0 0 0 0 0 0 -0.46 cfa-miR-29b 
COL2A1 1 1 0 0 0 0 0 0 -0.44 cfa-miR-29b 
ADAMTS18 2 1 1 0 0 0 0 0 -0.44 cfa-miR-29b 
COL6A3 1 1 0 0 0 0 0 0 -0.43 cfa-miR-29a 
COL22A1 1 1 0 0 1 0 0 1 -0.43 cfa-miR-29a 
LRP6 2 0 2 0 0 0 0 0 -0.42 cfa-miR-29b 
 
9.3.12 miR-103 / 107 
Target Gene 














VCAN 1 1 0 0 2 0 0 2 -0.47 cfa-miR-103 


















IL16 0 0 0 0 1 1 0 0 -0.32 cfa-miR-181a 


















BMP8A 0 0 0 0 1 1 0 0 -0.6 cfa-miR-99a 
HS3ST2 1 1 0 0 0 0 0 0 -0.58 cfa-miR-99a 
HS3ST3B1 1 1 0 0 0 0 0 0 -0.56 cfa-miR-99a 
MMP13 0 0 0 0 1 1 0 0 -0.54 cfa-miR-99a 
FGFR3 1 1 0 0 0 0 0 0 -0.44 cfa-miR-99a 
ITFG2 0 0 0 0 1 0 1 0 -0.36 cfa-miR-99a 
CDH6 0 0 0 0 1 0 1 0 -0.32 cfa-miR-99b 
ITGA2 0 0 0 0 1 0 0 1 -0.3 cfa-miR-99a 
CLDN11 1 0 1 0 0 0 0 0 -0.28 cfa-miR-99a 
BMPR2 1 0 0 1 0 0 0 0 -0.27 cfa-miR-99a 




LAMC1 0 0 0 0 1 0 0 1 -0.21 cfa-miR-99a 
 
9.3.15 miR-25 / 32 / 363 
Target Gene 














ITGAV 1 1 0 0 3 0 1 2 -0.42 cfa-miR-32 
ADAM23 1 1 0 0 0 0 0 0 -0.42 cfa-miR-25 
ADAM21 0 0 0 0 1 1 0 0 -0.41 cfa-miR-32 
ADAMTSL3 1 1 0 0 0 0 0 0 -0.38 cfa-miR-32 
BGN 1 1 0 0 0 0 0 0 -0.38 cfa-miR-25 
KERA 0 0 0 0 2 0 1 1 -0.37 cfa-miR-32 
PCDH9 1 0 0 1 1 0 1 0 -0.36 cfa-miR-363 


















SRGAP2 3 3 0 0 2 0 1 1 -0.95 cfa-miR-145 
ITGB8 3 1 2 0 0 0 0 0 -0.58 cfa-miR-145 
SRGAP1 3 1 2 0 1 1 0 0 -0.57 cfa-miR-145 
ITGA2 0 0 0 0 2 2 0 0 -0.43 cfa-miR-145 
ITFG1 0 0 0 0 1 1 0 0 -0.38 cfa-miR-145 
ACTG1 1 1 0 0 0 0 0 0 -0.38 cfa-miR-145 
CTSL2 0 0 0 0 2 1 1 0 -0.36 cfa-miR-145 
 
9.3.17 miR-130 / 301 / 454 
Target Gene 














IL15 0 0 0 0 2 0 2 0 -0.44 cfa-miR-130a 
LRP8 1 1 0 0 1 0 0 1 -0.42 cfa-miR-130a 
ADAM12 1 1 0 0 0 0 0 0 -0.4 cfa-miR-301a 
LDLR 3 0 3 0 0 0 0 0 -0.39 cfa-miR-130b 
ADAM28 0 0 0 0 1 1 0 0 -0.38 cfa-miR-454 
CTNNA3 0 0 0 0 1 0 1 0 -0.35 cfa-miR-130a 


















PCDH7 1 1 0 0 1 1 0 0 -0.64 cfa-miR-1843 
COL3A1 0 0 0 0 1 1 0 0 -0.46 cfa-miR-1843 





















ADAMTS5 1 1 0 0 4 0 2 2 -0.79 cfa-miR-197 
AFAP1L2 0 0 0 0 2 1 1 0 -0.65 cfa-miR-197 
HTR7 1 1 0 0 1 0 1 0 -0.58 cfa-miR-197 
ITGAM 0 0 0 0 2 1 0 1 -0.5 cfa-miR-197 
CTNND1 1 1 0 0 0 0 0 0 -0.4 cfa-miR-197 
HTR2C 0 0 0 0 1 1 0 0 -0.4 cfa-miR-197 
CTSL1 0 0 0 0 1 1 0 0 -0.37 cfa-miR-197 
PCDH18 0 0 0 0 1 1 0 0 -0.36 cfa-miR-197 
LAMC1 0 0 0 0 1 1 0 0 -0.35 cfa-miR-197 
COL5A2 0 0 0 0 2 0 1 1 -0.32 cfa-miR-197 


















FNDC7 0 0 0 0 3 2 1 0 -0.69 cfa-miR-143 
ITGAL 0 0 0 0 2 1 1 0 -0.38 cfa-miR-143 
FGF9 1 1 0 0 0 0 0 0 -0.38 cfa-miR-143 
CLDN1 0 0 0 0 1 1 0 0 -0.3 cfa-miR-143 
ITGA6 1 1 0 0 1 0 0 1 -0.3 cfa-miR-143 
COL6A5 0 0 0 0 2 0 1 1 -0.28 cfa-miR-143 


















ACTC1 0 0 0 0 1 1 0 0 -0.39 cfa-miR-872 
PCDHAC1 0 0 0 0 1 1 0 0 -0.37 cfa-miR-872 
ECM2 0 0 0 0 1 1 0 0 -0.31 cfa-miR-872 
ITGAV 0 0 0 0 2 1 1 0 -0.29 cfa-miR-872 
ADAMTS19 0 0 0 0 2 0 1 1 -0.25 cfa-miR-872 
COL14A1 0 0 0 0 1 0 1 0 -0.25 cfa-miR-872 
ANGPTL3 0 0 0 0 1 0 1 0 -0.25 cfa-miR-872 


















HTR2C 2 0 2 0 1 0 1 0 -0.37 cfa-miR-545 
SNAI2 1 1 0 0 1 0 0 1 -0.33 cfa-miR-545 
MMP16 0 0 0 0 1 1 0 0 -0.26 cfa-miR-545 
 
